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Influenza virus continues to be an important global pathogen which poses serious health 
and economic challenges. Influenza virus causes regular seasonal epidemics, intermittent 
and unpredictable pandemics and deadly zoonotic outbreaks. The currently available 
antiviral strategies used against influenza are limited in their effectiveness. The rapid 
evolution of influenza viruses has precluded the development of a universal vaccine and 
has meant that the annually administered vaccine is only variably effective. Furthermore, 
the two classes of antiviral drugs used against influenza have only limited effectiveness due 
to rise in drug resistance. Therefore, there is a pressing need to develop a greater 
understanding of the virus-host interactions that are critical for influenza virus 
multiplication and pathogenesis. Such understanding would aid in the development of 
more effective and long lasting anti-influenza virus strategies. 
This PhD investigates the role of host histone deacetylase HDAC4, in influenza A virus 
(IAV) infection, the most significant genus of influenza. Histone deacetylases (HDACs) 
are a family of enzymes that catalyse the deacetylation of acetylated histone and non-
histone proteins. Previously, it has been shown that HDAC1, HDAC2, HDAC6 and 
HDAC11 all possess anti-influenza virus properties. HDAC1, HDAC2 and HDAC11 are 
involved in promoting the innate immune response during influenza infection. HDAC6 
restricts influenza virus release by deacetylating α-tubulin and decreases viral replication by 
degrading the viral polymerase and enhancing the RIG-I innate immune response. 
Currently, no studies have investigated the role of HDAC4 in IAV infection. Given the 
similarity between different HDAC members, we hypothesised that HDAC4 also plays a 
role in inhibiting IAV replication. Hence, we investigated the effects of HDAC4 depletion 
and overexpression on IAV replication using primarily human lung epithelial cells and IAV 
PR/8/34(H1N1) strain as a model. 
The outcomes of this project reveal that depletion of HDAC4 enhances the replication of 
influenza virus by up to 4-fold. Conversely, influenza virus replication was inhibited by up 
to 49% in cells overexpressing HDAC4, indicating an antiviral role for HDAC4. 
Mechanistically, HDAC4 was found to be involved in the influenza virus-induced host 
innate antiviral response. Specifically, we observed decreased phosphorylation of STAT1 
in HDAC4 depleted cells, which corresponded to decreased levels of the interferon 
effector genes (IFITM3, ISG15 and viperin). Conversely, HDAC4 overexpressing cells 
enhanced STAT1 phosphorylation, resulting in greater expression of the downstream 
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interferon effector genes. We also found that influenza virus actively targets HDAC4 to 
downregulate its expression both at mRNA and polypeptide levels, likely as a means to 
inhibit its antiviral function. The HDAC4 mRNA is degraded by the IAV endonuclease 
PA-X while HDAC4 polypeptide is cleaved by IAV-induced host caspase 3.  
In summary, the outcomes of this PhD implicate HDAC4 as an anti-influenza host factor 
that is a component of host innate antiviral response. In addition, it is revealed that 
influenza virus strongly antagonises HDAC4 to subvert its antiviral activity. Thus, the data 
presented here contributes to our molecular understanding of host HDACs-influenza virus 
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Section A – Influenza and influenza A virus 
1.1 The global burden of influenza  
Influenza is an acute febrile disease, commonly referred to as “flu”. In humans it is caused 
by influenza A virus (IAV) and influenza B virus (IBV). The disease is typically associated 
with a somewhat mild upper respiratory tract infection, consisting of sore throat, cough, 
fever, muscle aches and headache [1]. However, in severe cases the disease can develop 
into pneumonia when the virus infects the lower respiratory tract and destroys the airway 
cilia allowing secondary bacterial infections to occur. In susceptible individuals such as 
young children (6-60 months), the elderly and immunocompromised, influenza infection 
can also lead to a variety of other health complications affecting the heart, brain and other 
organ tissues [2]. According to the World Health Organisation estimates, there are 
approximately 1 billion cases of flu every year. About 3 – 5 million of these are categorised 
as a severe illness, resulting in 300,000 – 500,000 deaths worldwide. In addition to the 
health related issues, an often underappreciated impact is the socio-economic burden: 
increase in hospitalizations and work absenteeism leading to loss of productivity and trade 
associated with influenza [3].  
The spread of influenza is characterised by annual seasonal epidemics and unpredictable 
pandemics. Due to the introduction of IAV strains from avian or swine populations, there 
have been 4 resulting pandemics since 1918. The incidence of influenza infections 
increases during a pandemic due to a lack of pre-existing immunity to the new virus, 
however severity depends entirely on the pandemic virus itself. The 1918-1919 “Spanish 
flu” was the most severe pandemic in the last 100 years, which first arose in the United 
States and spread across the world. It is estimated that 500 million people were infected 
which resulted in 40 million deaths [4]. The second recorded pandemic was the 1957-1958 
“Asian flu” which began in China and caused approximately 2 million deaths worldwide 
[5]. The third pandemic occurred from 1968-1969, first appearing in Hong Kong and was 
so dubbed “Hong Kong flu”. This pandemic caused between 1-4 million deaths 
worldwide, with a secondary outbreak occurring from 1970-1972 [6]. The most recent 
pandemic, dubbed “Swine flu”, originated in Mexico in 2009-2010 and resulted in about 
18,000 deaths globally [4, 7].  
In addition to the seasonal and pandemic outbreaks of influenza, there is growing concern 
regarding zoonotic outbreaks, in particular the emergence of highly pathogenic avian 
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influenza (HPAI). The first reported outbreak of HPAI occurred in Hong Kong in 1997 
where an H5N1 strain infected 18 people, of which 6 died. The WHO has reported that 
between 2003 and June 2019, there have been 861 confirmed cases of H5N1 which caused 
455 deaths [8]. In 2013 another HPAI strain, H7N9, emerged in China and between 2013 
and 2018 1567 human cases were reported, resulting in 615 deaths [9]. In addition, 
outbreaks of HPAI is a major disease burden in animals. In the first 10 years since HPAI 
emerged, it has resulted in the deaths of more than 400 million birds with economic losses 
totalling US$10billion [10]. 
 
1.2 The structure of influenza A virus 
Influenza virus belongs to the Orthomyxoviridae family, which encompasses seven genera of 
RNA viruses including the 4 influenza genera: influenza A, B, C and D [11]. All influenza 
viruses are enveloped with a negative sense, single stranded, RNA genome. IAV and IBV 
viruses contain 8 RNA gene segments, whereas influenza C and D viruses only contain 7. 
The latter do not cause substantial disease in humans [12-15]. IAV and IBV are of much 
greater concern in terms of global disease burden, with IAV being the most significant 
because of its unique pandemic potential. Unique among the influenza genera, IAV 
circulates not only in humans, but also in pigs, horses and poultry as well as migratory 
birds. The wild aquatic birds are considered the natural reservoirs of IAV [16].  
IAV virions vary in size from 80-120nm and predominantly exist in a spherical form 
(Figure 1) [17]. The 8 gene segments that make up the genome of IAV encode up to 17 
proteins [18]. The most characterised proteins are the RNA polymerase subunits, 
polymerase basic 1 and 2 (PB1, PB2) and polymerase acidic (PA) and together they carry 
out gene transcription and genome replication. Segments 4 and 6 encode the viral 
glycoproteins hemagglutinin (HA), which mediates viral entry and neuraminidase (NA) 
which is required for releasing newly formed virus particles from the plasma membrane, 
facilitating viral spread. Viral nucleoprotein (NP) is encoded on segment 5 and plays 
important roles in genome encapsulation [516], nuclear trafficking [517] and vRNA 
transcription and translation [518]. Segments 7 and 8 encode multiple proteins, most 
importantly matrix protein (M1), membrane ion-channel protein (M2), non-structural 
protein 1 (NS1) and nuclear export protein (NEP, also known as NS2). M1 provides a 
scaffold that helps to form the structure of the virus particle and together with NEP, 
regulates trafficking of the viral RNA segments inside the cell. M2 is transmembrane 
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protein that acts as a proton ion channel required for viral entry and exit. The protein is 
characterised by 4 transmembrane helices which are packed tightly together to keep the 
pore closed. Lowering the pH weakens the helix-helix interactions and opens the channel, 
allowing protons to flow through. NS1 is an important virulence factor that carries out a 
range of functions to promote viral replication and inhibit the antiviral immune response.  
More recently, additional IAV proteins have been identified including PA-X (a frameshift 
product of PA), M42 (a splice variant of M), PA-N155 (N-terminal truncation of PA), PA-
N182 (N-terminal truncation of PA) and NS3 (point mutation in NS1) [19, 20]. The 
functional role of these proteins is not completely understood, however, PA-X has been 
recognised as an important virulence factor, owing to its ability to selectively degrade host 
mRNAs [21].  
The envelope of IAV is composed of a lipid bilayer derived from the host cell. It contains 
the 2 viral surface proteins HA and NA which are the most antigenically variable and are 
used to classify antigenically diverse subtypes. Currently, a total of 16 HA and 9 NA 
subtypes have been identified (18 HA and 11 NA when including the phylogenetically 
similar bat IAV-like viruses, however these are unable to reassort with other IAVs) [22-
25]. The diverse range of animal reservoirs is an important source of antigenically varied 
HA and NA genes that are able to be exchanged between different IAV strains during co-
infection of the same host cell. This allows for a greater viral diversity and in some cases 
leads to the emergence of human pandemic strains with HA and/or NA derived from 














Figure 1. Structure of influenza A virus. This figure represents an IAV particle. IAV is an 
enveloped negative-sense single stranded RNA virus with 8 individual RNA segments contained 
within the virus particle. Adapted and modified from [26] 
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1.3 Pathophysiology of influenza A virus 
In humans, IAV is transmitted via the respiratory route while in birds it is transmitted 
through the faecal-oral or faecal-respiratory route [519]. Depending on the route of 
transmission, the virus usually infects the epithelial cells of the upper respiratory tract or 
the epithelial cells of the intestinal tract [520]. Upon binding to the surface of a target cell, 
the cellular life cycle of IAV begins where it exploits many cellular components, in a 
complex, multistep process (Figure 2). 
1.3.1 Entry 
The binding of IAV to the host cell surface is mediated by the viral HA which bind to the 
sialic acid receptors present in the oligosaccharides and glycoproteins at the cell surface 
[27]. Human IAV HA preferentially binds sialic acids linked by an α-2,6 linkage to the rest 
of the oligosaccharide, whereas avian IAV HA favours α-2,3 linked sialic acids [28]. This 
is because these bonds are the predominant sialic acid linkages in the upper human airway 
epithelium and avian intestinal tract, respectively. It was thought that sialic acid receptors 
were a requirement for the successful absorption of IAV into the host cell, however, a 
recent study has shown that IAV can infect cells without sialic acid [29], indicating that 
perhaps IAV has evolved several strategies to enter a host cell. After binding, the viral 
particle is internalized in an endosome via receptor-mediated endocytosis. Endocytosis 
occurs in a clathrin-dependent manner, involving dynamin and the adapter protein Epsin-
1 [30, 31], or by micropinocytosis [32].  
1.3.2 Envelope fusion and nuclear import 
Once internalized into an endosome, host proteases cleave the viral HA (or HA0) into 
HA1 and HA2 [33]. Acidification of the endosome induces a conformational change in 
HA that exposes the HA2 fusion peptide. The HA2 fusion peptide then inserts into the 
endosomal membrane which induces fusion of the viral envelope with that of the 
endosome [33]. Because the pH of endosomes varies between host species, the pH stability 
of HA is an important determinant of viral tropism [34]. After fusion of the 2 membranes, 
protons from the endosome enter the virion through the viral M2 ion channel which 
acidifies the virus particle leading to dissociation of M1 from the vRNP complex [35, 36]. 
Host vacuolar ATPase is important for both the acidification and fusion of the viral and 
endosomal membranes, allowing the genetic material of the virus bound in the form of 8 
vRNPs to be released into the cytoplasm [37]. The vRNPs are then imported into the 
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nucleus through the nuclear pore complex. This process is aided by importin α and through 
the action of the nuclear pore complex proteins Nup98 and Nup153 [38-40]. 
1.3.3 Replication and transcription 
Transcription and replication of the viral RNA occurs within the nucleus and is catalysed 
through the action of the viral polymerase complex (PB1, PB2 and PA) which is attached 
to the vRNPs [41]. Replication of the viral RNA occurs through positive-sense 
intermediate known as the complementary ribonucleoprotein (cRNP) complex [38]. Many 
copies of viral RNA are transcribed from the cRNP which are themselves transcribed into 
viral mRNAs [41]. Cap snatching of host mRNA is an important step in the transcription 
of the viral mRNA. The PB2 protein binds to the 5’-cap of the host pre-mRNAs which 
allows viral PA to cleave the 10-13nt long 5’ cap. This capped oligonucleotide primer is 
then used to initiate transcription of the viral RNA. Finally, the viral mRNA is matured by 
the addition of a poly(A) tail through the catalytic activity of PB1 [42]. Additionally, M 
mRNA is spliced into M1 and M2 mRNAs as are NS1 and NEP from NS mRNA [43]. 
This splicing occurs through the activity of host mRNA splicing factors Tat-SF1 and BAT1 
[44]. The positive-strand mRNAs which are capped and polyadenylated are then exported 
into the cytoplasm for translation into viral proteins. 
1.3.4 Translation 
Translation of the IAV mRNA is entirely dependent on the host cell translation machinery. 
The viral mRNAs are exported from the nucleus into the cytoplasm, where translation is 
divided between cytosolic ribosomes (for PB1, PB2, PA, NP, NS1, NS2 and M1) and 
endoplasmic reticulum-associated ribosomes for the membrane proteins HA, NA and M2. 
Newly synthesised viral polymerases (PB1, PB2 and PA) and viral NP, NS1, NEP and M1 
are imported into the nucleus to further increase the rate of viral RNA synthesis while the 
membrane proteins (HA, NA and M2) are trafficked and inserted into the plasma 
membrane [45, 46]. To further aid in viral replication, many of the viral non-structural 
proteins actively inhibit host protein synthesis or promote viral mRNA synthesis to favour 
translation of viral mRNAs. For example, NS1 contributes to viral mRNA export by 
linking the viral transcripts to the cellular nuclear export components and the nucleoporin 
NUP98 [39]. Additionally, PB1, PB2 and PA interact with host DNA-dependent RNA 
polymerase II, which is believed to contribute to shutdown of host mRNA synthesis [47].  
The viral protein PA-X targets host mRNAs transcribed by host RNA polymerase II (Pol 
II), while leaving viral mRNAs transcribed by viral RdRp intact. Initially, PA-X cleaves the 
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target which allows complete degradation of the mRNA to be carried out through the 
activity of the host 5’ -> 3’ exonuclease Xrn1 [48]. Interestingly, even non-coding mRNAs 
transcribed by Pol II are targeted by PA-X, likely as a means to free up ribosomes to 
translate more viral mRNAs (reducue ribosomal load), allowing for increased viral protein 
synthesis [48].  
1.3.5 Post-translational modifications 
Newly translated viral proteins are subject to a diverse range of post-translational 
modifications (PTMs) in order to diversify their function. IAV itself encodes no known 
protein-modifying enzyme and so all of these PTMs are carried out by host machinery. 
Recently, it has been discovered that viral NP is acetylated which is important for viral 
growth and replication. Lack of acetylation at lysine residue 229 results in decreased viral 
replication as a result of impaired particle release. Furthermore, hyper-acetylation at lysine 
residues 77 and 229 severely diminish viral polymerase activity [49]. Viral NP is both 
phosphorylated and SUMOylated, both of which affect the trafficking of NP to and from 
the nucleus. During the early stage of infection NP localises to the nucleus with the vRNP 
while in the late stage of infection, NP is important for exporting the vRNP complexes [6, 
7]. Phosphorylation of NP at serine 3 residue, located at the N-terminal nuclear localization 
signal (NLS), inhibits interaction with nuclear import factors and prevents its nuclear 
localization [50]. Meanwhile, phosphorylation at the serine 296 residue prevents NP 
interacting with nuclear export factors [51]. SUMOylation plays an important role in the 
retention of NP within the nucleus as mutant NPs lacking SUMOylation sites are 
prematurely exported to the cytoplasm [52]. Ubiquitination of all of the RNP components 
serve as a means to promote the function of the RNP but in some circumstances also can 
lead to its degradation through the addition of polyubiquitin chains [53, 54]. 
Phosphorylation of NS1 disrupts its protein-RNA interactions as well as its protein-protein 
interactions [55-58]. In this way, the host cell is able to interfere with the antagonistic 
properties of NS1. Additionally, HA is subject to glycosylation which helps in immune 
evasion as it inhibits antibody recognition and neutralization [59]. Furthermore, 
glycosylation of HA has also been linked with an increase in virulence and fitness after 
immune escape [60, 61]. 
1.3.6 vRNP nuclear export 
In the nucleus, vRNA is matured into vRNP complexes through assembly with NP, PA, 
PB1 and PB2. These vRNP complexes are then exported out of the nucleus through two 
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different pathways mediated by nuclear RNA export factor 1 (NXF-1) and chromosome 
region maintenance-1 (CRM-1) [62, 63]. NS1 is believed to aid in exporting viral 
components through the NXF-1 nuclear export pathway [64, 65]. Additionally, M1 acts as 
an adaptor protein and links NEP to vRNPs whereby NEP interacts with CRM-1 to guide 
the vRNPs to the CRM-1 nuclear export pathway to be transported to the cytoplasm [66-
68].  
1.3.7 Maturation of IAV membrane proteins 
The viral membrane proteins, HA, NA and M2 are synthesised by ribosomes associated 
with the ER membrane [69-72]. Following synthesis, HA, NA and M2 oligomerize and are 
trafficked through the Golgi to the plasma membrane. During this trafficking process from 
the ER to the Golgi, HA is trafficked as a fusion incompetent precursor termed HA0. In 
order to gain its fusion function, HA must be cleaved into subunits HA1 and HA2 [73-
75]. Different proteases are known to cleave HA, depending upon the particular strain of 
IAV, therefore the cleavage site of HA is important for the tissue tropism of the virus. All 
influenza viruses have a cleavage site that is recognised by extracellular proteases present 
in respiratory and epithelial cells except for HPAI viruses, which contain a multibasic 
cleavage site in HA that is recognised by furin, a ubiquitously expressed protease [76, 77].  
1.3.8 Viral budding and release 
During the late stages of infection, viral M1 and NEP localize to the nucleus where they 
bind with vRNPs to mediate their export to the cytoplasm. Then, through interactions 
with the recycling endosome and microtubules, they migrate to the plasma membrane and 
are packaged into the 8 vRNPs that makeup the viral genome [67, 78, 79]. Budding of new 
virions takes place through the clustering of HA and NA in lipid raft domains. M1 binds 
to the cytoplasmic tails of HA and NA and serve as docking sites for the vRNPs. 
Polymerization of M1 proteins cause the bud to elongate and then the M2 protein forms 
a positive curvature at the periphery of the bud. Membrane scission occurs via the insertion 
of the M2 amphipathic helix at the budding neck of the lipid phase boundary, resulting in 
the release of the budding virion [80, 81]. Once the virion is released it may still be bound 
to the cell membrane via interactions between host silica acid and virion-associated HA. 
NA then plays the final role in release as it is able cleave HA bound to sialic acid receptors 
through its sialidase activity [81]. Viral replication results in cell death, inducing pro-
inflammatory responses that promote recruitment of innate and adaptive immune cells 
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which clear the infection, but in overabundance can cause immunopathology and 















Figure 2. Influenza A virus life cycle. IAV enters the cell once the viral surface protein HA 
binds to sialic acid receptors on the surface of the host cell. The virus is then internalized into an 
endosome where the low pH induces fusion of the viral and endosomal membranes. Following 
membrane fusion, the vRNP is released into the cytoplasm and is then imported into the nucleus 
where the replication cycle begins. The negative sense strand is converted into positive sense or 
complementary RNA (cRNA) which is used as the template for viral RNA synthesis. Viral mRNAs 
are exported from the nucleus and translated into viral proteins in the cytoplasm, and these are 
assembled into new virions together with newly synthesised vRNPs. Newly formed virus particles 
bud from the surface of plasma membrane and NA cleaves the sialic acid receptors to release the 




1.4 Evolution of IAV 
The most important driver of IAV evolution is the viral RNA-polymerase which 
lacks any proofreading function. Therefore, during viral replication, the integration 
of incorrect nucleotides occurs at rate of 10-3 to 10-4 which allows for a rapid 
mutation rate of the viral genome [82, 83]. The effect of this rapid mutation rate is 
most profound in the context of the two IAV surface proteins, especially HA. Due 
to its role in receptor recognition and attachment, HA is the principal determinant 
in IAV host range. The specificity of avian HA is for α2,3 sialic acid receptors found 
in the intestinal tract of birds, while human influenza HA preferably binds α2,6 sialic 
acid receptors, which are predominantly found in the respiratory tract of humans. 
However, sialic acids with α2,3-linkages are found in the lower respiratory tract in 
humans, allowing avian IAV subtypes to infect humans occasionally, usually at a 
much greater mortality rate than human IAV. Importantly, pigs and some avian 
species (pheasants, turkeys, quails) possess both α2,3 and α2,6 linkages particularly 
in alveoli epithelial cells, allowing them to be infected by both human and avian 
IAV strains. Thus, these animals can act as mixing vessels capable of generating re-
assortment viruses during co-infection with different IAV strains. This is the 
mechanism by which the 2009 “swine flu” pandemic virus emerged [84-86]. In 
addition to determining host range specificity, the rapid mutation rate of IAV 
surface proteins also contributes to the viruses’ ability to effectively evade the host 
immune response [87]. There are three main mechanisms that drive evolutionary 
changes in the virus which include antigenic drift, antigenic shift and occasionally, 
recombination.  
1.4.1 Antigenic drift 
Antigenic drift is a mechanism of IAV evolution that is characterised by the gradual 
accumulation of mutations in key antigenic sites. This results in antigen migration to 
produce new influenza subtypes which escape the immune pressure of the population [88]. 
Immune escape occurs when the surface proteins HA and NA accumulate minimal 
structural changes that are enough to circumvent immune protection (acquired through 
previous infection or vaccination), but do not significantly alter the function of these 
proteins. Antigenic drift is important in altering host range as well as immune evasion, but 
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also plays an important role in the emergence of drug resistance. Some single point 
mutations in the drug targets of influenza have been identified as enough to change the 
structure of these targets so that drug binding becomes ineffective, allowing for the 
evolution of drug resistant strains. Antigenic drift is the main driver of new IAV variants 
with the ability to cause annual influenza epidemics [89]. While these changes are not 
sufficient to lead to pandemics, over long periods of time, antigenic drift can cause strains 
to become considerably different from the original pandemic virus.  
1.4.2 Antigenic shift 
One of the most distinctive advantages of the segmented genome of IAV is that it 
enables the exchange of RNA segments between genotypically different influenza 
viruses. This re-assortment of the viral genome allows for the production of entirely 
new IAV strains and subtypes that have the potential to become pandemic strains 
[90]. These novel strains are generated as a result of antigenic shift and contain 
elements from the parental strains but are significantly different antigenically. The 
1957 and 1968 pandemics of last century as well as the 2009 pandemic of this 
century arose as a result of re-assortment between human IAV and IAV from other 
host species [91]. It is believed that the HA, NA and PB1 genes from the H2N2 
1957 pandemic strain as well as the HA and PB1 segments from the 1968 H3N2 
pandemic strain are of avian origin, while the remaining fragments may come from 
the 1918 “Spanish flu” strain [92]. The H1N1 2009 “Swine flu” pandemic strain is 
a re-assortment from multiple mixed recombination’s between European H1N1 
swine IAV, North American H1N2 swine influenza, North American avian 
influenza, and human H3N2 influenza [93]. The re-assortment resulted in a novel 
H1N1 strain containing PB2 and PA segments from the North American swine 
influenza, PB1 from human H3N2 influenza, HA, NP and NS from a classic swine 
influenza virus and, NA and M from a European H1N1 swine influenza virus [92].  
1.4.3 Recombination 
Recombination is another means which can shape the evolution of IAVs and can 
occur through two mechanisms. The first is by non-homologous recombination 
which occurs between two different RNA segments [94, 95], while the other is 
homologous recombination which is thought to participate in template switching 
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while the RNA is being copied by the polymerase. However, during IAV replication, 
the RNA genome is rapidly packed with ribonucleoprotein which prevents the 
occurrence of template switching, making homologous recombination in influenza 
viruses a rare event [96]. Nevertheless, several studies have provided evidence for 
homologous recombination in IAV, for example, between PB2 and PA (between 
H1N1 strains) as well as HA and NP (between human H1N1 and H3N2 strains) 
[97].  
1.4.4 Adaptations to new hosts  
Aquatic waterfowl and shorebirds are the main natural host species of IAV and are 
often referred to as the ‘reservoir hosts’ [98]. Some IAV strains (presumably from 
waterfowl), have adapted to be able to successfully infect other birds (including 
domestic poultry and ducks) and mammals (including humans, swine, equine, dogs, 
mink and marine mammals) [99]. The virus is often propagated through animal 
faeces and contaminated water which enables contact with a broad host range, 
significantly increasing the chances of genetic mutation and re-assortment. This also 
allows for greatly increased intra-host genetic diversity (referred to as quasi-species) 
resulting in a pool of viral mutants that facilitate the adaptation to new hosts and 
selection pressures [100]. Adaptation to transmission in new hosts requires 
mutations in the viral HA and NA to optimize receptor binding [101] and sialic acid 
cleaving activities [102], respectively, and to enable HA activation at different pH 
levels [103]. Additionally, changes in the viral RNA polymerase subunits can affect 
activity in different hosts as well as its temperature sensitivity which varies 
depending on the internal temperature of the host organism [104, 105]. 
Furthermore, changes in NP can affect susceptibility to the host interferon-
stimulated gene (ISG), Mx1 [106], whereas changes in M1 and M2 affect viral 
morphology which is an important facilitator in respiratory transmission in new 
hosts [107]. These changes can also be acquired through re-assortment, as occurred 
with the 1957, 1968 and 2009 pandemics [108]. 
Genetic adaptations often occur between wild aquatic birds and domestic ducks or 
geese. It can also occur between aquatic and domestic poultry (which is how the 
avian IAV strains H5N1, H7N9 and H10N8 emerged) or within swine (as occurred 
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with the emergence of the 2009 pandemic). H3N8 was initially an endemic strain 
circulating in equine but has since been transmitted to dogs in the United States 
[109]. Recently, a species of bat from Guatemala and Peru have been found to carry 
a new influenza A-like virus with new subtypes of HA and NA (H17, H18 and N10, 




Figure 3. The ecological cycle of influenza A virus. Influenza A viruses have been found in a 
multitude of species all seemingly derived from viral ancestors in wild birds, with the exception of 
the bat influenza-like viruses which are still of uncertain origin. Viruses from wild birds can be 
transmitted to marine mammals and domestic free range ducks and poultry. Transmission from 
ducks occurs through ‘backyard’ farming where the animals are raised together or in live animal 
markets. Humans can be infected from poultry and swine viruses through aerosols, fomites or 
contaminated water. Other domestic animals known to be susceptible to IAV infections are dogs 
and cats. Dashed lines represent transmissions that bypass a domestic duck intermediate. Adapted 




1.5 Current anti-IAV strategies and their limitations 
Currently, the annual influenza vaccination program alternating in the Northern and 
Southern Hemispheres is the main strategy that is used to prevent and control seasonal 
influenza epidemics. Because of the rapid mutation rate of IAV and IBV resulting in the 
emergence of novel strains, the vaccine needs to be reformulated, manufactured and 
distributed to the global human population each year, prior to the start of flu season [111]. 
The most important factor in determining the success or failure of the vaccine is the global 
influenza surveillance program known as the Global Influenza Surveillance and Response 
System (GISRS), spearheaded by the WHO. Laboratories and collaborating centres in 113 
member states conduct surveillance on circulating influenza strains as well as provide 
recommendations on vaccine formulation and global influenza risk-assessment. Vaccine 
efficacy varies each influenza season and depends upon the strains included in the vaccine 
(recently, an IAV H1N1 strain, an IAV H3N2 strain and 2 IBV strains) and which strains 
end up being the dominant circulating strains [112]. In addition to the challenge of 
predicting the circulating strains, vaccine effectiveness is also dependent upon global 
vaccine uptake. New strategies are being utilised to improve vaccine efficacy through 
development of next-generation vaccines. These include synthesis of a universal vaccine 
which targets the extracellular domain of the M2 protein or the stalk domain of HA, both 
of which are highly conserved and less prone to mutation. Another approach includes 
vaccines which enhance the numbers of cytotoxic lymphocytes as these target more 
conserved IAV proteins. In addition, the use of DNA vaccines against other IAV antigens 
are being explored, as well as the use of different vectors such as baculovirus expression 
systems and influenza virus-like particles [113-115]. However, the development of a 
universal vaccine still remains an elusive goal and as such, if the vaccine becomes 
ineffective, we are reliant on the second line of anti-influenza strategies - the antiviral drugs.  
The adamantanes: amantadine (Symmetrel), and rimantadine (Flumadine) were the first 
class of anti-IAV drugs approved, however, they are ineffective against IBV [116]. This 
class of drugs works by binding to the M2 ion channel and blocks the entry of protons 
into the virion, consequently inhibiting vRNP release and IAV replication [117, 118]. When 
amantadine and rimantadine were first introduced in 1966 and 1993 respectively, both 
drugs were highly successful in inhibiting IAV replication with an efficacy of up to 90% 
[119-121]. However, since 2005, resistance to adamantanes has risen exponentially to a 
point where they are no longer recommended by the CDC or WHO as an effective anti-
IAV drug [122]. Widespread resistance arose mainly due to the emergence of a single serine 
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substitution at position 31 of the M2 protein for an asparagine (S31N) [123, 124]. The 
S31N mutation and others (L26F, L38F) effect the tetramer helix-helix packing, resulting 
in the destabilization of the helix-helix assembly which decreases the pore size [125-128]. 
Other mutations (V27A, A30T/V, G43E, L38F) occur within the M2 transmembrane 
domain and results in an increase in the pore size and hydrophilicity of the channel [129-
131]. Neuraminidase inhibitors (NAIs), were the second class of approved anti-IAV drugs 
and are the only antiviral currently used against influenza. NAIs target the surface protein 
NA and function by acting as sialic acid or transition state analogous that compete with 
cell surface sialic acid-viral NA interactions and inhibit the enzymatic reaction and release 
of the newly formed IAV progeny [132-135]. This inhibits budding of the viral particle, 
preventing spread and further infection. However, similar to the M2 inhibitors, IAV has 
developed resistance to these inhibitors through mutations in several different amino acids 
within the NA protein, most notably, E119V, I222V, H274Y, R292K and N294S [136, 
137]. These mutations occur in or around the active site of NA which subsequently alters 
the architecture of the active site and reduces the binding efficiency of NAIs by many fold 
[138-142]. Zanamivir (Relenza) and oseltamivir (Tamiflu) were the first approved NAIs 
[143-146], although due to the emergence of resistance to these drugs, two related NAIs, 
peramivir and laninamivir have since been developed [147-151]. However, mutations in 
the NA have also been detected in circulating strains that confer resistance to these new 
drugs [152]. While adamantane-resistant IAV strains have become the predominant 
circulating strains, the mutations that confer resistance to NAIs occur around the NA 
active site, which commonly decreases viral fitness [153, 154]. This means that NAI-
resistant strains are often out-competed with NAI-sensitive strains in the absence of NAIs 
and so are not often maintained within the circulating population. 
However, the lack of a universal vaccine and the emergence of drug resistant strains 
highlights vulnerabilities in our preparedness against IAV outbreaks. Therefore, there is a 
pressing need to further understand the interactions between virus and host that are 
important for the IAV replication and pathogenesis in order to aid in the development of 
alternative, effective and long lasting anti-IAV strategies. One such strategy is to target the 
naturally occurring antiviral defences already present in the cell as these are capable of 
targeting nearly every stage of the virus life cycle, and are potentially less likely to be rapidly 
overcome as a result of IAV evolution.  
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1.6 Host factors and their role in IAV infection 
During the infection cycle, a virus interacts with a multitude of host factors in order to 
successfully replicate. These interactions can positively affect viral replication and are 
otherwise known as proviral host factors, while others will interfere with and inhibit viral 
replication and are known as antiviral host factors [155]. Recognizing the role that these 
host factors play in both promoting and inhibiting IAV replication would broaden our 
understanding of the virus-host interaction and could potentially uncover novel drug 
targets [156]. 
1.6.1 Proviral host factors 
Significant progress has been made in identifying many proviral host factors that are 
important in promoting IAV replication, these are summarised in Table 1. An initial 
ground breaking study using an RNA interference (RNAi) screen in Drosophila cells, was 
able to identify a plethora of host genes involved in influenza virus infection. The screen 
targeted 90% of the host genes and of these, 100 were found to either promote or inhibit 
influenza replication. Most notably, vacuolar ATPase subunit D (ATP6V0D1), 
cytochrome c oxidase subunit 6a 1 (COX6A1) and nuclear RNA export factor 1 (NXF1) 
were found to positively regulate influenza replication. Most significantly, the depletion of 
these genes resulted in a decrease in viral replication [157]. In a similar study using an RNAi 
screen, 295 host factors were identified to be involved in IAV replication of which, 219 
were considered to be essential for virus replication. A subset of 23 proteins from this list 
were found to be crucial for virus entry including members of the vacuolar ATPase family, 
coatomer protein I (COPI) family, fibroblast growth receptor (FGFR) and glycogen 
synthase kinase 3 beta (GSK3B). Additionally, 25 proteins were found to be important 
post-entry, including nuclear import components, proteases, and calcium-calmodulin 
proteins [158]. Another RNAi screen identified 135 host proteins that were regulated 
during H1N1 infection while only 81 were regulated during H3N2 infection, highlighting 
the differences in the host response to infection with IAV different strains [159]. A further 
genome-wide RNAi screen identified another 287 host factors that were important for 
IAV replication. Upon depletion of these host factors, 119 were found to inhibit the 
replication of the influenza strain A/WSN/33 and 121 inhibited the replication of the 
pandemic strain A/Hamburg/04/2009. Comparison analysis revealed that 72 of these host 
factors were common between the 2 strains, indicating their strong inhibitory potential in 
IAV infection [160]. Another study conducted a genome-wide RNAi screen using shRNA 
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and was able to identify 110 host factors important for IAV replication. Most notably, the 
study revealed the role of Itch, an E3 ubiquitin ligase that plays an important role in the 
release and transport of vRNP from the endosome into the nucleus. The knockdown of 
Itch decreased endosomal trafficking of the viral RNA and subsequently viral titres were 
reduced by up to 10 fold [161]. Itch has also been shown to play a similar role in other viral 
infections such as T-cell leukemia virus 1 [162]. A more recent study employed affinity 
purification followed by mass spectrometry in order to identify cellular proteins that 
interact with the IAV RNA-dependent RNA polymerase (RdRp). Using this method, they 
were able to identify 171 host factors involved in IAV infection consisting of chaperones, 
cytoskeletal proteins, kinases, phosphatases and ubiquitin ligases. Most importantly, they 
were able to identify that serine/threonine protein phosphatase 6 (PP6) interacted directly 
with the PB1 and PB2 complex to promote viral RNA synthesis. Unsurprisingly, when the 
researchers knocked down PP6, viral replication was inhibited [163]. Another study using 
RNAi was able to identify the importance of TNSF13, TNSF12-TNSF13 and USP47 in 
promoting IAV replication. Depletion of USP47 inhibited IAV entry, whereas silencing of 
TNFSF13 and TNFSF12-13 inhibited the late stage of IAV replication [164]. A microarray 
study was able to determine that the host factor DR1 was involved in viral RNA and 
protein synthesis and also involved in inhibiting the host innate immune response. DR1 
was found to bind directly with the viral RdRp while also inhibiting IFNβ synthesis [165]. 
Further analysis of the microarray data revealed that prodilase [166] and cathepsin W [167] 
were both important in the early stages of IAV infection by action of their dipeptidase and 
proteolytic activities, respectively. Additionally, the PI3K pathway has been shown to be 
beneficial in the early stages of IAV infection by promoting viral entry into the host cell, 
however, during the later stages of infection this pathway promotes the antiviral response 
through expression of interferon (IFN) and ISGs [168]. Another study showed that 
silencing of the squamous antigen recognized by T-cell 1 (SART1) decreased viral HA, NP 
and M2 expression as viral protein synthesis was impaired. Furthermore, they found that 
vesicular transport complex and COPI are important host factors in the secretion and 
trafficking of viral HA to the plasma membrane via the ER-Golgi transport network [169, 
170]. Recently, the nuclear protein ANP32, was shown to be essential for viral RNA 
polymerase activity, where cells depleted of ANP32 that were infected with IAV resulted 
in an approximate 70% decrease in IAV replication [171].  
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Table 1. Host factors that promote IAV replication 
 
Host Factor 





ATP6V0D1 Entry Low pH dependent entry [157] 
COX6A1 RNA replication Unknown [157] 
NXF1 RNA replication Viral RNA nuclear export [157] 
COPI Entry/late endosome Endosomal trafficking [158] 
Proteases, CTSW Late endosome HA  cleavage [158, 167] 
CAMK2B RNA replication Transcriptional regulation [158] 
Itch Late endosome 
Endosomal release of viral 
particles 
[161] 
PP6 RNA synthesis RdRp interaction [163] 
TNSF12-13 Late stage of replication Unknown [164] 
USP47 Entry Unknown [164] 
DR1 
RNA and Protein 
synthesis 
Inhibits innate immune 
response 
[165] 
Prodilase Entry Early endosome trafficking [166] 
PI3K Entry Unknown [168] 
SART1 Protein synthesis Unknown [169, 170] 
ANP32 RNA replication RdRp interaction [171] 
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1.6.2 Antiviral host factors 
Infection of host cells by viruses, including influenza viruses induces host cells to secrete 
type I IFN. An infecting virus is detected by pattern recognition receptors (PRRs) which 
recognise viral conserved components known as pathogen associated molecular patterns 
(PAMPs) [172, 173]. Depending upon the virus and the host cell that is infected, different 
pathways can be activated that lead to the secretion of type I IFN. In the case of RNA 
viruses such as influenza, there are two different classes of PRRs that detect the invading 
virus, these are Toll-like Receptors (TLRs) and retinoic acid inducible gene (RIG)-I-like 
receptors (RLR) [174, 175]. TLR3 and TLR7 are expressed in endosomal compartments 
and sense dsRNA and ssRNA respectively to promote IFN expression [176-178]. In the 
cytoplasm of cells, members of the RLR family including RIG-I and melanoma 
differentiation associated gene (MDA)-5 are capable of recognizing cytoplasmic viral RNA. 
RIG-I detects short RNA ligands with 5’-triphosphate caps which are generated during 
viral replication [172, 173] whereas MDA-5 recognizes the long genomic viral RNA 
segments and replication intermediates [179]. Generally, in airway epithelial cells (the 
primary target cell type of IAV), IFN induction in response to IAV infection is 
predominantly RIG-I dependent [179-181]. Upon intracellular sensing of viral PAMPs, 
type I IFNs are secreted from virus-infected cells which then bind to the interferon α/β 
receptor of neighbouring cells which activates the IFN signalling pathway. This signalling 
pathway results in the transcription of hundreds of ISGs and induces the cell into an 
‘antiviral state’ which limits further spread of the virus [182]. Cells have evolved a plethora 
of proteins to inhibit viral replication, some of which are mentioned below and are 
summerized in Table 2.  
1.6.2a Host factors that target viral entry 
The interferon-inducible transmembrane (IFITM) family of proteins are some of the most 
widely studied host factors that restrict IAV replication. The IFITM family consists of 
ifitm1, ifitm2, ifitm3, ifitm5 and ifitm10 with IFITM1, IFITM2 and IFITM3 recognised as 
anti-influenza host factors [183, 184]. The anti-influenza activities of IFITM3 are the most 
well studied, whereby it prevents acidification of endosomes, trapping the virions inside 
and resulting in their degradation [183, 185]. IFITM3 knockout mice studies have shown 
that they are more susceptible to IAV infection with exacerbated disease and mortality 
[185, 186]. Additionally, in humans infected with 2009 pandemic IAV, correlations have 
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been made between the enrichment of IFITM3 expression and the severity of influenza 
[186]. The role of IFITM1 and IFITM2 in IAV infection is not well understood.  
More recent studies have identified the antiviral role of zinc metallopeptidase STE24 
(ZMPSTE24), specifically against viruses that require endosomal compartments in order 
to enter the host cell [187]. Interestingly, ZMPSTE24 has been detected in association with 
IFITM protein complexes and is known to inhibit a similar assortment of viruses to the 
IFITM family of proteins. Furthermore, it has been shown that ZMPSTE24 is required 
for the antiviral activity of IFITMs, however, the exact mechanism by which ZMPSTE24 
acts is still undetermined.  
Another study used CRISPR/Cas9 technology to perform a genome-wide overexpression 
study to identify anti-IAV host factors. Using this method, they were able to show that 
upon overexpression of the glycosyltransferase B4GALNT2, cell surface attachment by 
IAV was inhibited in strains with the HA preference for α2,3-linked sialic acids [188]. It is 
believed that this inhibition is due to the activity of B4GALNT2, which adds GalNAc 
residues to the sub-terminal galactose moiety of α2,3-linked sialic acids, which impairs HA 
binding.  
1.6.2b Host factors that interfere with viral transcription and translation 
The majority of the currently identified host factors that restrict IAV replication are known 
to target the genomic replication and translation steps of the virus lifecycle. Myxovirus 
resistance (Mx) proteins are expressed in almost all vertebrates and are well known for 
their antiviral activities. In humans, Mx1 proteins display potent antiviral effects against 
IAV by targeting the vRNPs in two ways. Firstly, vRNPs are inhibited from entering the 
nucleus and so are retained in the cytoplasm [189, 190]. Secondly, the amplification of 
vRNA from cRNA is blocked, possibly through sequestering of viral NP and PB2 [191, 
192]. The biggest determinant to the viral sensitivity to Mx1 is the viral NP as this is the 
main structural component of the vRNP [191].  
Protein kinase R (PKR) is an IFN-inducible protein kinase that is activated by the presence 
and binding of dsRNA and displays broad antiviral activity against a range of viruses, 
including IAV. Upon activation, PKR phosphorylates itself and downstream substrates; 
two of the most important being eukaryotic initiation factor 2α-subunit. (eIF-2α) and IκB. 
Once phosphorylated, eIF-2α drastically impairs viral protein synthesis and as a result, viral 
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replication is inhibited. PKR also phosphorylates IκB which then goes on to activate NF-
ΚB to promote the expression of IFN genes [193].  
The 2’,5’-oligoadenylate (2-5A) synthetases (OAS) are a family of ISGs which synthesize 
2-5A, which results in RNA degradation through the activation of RNaseL. Upon binding 
to dsRNA, OAS1, 2 and 3 become activated and begin to synthesise 2-5A from ATP. The 
OAS-synthesised 2-5A then binds to cytoplasmic RNaseL and trigger its dimerization and 
subsequent activation. After becoming activated, RNaseL is then able to degrade ssRNA 
(both viral and cellular) to limit viral replication and induce apoptosis of the infected cell 
[194]. In addition, it has been shown that these degraded products can then go on to 
activate RIG-I to further promote the IFN response [195].  
There are 4 members of the IFN-induced protein with tetratricopeptide repeats (IFIT)-
family of proteins in humans, IFIT1 (ISG56), IFIT2 (ISG54), IFIT3 (ISG60) and IFIT5 
(ISG58) [196]. This family of proteins are known to directly bind with viral RNA which 
suppresses initiation of translation. Also, they bind to uncapped vRNA and can sequester 
viral proteins and RNA in the cytoplasm [197]. However, in the context of IAV infection, 
these functions remain to be determined, although it has been determined that IFIT bind 
directly with IAV RNA and that depletion of IFT1, IFIT2 and IFIT3 results in enhanced 
replication of IAV [198].  
Other antiviral host factors function by binding directly with viral proteins to inhibit their 
function. Moloney leukemia virus 10 (MOV10) is an IFN-inducible host factor that binds 
directly with IAV NP to inhibit its interaction with importin-α. This results in NP being 
retained within the cytoplasm, preventing formation of the vRNP complex [199]. In 
addition, DDX21 RNA helicase functions to inhibit the assembly of the viral RNA 
complex through interacting with PB1, reducing viral RNA and protein synthesis. 
However, DDX21 itself is the target of NS1 to impair its antiviral function and even 
promotes its interaction with other viral proteins as a means of promoting viral replication 
[200]. Plakophilin 2 (PKP2) is another host factor that competes with PB2 for binding 
with PB1 in order to reduce the activity of the IAV RdRp [201]. Cyclophilin A (CypA) is 
a member of the immunophilin superfamily that has been shown to interact with the IAV 
M1 protein [202]. Recently, this has been to accelerate the degradation of M1 via the 
ubiquitin proteasome 2 pathway [203]. Another member of this family, CypE, also interacts 
with IAV NP which interferes with NP self-association, NP-PB1 and NP-PB2 interactions 
[204]. Zinc finger antiviral protein (ZAP) is another IFN-inducible host factor that has two 
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isoforms that are expressed as a result of alternative splicing, giving rise to long (ZAPL) 
and short (ZAPS) isoforms, differing at the C-termini [205]. ZAPL is able to bind with 
IAV PA and PB2 proteins to induce their proteasomal degradation [206]. Meanwhile, 
ZAPS is able to inhibit the translation of PA, PB2 and NA through downregulating the 
viral mRNA [207]. Another IFN-inducible gene, ISG15, is an ubiquitin-like protein that 
binds covalently to target proteins through the enzymatic activity of the E1 activating 
enzyme UbE1L, the E2 conjugating enzyme UbcH8, and the major E3 ligase Herc5 [208]. 
During IAV infection, the major target of ISG15 is the viral protein NS1, whereby 
conjugation of ISG15 with NS1 impairs its functional activity [55]. The tripartite motif 
(TRIM) proteins are a group of at least 80 members that function as antiviral host factors 
through their involvement in the innate and adaptive immune responses. Many members 
of the TRIM family regulate the PRR-mediated signalling pathways induced as a result of 
viral infection. Others act as direct antiviral restriction factors such as TRIM22 which 
induces E3 ligase-dependent polyubiquitination of the IAV NP in order to induce its 
degradation via the proteasome degradation pathway [209]. Additionally, TRIM32 is 
known to bind with and ubiquitinate viral PB1, again, tagging it for proteasomal 
degradation [210].  
1.6.2c Host factors that block assembly and viral release 
There are several cellular host factors which have been identified that target the later stages 
of the IAV replication cycle. For example, cyclin D3, an important regulator of cell cycle 
has also been shown to play an antiviral role during IAV infection. Overexpression studies 
on cyclin D3 have revealed that it directly binds with viral M2, which subsequently 
interferes with M1-M2 binding, which is an important requirement for the proper assembly 
of viral progeny [211]. 
Bone marrow stromal cell antigen (BST)-2 is an IFN-inducible protein that inhibits the 
release of IAV from the surface of infected cells [212]. BST-2 is a transmembrane protein 
that is able to tether enveloped viruses including IAV to the plasma membrane of the host 
cell, however, in the context of IAV, the inhibitory effects appear to be strain specific [213, 
214].  
Viperin (virus inhibitory protein, endoplasmic reticulum-associated, interferon inducible) 
is another host factor which has been shown to inhibit virus replication by several 
mechanisms [215]. In the case of IAV, viperin acts on the later stage of the lifecycle by 
preventing virion release from the plasma membrane. Viperin reduces biosynthesis of 
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isoprenoids and thereby disrupts lipid raft formation which IAV uses to bud from the 
plasma membrane [216]. 
Plasminogen activator inhibitor 1 (PAI-1) is an ISG that inhibits IAV spread through its 
ability to inhibit airway proteases required to cleave IAV HA glycoprotein, which is an 
important step in that maturation of the protein. In humans, complete or partial depletion 
of PAI-1 due to genetic polymorphism in the SERPINE1 gene leads to increased 
susceptibility to IAV in vitro [217]. PAI-1 is the first ISG shown to inhibit IAV replication 
within the extracellular environment.  
1.6.3 Histone deacetylases, a recently discovered family of antiviral host factors 
Recently, there has been growing interest in a class of cellular enzymes known as histone 
deacetylases (HDACs) and their emerging role in a number of human diseases including 
cancer [218], neurodegenerative [219] and cardiovascular complications [220] and various 
other diseases [221]. Interestingly, there is growing evidence for the role of HDACs in viral 
infection with numerous studies identifying their dual role in both promoting and 
inhibiting viral infections [222, 223]. Recently, our lab has identified the role of several 
different HDACs and the inhibitory role they play against IAV infection. Currently, we 
have shown that HDACs 1, 2, 6 and 11 all play antiviral roles during IAV infection, and 
that they themselves are targeted by IAV to downregulate their expression, likely as means 
to reduce their antiviral function [79, 224-226].  
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Table 2. Host factors that inhibit IAV replication 
  
Host Factor 






Prevents acidification of the 
endosome 
[183, 187] 
MX1 RNA replication Interferes with viral RdRp 
[189, 190, 
191, 192] 
eiF-2α Viral protein synthesis Inhibits translation [193] 
OAS RNA replication 
Degradation of viral RNA via 
RNaseL activity 
[194] 
IFIT1, 2, 3, 5 Viral protein synthesis 
Bind to viral RNA and 
prevent translation 
[196, 197] 
MOV10 RNA replication 
Prevents NP from entering 
nucleus, inhibiting vRNP 
complex formation 
[199] 
DDX21 RNA replication 
Inhibits vRNP complex 
formation by binding PB1 
[200] 
PKP2 RNA replication 
Competitively binds PB1, to 
prevent RdRp formation 
[201] 
CypA/E RNA replication 
Prevents NP binding with 
PB1 and PB2, preventing 
RdRp formation 
[204] 
ZAPS RNA replication 
Inhibits viral mRNA  
synthesis 
[207] 
ISG15 Viral replication 
Cellular protein conjugation 
and antiviral defence 
[208] 
TRIM32 Viral replication 
Induces proteasomal 
degradation of viral NP and 
PB1 
[209, 210] 
Cyclin D3 Virion assembly 
Interferes with M1-M2 
binding, inhibiting proper 
virion assembly 
[211] 
BST-2 Virion release 
Tethers enveloped viruses to 
the plasma membrane 
[213, 214] 
Viperin Virion release 
Reduces synthesis of lipid 
rafts needed for budding 
[216] 
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Section B – Histone Deacetylases (HDACs) 
 
HDACs are a family of enzymes that were originally discovered to regulate gene expression 
by inducing conformational changes in the structure of chromatin. Chromatin is a highly 
condensed and packed structure comprised of a dynamic-protein DNA complex. 
Chromatin is comprised of nucleosomes which are made up of core histones (H2A, H2B, 
H3 and H4). The posttranslational modification of these histones can cause changes in 
gene expression and chromatin structure. One of the most common modifications of 
histones (and the first discovered) is acetylation, which occurs at the ε-amino group of 
lysines. The acetylation of these lysine residues is a reversible process under the influence 
of two families of enzymes. Acetylation of these histones is under the influence of the 
histone acetyl transferases (HATs), while removal of the acetyl groups is catalysed by the 
HDACs [227]. The acetylation reaction is processed by generating acetyl groups from 
Acetyl-CoA which is generated as a result of cellular metabolism. Acetyl groups are 
negatively charged and the addition of these groups generates a repulsive force between 
the histones and the DNA [228]. This opens the DNA to becoming more accessible to 
transcription factors, thereby promoting expression of genes [228, 229]. In contrast, 
deacetylation of histones induces the histone-DNA complex to become more condensed, 
thus inhibiting transcription factor binding and silencing gene expression [230]. However, 
recent findings have shown that the activity of HDACs can also be associated with active 
gene transcription [231-233]. In addition, HDACs have also now been shown to 
deacetylate non-histone proteins, indicating a highly diverse role for this family of enzymes 
[234].  
 
1.7 Classification of HDACs  
HDACs are evolutionarily conserved enzymes found in plants, animals, fungi and bacteria 
[235]. In humans, there are 18 different HDACs which are grouped into 4 separate 
categories referred to as classes based upon their structure, enzymatic activity, intracellular 
localisation and expression pattern (Figure 4) [236, 237]. The Class I, II and IV HDACs 
are considered ‘classical HDACs’ and their activity is zinc dependent whereas the Class III 
HDACs require NAD+ for their enzymatic activity [238-241]. The Class I HDACs 
(HDAC1, HDAC2, HDAC3, and HDAC8) have sequence similarity to the yeast 
equivalent, Rpd3 protein. They are generally located in the nucleus and are ubiquitously 
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expressed. However, recent studies have shown that HDAC3 expression is restricted to 
certain tissues and that these HDACs can be localized to the cytoplasm [242, 243]. The 
Class II HDACs (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10) have 
sequence similarity to the yeast equivalent, Hda1 protein. The Class II HDACs are 
ubiquitously expressed but with enriched expression in specific tissues which varies 
depending on the Class II HDAC. Interestingly, these HDACs show mixed subcellular 
distribution, with all showing at least some cytoplasmic distribution, indicating a 
cytoplasmic role for all Class II HDACs. The divergence of the Class I HDACs and the 
Class II HDACs appears to have happened relatively early on in the evolutionary history 
of these proteins. In fact, because of their diversity, the Class II HDACs have since been 
further subdivided into subclasses; Class IIa (HDAC4, HDAC5, HDAC7 and, HDAC9) 
and Class IIb (HDAC6 and HDAC10). The Class III HDACs, also known as Sirtuins, 
(SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, and SIRT7) have sequence similarity to the 
yeast equivalent Sir2 protein. Sirtuins are different from the classical HDACs in that they 
have two enzymatic activities: mono-ADP-ribosyltransferase and histone deacetylase. 
Another interesting characteristic is their cellular distribution, with SIRT1 and SIRT2 
found in the nucleus and cytoplasm, SIRT3 in the nucleus and mitochondria, SIRT4 and 
SIRT5 found only in the mitochondria, SIRT6 only in the nucleus and SIRT7 in the 
nucleolus. In a similar fashion to the classical HDACs, sirtuins also have non-histone 
substrates. The sole member of the Class IV family, HDAC11, shares little sequence 
similarity with Class I and Class II HDACs, however, it possesses all 9 catalytic sites 
required for deacetylase activity [244]. HDAC11 exhibits enriched expression in the kidney, 




Figure 4. Classification of human HDACs. The HDACs are classified into 4 classes. The 
number of amino acid residues is depicted on the right of each protein. Enzymatic domains are 
shown in their respective colours. Note, nuc – nucleous, cyt – cytoplasm, mito – mitochondria. 
Adapted from [430]. 
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1.8 Traditional physiological roles of HDACs 
The most obvious function of HDACs is that they oppose the functions of the HATs, 
which is a crucial part of maintaining the dynamic equilibrium of protein 
acetylation/deacetylation. Deacetylation of histones and non-histone proteins induces 
chromatin conformational changes or can alter the activity of transcription factors resulting 
in significant changes in gene expression. A high-resolution mass spectrometry analysis 
identified at least 3,600 acetylation sites in 1,750 histone and non-histone proteins within 
the cell [245]. Therefore, the molecular changes induced by HDACs can have significant 
impacts on cellular function and as such, play important roles in health and disease. 
1.8.1 HDACs indirectly control many post-translational modifications 
The lysine ε-amino group is capable of receiving many different PTMs, including 
acetylation, methylation, ubiquitination, sumoylation, neddylation, propionylation, 
butyrylation, and crotonylation [246]. Therefore, acetylation of the ε-amino group excludes 
other modifications on the same residue. In this way, HDACs act indirectly to promote 
the regulation of other modifications which can drastically alter how a protein behaves 
within the cell. For example, acetylation is known to inhibit ubiquitination, which can lead 
to proteasome-mediated degradation of the ubiquitinated protein [247]. Consequently, 
HDACs can indirectly accelerate the degradation of proteins by exposing ε-amino group 
for ubiquitination. HDACs are also important regulators of histone and chromatin 
crosstalk through regulating histone acetylation and methylation. For example, acetylation 
of lysine 9 of histone 3 (H3K9) inhibits methylation at the same residue and also promotes 
methylation at the lysine 4 residue (H3K4) [248]. Subsequently, the combination of these 
modifications induces the chromatin structure to become more accessible, promoting 
transcription activation. Therefore, HDACs that deacetylate H3K9 inhibit H3K4 
methylation, and ultimately repress transcription. The role of the different HDACs is 
summerized in Table 3. 
1.8.2 HDACs control gene transcription 
The traditional view of acetylation regulating transcriptional activity dictated that 
acetylation of core histones reducing DNA binding, making the DNA more accessible for 
transcription. Alternatively, histone deacetylation strengthens histone-DNA interactions, 
thereby repressing transcription [249]. However, recent evidence is now indicating a role 
for acetylation/deacetylation providing a specific docking surface for proteins. In other 
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words, acetylation of histones might induce interactions with transcriptional activators 
while deacetylation creates binding sites for transcriptional repressors. Interestingly, it 
appears that HDACs are capable of repressing transcription, independent of their 
deacetylase activity as determined in a recent study on HDAC5 and HDAC7 [250]. 
Furthermore, recent evidence shows that transcriptional repression may also be 
determined by the particular lysine residue that HDACs deacetylate. For example, 
deacetylation of H4K16 may result in global transcription repression, while deacetylation 
of H4K5, H4K8, or H4K12 alone has little effect, but in combination has a cumulative 
effect on transcription [251]. Finally, there is growing evidence that suggests HDACs may 
not only repress transcription, but can actually promote transcription of certain genes. For 
example, HDAC3 represses transcription when targeted to promoters but in contrast, it is 
also required for the transcription of at least one class of retinoic response elements [252, 
253]. In support of this, cells derived from Hdac3 knockout mice show both upregulation 
and downregulation of gene expression [254]. Furthermore, gene expression profiles of 
cells treated with HDAC inhibitors compared to untreated cells showed similar levels of 
gene upregulation as the Hdac3 knockout derived cells [255]. It is possible that HDACs 
may downregulate transcription of transcriptional repressors, indirectly promoting gene 
expression. Another possibility is that HDACs may deacetylate and therefore, activate 
transcriptional activators or alternatively inhibit the activity of transcriptional repressors 
independent of modifying histones. Regardless, it is obvious that HDACs are clearly 
diverse in their role in controlling gene transcription, however the exact mechanisms of 
these activities remains to be determined.  
1.8.3 The importance of HDACs in health and disease 
Given the degree with which HDACs affect gene expression as well as their effects on 
protein function through non-histone deacetylation, it is unsurprising that HDACs have 
been implicated in almost every aspect of human health and disease. Most noteworthy are 
the roles HDACs have been shown to play in development, cancer, neurodegenerative 
diseases, immunological disorders, cardiac diseases and pulmonary diseases [221].  
1.8.3a Class I 
HDAC1 has been implicated in playing an essential role in cell cycle progression [256, 257], 
proliferation and differentiation [258, 259], adipogenesis [260], muscle development [231, 
261], and autophagy [262]. HDAC1-null mice die before embryonic day 10.5 and display 
severe cardiac abnormalities [231, 259]. In addition, knockdown of hdac1 in zebrafish 
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results in a variety of lethal defects in skeletal and neuronal development [263-267]. 
HDAC1 has also been shown to play a role in intestinal metabolism through regulation of 
the levels of acetylation of certain inflammatory genes in order to minimise metabolic stress 
and an impaired response to oxidative stress. HDAC1 has also been linked to nutrient 
sensing and metabolism through activation of the adenosine monophosphate activated 
kinase [268].  
HDAC2 has been defined as playing a major role in cell differentiation and proliferation 
[256], with HDAC2 knockout mice being only partially viable, depending on the knockout 
allele. Knockout of HDAC2 usually results in severe cardiac defects leading to cardiac 
hypertrophy [231]. Dysregulated HDAC2 expression has also been linked to several 
different cancers including gastric, colon and prostate cancer [269-271]. Additionally, 
HDAC2 activity has been reported to be important for normal brain development, which 
otherwise can result in perinatal lethality [272].  
Loss of HDAC3 in the liver results in the disruption of lipid and cholesterol homeostasis 
leading to an accumulation of lipids and a decrease in glycogen storage [273]. Additionally, 
deletion of HDAC3 in cardiomyocytes has been shown to lead to a significant increase in 
lipid storage in the heart, resulting in massive cardiac hypertrophy [274]. HDAC3 has been 
shown to be important in promoting various cancers including pancreatic, colon, breast 
and ovarian [275-278]. 
HDAC8 has been identified as an important mediator of normal cranial development, 
where HDAC8-knockout mice die during the perinatal period as a result of skull instability 
leading to brain trauma [279]. HDAC8 is expressed in several cancer tissues, including 
colon, breast, lung and pancreas. Knockout of HDAC8 by RNAi, inhibits proliferation of 
human lung, colon and cervical cancer cell lines, whereas upregulation of HDAC8 
promotes proliferation [280-282].  
1.8.3b Class IIa 
HDAC4 has been highly implicated for its role in the development of the skeleton [283]. 
Mice with a global deletion of HDAC4 die early on due to ectopic ossification of 
endochondral cartilage, which prevents expansion of the ribcage which prevents normal 
breathing. Furthermore, HDAC4 has been implicated in the pathogenesis of Huntington’s 
disease as well as other neurodegenerative diseases [284]. HDAC4 has also been shown to 
be associated with several forms of cancer including colonic and gastric cancer [285, 286]. 
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HDAC5 is important in protecting against cardiac hypertrophy as a study showed that 
HDAC5 knockout mice develop cardiac hypertrophy with age in response to excess 
workload or neuronal signalling [287]. Cytoplasmic accumulation of HDAC5 is necessary 
for axon regeneration, as expression of an HDAC5 mutant which is only present in the 
nucleus, interferes with axon regeneration [288]. This is consistent with the role that 
HDAC5 is known to play in controlling memory function with the dysregulation of 
HDAC5 being linked to Alzheimer’s disease [289].  
HDAC7 is highly expressed in developing thymocytes at the CD4+ and CD8+ double-
positive stage [290]. More recently it was shown that deletion of HDAC7 results in a 
significant reduction in the survival or positive selection of single-positive CD4+ 
lymphocytes [291]. In addition to its role in T cell development, HDAC7 has also been 
shown to be important in the development of B lymphocytes [292]. It is believed that 
HDAC7 is an important transcriptional repressor of lineage-inappropriate genes in B 
lymphocytes, however the effects of this in vivio remain to be established.  
In a similar fashion to HDAC5, HDAC9 has also been reported to be important for 
protecting against cardiac hypertrophy. In fact, a combined deletion of both HDAC5 and 
HDAC9 genes in mice show a propensity for lethal ventricular septal defects and thin-
walled myocardium, both of which arise from abnormal growth and maturation of 
cardiomyocytes [287]. Recently, HDAC9 has also been linked to neuronal physiology and 
pathology. HDAC9 is expressed in the mouse cerebellar cortex during postnatal cortical 
development. During development of postnatal cortical neurons, HDAC9 is exported to 
the cytoplasm leading to the expression of the c-Fos gene which promotes dendritic growth 
[293]. In the context of neuronal pathology, the effects of HDAC9 depletion in mice 
remains to be determined. Tt has been reported that in patients with schizophrenia, 
HDAC9 is hemizygously deleted suggesting a link between HDAC9 and schizophrenia 
[294].  
1.8.3c Class IIb 
HDAC6 is a unique enzyme within the HDAC family owing to the fact that it possesses 2 
catalytic domains. While HDAC6 knockout mice are viable, aberrant expression of 
HDAC6 has been linked to certain pathological conditions. In particular, abnormal 
HDAC6 expression has been linked to neurodegenerative diseases, including Alzheimer’s 
disease, Parkinson’s disease and Huntington’s disease [295]. Overexpression of HDAC6 
has also been implicated in tumorigenesis, cell survival and tumour metastasis [296-298].  
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HDAC10 has been reported to be involved in homologous recombination, melanogenesis, 
cell autophagy, cell cycle regulation and DNA mismatch repair [299-303]. Additionally, 
HDAC10 has been shown to be involved in a number of different carcinomas, a recent 
study showed that overexpression of HDAC10 promotes lung cancer growth. Conversely 
they showed that knockdown of HDAC10 induces G1 arrest and apoptosis in lung cells 
[304].  
1.8.3d Class III  
SIRT1 mainly regulates cellular metabolic patterns, while its own activity is influenced by 
nutrient availability, specifically, induction during under-nutrition [305]. SIRT1 performs a 
variety of functions, including mitochondrial biogenesis as well as catabolism of 
triglycerides and cholesterol in the liver, skeletal muscles and adipose tissue [306, 307]. 
Furthermore, it inhibits glycolysis while also activating gluconeogenesis and fatty acid 
oxidation in most tissues [308, 309]. Several studies have linked lack SIRT1 to an increase 
in susceptibility to diet-induced obesity [310]. SIRT1 has also been shown to be involved 
in carcinogenesis through its activity in promoting DNA damage repair, inhibiting chronic 
inflammation, downregulation of the HIF-1α and upregulation of another sirtuin – SIRT6 
[311-313]. 
In humans SIRT2 is mainly active in the cytoplasm, where one of its main substrates is the 
α-tubulin in microtubules [314]. SIRT2 has similar effects to SIRT1 on carbohydrate and 
lipid metabolism by promoting gluconeogenesis and inhibiting adipocyte differentiation 
[315]. Knockout studies of SIRT2 reveal that SIRT2-deficent mice show increased 
prevalence and incidence of cancer [316]. Furthermore, SIRT2 also possesses anti-
inflammatory functions through repression of nuclear factor KB (NF-KB) [317]. 
SIRT3 is located in the mitochondria and has a number of mitochondrial substrates 
including: complex I, complex III, manganese superoxide dismutase (MnSOD) and 
isocitrate dehydrogenase [318, 319]. The deacetylase activity of SIRT3 is known to increase 
the efficacy of the electron transport chain, preventing production of reactive oxygen 
species (ROS) from oxidative phosphorylation byproducts [320]. In addition, SIRT3 
activates MnSOD, which facilitates the further removal of ROS from cells [321]. 
Deficiency of SIRT3 is characterized by an increase in ROS which induces DNA damage 
and activation of the HIF-1α transcription factor, thus it is believed that SIRT3 possesses 
cancer-preventative functions [322, 323]. 
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SIRT4 is thought to regulate ATP homeostasis and to provide retrograde signalling from 
the mitochondria to the nucleus. SIRT4 activity within the mitochondria improves the 
efficacy of ATP synthesis by inhibiting the oxidative phosphorylation uncoupler – ANT2 
[324]. During the cell response to DNA damage, SIRT4 activity enables the use of the 
glutamine-derived nitrogen atoms in the purine nucleotide synthesis which is essential for 
DNA repair [325]. Loss of SIRT4 promotes the accumulation of DNA damage through 
impairment of the DNA repair system. As such, SIRT4 knockout mice have increased 
susceptibility to cancers, in particular lung tumours [326].  
SIRT5 promotes the urea cycle by activating carbamoylophosphate synthetase with SIRT5 
deficient mice exhibiting elevated levels of ammonia in the blood [327]. SIRT5 has also 
been shown to be involved in decreasing cellular ROS concentrations by activating CU/Zn 
superoxide dismutase 1 [328].  
SIRT6 plays a key role in mediating DNA repair and genomic stability by integrating the 
actions of DNA-damage signalling factors with recruitment of DNA repair enzymes, 
particularly during oxidative stress [329]. SIRT6 knockout mice die within 4 weeks due to 
severe metabolic disorders such as: loss of subcutaneous fat, lordokyphosis, colitis, 
lymphopenia, osteopenia and progressive hypoglycaemia [330]. Additionally, SIRT6 has 
been identified as a potent tumour suppressor through suppression of cancer metabolism 
[331]. In fact, overexpression of SIRT6 causes profound apoptosis in cancer cells but not 
in normal cells [332]. 
SIRT7 is a nuclear protein where it promotes rDNA transcription, particularly in 
proliferating cells [333]. Global SIRT7 depletion has been linked to premature aging, 
especially in certain tissues such as the backbone, white adipose tissue and the heart [334]. 
Contrastingly, elevated levels of SIRT7 have been associated with aggressive cancer 
phenotypes, metastatic disease and poor patient prognosis [335].  
1.8.3e Class IV 
HDAC11 is the sole member of the Class IV HDAC family and it shares similarities 
between both Class I and Class II HDACs [244]. HDAC11 has been defined as having an 
important role in immune cells. Elevated levels of HDAC11 have been observed in 
neutrophils as compared to other innate immune cells, and increased levels of HDAC11 
correlate with more aggressive neutrophil phenotypes [336]. Depletion of HDAC11 in T 
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cells enhances their proliferation, inflammatory cytokine production and become less 
responsive to suppression by regulatory T cells [337].  
 
1.9 Emerging role of HDACs in virus infection 
While considerable research has looked into the role HDACs play in physiological diseases, 
emerging research is now looking into the role they play in infectious diseases, particularly 
viral infections. HDACs have been shown to have differential roles during viral infections 
which is dependent on the nature of the virus infection. During chronic infection HDACs 
appear to promote viral latency and thereby allowing the infection to persist whereas 
during an actively replicating viral infection, HDACs promote the antiviral immune 
response through promotion of the IFN immune response. Additionally, new research is 
being done by combining HDAC inhibitors with oncolytic viral therapy to enhance tumour 
cell killing. The role of HDACs in viral infections is summerised in Table 3.  
1.9.1 Role in chronic viral infections and promoting viral latency 
The nature of chronic virus infections means that much of the life cycle of the virus is 
present in a latent stage, whereby no active virus replication is carried out. In this state, 
viruses can hide from the immune system, allowing the virus to persist within an infected 
individual, in some cases indefinitely. Under certain conditions the virus can switch from 
a latent infection to an active infection where new viral progeny is produced, often resulting 
in the infected individual becoming symptomatic and infectious. Numerous studies have 
reported on the role of HDACs in chronic viral infections as they are often portrayed as 
promoters of latency. Further research is being carried out looking into the role of using 
HDAC inhibitors combined with antiviral drugs in order to enhance the antiviral therapy 
[222].  
After gaining entry into the host cell, the human immunodeficiency virus (HIV) carries out 
reverse transcription of its RNA and integrates the newly transcribed DNA into the 
infected cells genome. It is now well understood that epigenetic modifications and changes 
in chromatin structure directly govern viral promoter activity to influence viral latency and 
reactivation. In this regard, HDACs have been highly studied in their role in promoting 
latency of HIV. HDAC1, HDAC2 and HDAC3 are all known to be recruited by various 
transcription factors including COUP-TF interacting protein, c-promoting binding factor-
1, c-myc and Sp1 to the HIV long terminal repeat (LTR) promotor [338-340]. Upon 
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recruitment to the LTR, these HDACs deacetylate histone proteins locally which leads to 
transcriptional silencing of viral genes.  
During hepatitis B virus (HBV) infection of hepatocytes, the virus induces expression of 
many pro-survival genes often linked with tumour growth and metastasis. One of the key 
HBV proteins responsible for inducing the expression of these genes is the HBx protein. 
HBx is known to induce HDAC1 to form a complex with Sp1, resulting in the 
deacetylation of Sp1 and reduced transcription of insulin-like growth factor binding 
protein 3 (IGFBP3-). The outcomes of these epigenetic changes promotes cell survival 
and proliferation allowing chronic HBV infections to develop [341]. In addition, HBx 
induces a complex to form between HDAC1/2 and metastasis-associated protein 1 
(MTA1) to stabilise HIF-1α which is believed to play an important role in angiogenesis and 
metastasis of HBV-associated hepatocellular carcinoma [342]. SIRT1 has been shown to 
be significantly upregulated during HBV infection and that SIRT1 enhances HBV core 
promoter activity through association with transcription factor Ap-1 which is important in 
promoting cell survival and inhibiting apoptosis [343]. Meanwhile depletion of SIRT1 has 
been shown to inhibit HBV replication [344].]. SIRT2 has also been shown to be 
upregulated during HBV infection by the activity of HBx. This upregulation of SIRT2 has 
been shown to promote HBV transcription and replication [345]. 
Epstein-Barr virus (EBV) is a gammahepresvirus that establishes latent infection, 
predominantly in B lymphocytes. Class I HDACs have been implicated in maintaining 
EBV latency, with several studies demonstrating the use of pharmacological inhibitors of 
these HDACs inducing reactivation [346]. Furthermore, HDAC1, HDAC2 and HDAC3 
have been found to be overexpressed in EBV-infected cells as compared to healthy cells 
[347].  
Changes in chromatin structure have also been reported to be important in regulating the 
latency of herpes simplex virus (HSV). An early study using the general HDAC inhibitor 
trichostatin A (TSA) on latently infected neurons revealed that the activity of the viral 
immediate early promoter increased substantially [348]. More recently, studies have been 
able to demonstrate that the HSV immediate early regulatory protein ICP0 is important 
for stimulating the initiation of the lytic cycle through inhibiting HDAC activity. 
Specifically, ICP0 dissociates HDAC1 and HDAC2 from the CoREST/REST complex 
which is normally bound to the viral genome, inhibiting viral gene expression [349]. 
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Permissiveness for human cytomegalovirus (HCMV) infection is dependent on the state 
of cellular differentiation and is linked to the repression of the viral major immediate early 
promoter (MIEP). HDAC1 has been shown to promote HCMV latency by interacting 
with the viral immediate early (IE) protein IE86 which results in repression of MIEP [350]. 
Meanwhile, HDAC3 is the target of IE1 and IE2, which antagonize HDAC3 to promote 
viral replication [351]. Contrastingly, the sirtuins appear to play an antiviral role during 
HCMV infection as siRNA-mediated knockdown of each of the sirtuins promotes HCMV 
infection [352].  
1.9.2 Role in acute viral infections and the innate antiviral response 
During acute viral infections, HDACs are primarily involved in regulating the host innate 
antiviral response, as they can act as co-activators and co-repressors of gene transcription. 
HDACs are known to positively regulate Toll-like receptor responses by regulating 
transcription factor function [353]. Members of the interferon response element (IRF) 
family such as IRF7 can be acetylated within their DNA binding domain, which is 
associated with impaired DNA binding. Thus, it is believed that deacetylation of IRF family 
members is important for IRF nuclear translocation and DNA binding, however the 
specific HDACs that are responsible for this remain unknown [354]. HIF-1α is another 
pro-inflammatory transcription factor that has been shown to be regulated via interactions 
with HDAC1, HDAC3, HDAC4, HDAC6 and HDAC7 to positively regulate its function 
[355, 356]. Another transcription factor which is involved in the antiviral response is NF-
KB. NF-KB can be deacetylated within the nucleus which promotes its nuclear export, 
attenuating its activity [357]. In addition, HDAC activity has been implicated in regulating 
the type I IFN response. Acetylation of the IFNα receptor leads to decreased association 
with IFNα, however this is reversed by the deacetylase activity of HDAC3 which enhances 
IFNα binding [358]. STAT proteins have been observed to directly interact with HDACs 
and inhibition of HDAC activity leads to hyperacetylation of STAT [359]. Several studies 
have revealed that HDAC activity is required for STAT-dependent gene expression. In 
particular, during the antiviral immune response, IFN-induced STAT1 and STAT2 
signalling is significantly impaired after general HDAC inhibition [360]. Importantly, 
during infection, many viruses are able to actively target these HDACs as a means to 
antagonise their antiviral function. 
During Japanese Encephalitis Virus (JEV) infection HDAC3 mediates the antiviral 
response by deacetylating NF-KB to promote its activation. In response, HDAC1, 
40 
HDAC2 and HDAC3 are all downregulated during infection after 12 and 24 hours of 
infection with JEV which corresponds with a decrease in NF-KB activation [361]. In 
contrast, HDAC6 appears to promote JEV replication as treatment with specific HDAC6 
inhibitors but not general HDAC inhibitors reduced JEV replication [362].  
During adenovirus infection HDAC1 activity inhibits virus replication through some 
unknown mechanism. However, adenovirus encodes an early gene product known as 
Gam1 which binds to HDAC1 and inactivates it [363].  
HDAC5 has been shown to be an important antiviral factor that restricts vaccinia virus, 
likely through the promotion of many ISGs. In turn, the vaccinia virus early protein C6 
targets HDAC5 for proteasomal degradation [364]. Furthermore, the use of the general 
HDAC inhibitor TSA has been linked with enhanced vaccinia virus growth, both in vitro 
and in vivo [365].  
Many of the HDACs have been reported to be involved in restricting influenza virus 
replication. HDAC1 and HDAC2 have both been shown to modulate the innate immune 
response to restrict IAV replication. However, they themselves are targeted by IAV to 
antagonise their antiviral function [225, 226]. HDAC6 is also known to restrict IAV in 
several ways. Firstly, it interferes with the trafficking of viral components destined for 
assembly through deacetylation of acetylated microtubules [79]. Secondly, it promotes the 
innate immune response by deacetylating RIG-I which enhances its viral-RNA sensing 
activities [366]. Depletion of HDAC6 impairs the cellular immune response to influenza 
and HDAC6 knockout mice are much more susceptible to influenza infection [367]. 
Finally, a recent study showed that HDAC6 impairs the activity of the IAV PA protein in 
two ways. HDAC6 deacetylates PA which suppresses viral RNA polymerase activity and 
subsequently viral replication. HDAC6 also induces the ubiquitination of PA which 
induces its degradation via the proteasomal pathway [368]. In order to minimise the 
antiviral potential of HDAC6, IAV induces its degradation via caspase 3 activity [369]. 
HDAC8 has also been reported to play a role in IAV infection as expression of the micro 
RNA miR-21-3p actively downregulates HDAC8 expression leading to enhanced IAV 
replication [370]. All members of the class III HDAC family have been shown to have 
anti-IAV properties as the knockdown of each member of this family promoted IAV 
replication [352]. Recently, HDAC11 has been identified as part of the host innate anti-
IAV immune response. Depletion of HDAC11 by RNAi resulted in greater IAV 
replication and decreased ISG expression during infection. Furthermore, IAV infection 
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induced a significant reduction in HDAC11 mRNA during infection, likely as a means to 
counteract its role in promoting ISG expression [224]. 
1.9.3 Role in oncolytic viral infection 
HDAC inhibitors have been recognised for their ability to weaken the cellular anti-viral 
immune response by impairing IFN and IFN-inducible gene expression. Therefore, several 
studies have looked into using HDAC inhibitors in combination with oncolytic viral 
therapy in order to supress the immune system in tumour cells to improve viral replication 
and ultimately destruction of the tumour cells.  
Vesicular stomatitis virus (VSV)Δ51 is a naturally occurring VSV variant which contains a 
deletion in the M gene, which renders the virus unable to counteract the IFN response in 
cells [371]. Therefore, VSVΔ51 replication and lytic activity can only occur in cancer cells 
with defective IFN responses, however some cancer cells possess residual IFN activity 
capable of restricting VSVΔ51 growth. In order to overcome this constraint, two HDAC 
inhibitors, vorinostat and MS-275 have been used in combination with VSVΔ51 in order 
to inhibit IFN-inducible gene expression. Both inhibitors were able to enhance growth of 
VSVΔ51 and promote the intrinsic apoptotic pathway, resulting in a synergistic induction 
of cancer cell death. These effects were accompanied by vascular shutdown, resulting in 
reduced blood flow within the tumour mass [372]. These inhibitors were shown to interfere 
with NF-KB signalling, suppressing the IFN-response and subsequently promoting VSV 
replication and apoptosis [373].  
Otuski et al. carried out a study using the HSV-1 oncolytic variant rQNestin34.5 in 
combination with the HDAC inhibitor valporic acid in glioma-derived cell lines [374]. 
rQNestin34.5 contains the RL1 gene which encodes the viral virulence factor ICP34.5 
which is under the control of the glioma-specific nestin promoter [375]. The study revealed 
that pre-treatment with valporic acid suppressed transcription of antiviral ISGs such as 
STAT1, PKR and promyelocytic leukemia (PML), which was sufficient to enhance HSV 
gene expression, replication and cytotoxicity. Another study used the general HDAC 
inhibitor TSA to enhance HSV replication and oncolytic activity of another HSV variant, 
R849 which lacks the virulence factor ICP34.5. Here, TSA treatment resulted in the 
enhanced activation of NF-KB as well as upregulation of p21 which induced G1 cell cycle 
arrest to inhibit tumour cell growth [376]. 
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The combination therapy of using oncolytic adenoviruses and HDAC inhibitors has 
become an attractive strategy for improving oncolytic viral therapy. Ad5 is the most 
commonly used oncolytic virus variant which infects host cells through the cellular 
coxsackievirus and adenovirus receptor (CAR) and α-integrin which mediate cell 
attachment and internalization respectively. However, in cancer cells CAR is often 
expressed at lower levels which impairs viral binding and consequently hampers the anti-
tumour efficacy of Ad5. Recently, a number of HDAC inhibitors have been reported to 
increase the infectivity of AD5 by promoting the expression of CAR and αvintegrin in 
various cancer cell lines [377-383]. Furthermore, this induced expression of CAR and 
αvintegrin appears to preferentially occur in cancer cells which minimises potential off-
target effects with Ad5 infecting normal cells [378, 379, 381].  
Vaccinia virus has also been shown to have enhanced oncolytic activity in combination 
with HDAC inhibitor treatment. TSA was found to be the most potent HDAC inhibitor 
by increasing vaccinia virus replication and tumour cell killing activity [365]. While pre-
treatment with IFN protected cancer cells from vaccinia virus infection, TSA treatment 
attenuates this protection and rescues vaccinia virus infectivity. Interestingly, TSA did not 
counteract the IFN response in normal cells, highlighting the specificity for cancer cells. 
Several cancer cell types have been tested with TSA co-treatment with vaccinia virus 
including lung and colon cancer cells [384, 385].  
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1.10 Aim of Thesis 
This research set out to uncover the role of class IIa HDAC, HDAC4 in the context of 
IAV infection which has not previously been reported. Given the previous work done in 
our lab where we have identified the anti-IAV role of several other HDACs, we 
hypothesized that HDAC4 is also an anti-IAV host factor. The first results chapter 
(Chapter II) aims to identify if HDAC4 possesses an inherent antiviral function using 
RNAi and HDAC4 overexpression studies to determine the effect on IAV replication. 
Chapter III then goes on to explore the antiviral function of HDAC4 in greater detail to 
understand the mechanism by which HDAC4 is able to exert its antiviral potential through 
regulation of the innate immune response. Finally, Chapter IV looks at how IAV targets 
HDAC4 to dysregulate its antiviral function by inducing degradation of the HDAC4 
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HDAC4 is a member of the class IIa in HDAC family which are characterised by a large 
N-terminal extension with conserved binding sites for the transcription factor MEF2 and 
the chaperone protein 14-3-3. HDAC4 is ubiquitously expressed with enriched expression 
in the brain, heart and skeletal tissues [386, 387]. HDAC4 has been shown to play a central 
role in the formation of the skeleton and is highly expressed in pre-hypertrophic 
chondrocytes in vivo. Mice with a global deletion of HDAC4 gene die during the perinatal 
period due to abnormal and premature endochondral ossification which prevents 
expansion of the rib cage and leads to an inability to breathe [283]. While HDAC4 is most 
characterised for its role in bone development, it is also known to play an important role 
in other tissues and its aberrant expression is linked to a number of health complications 
including heart disease, neuronal degeneration and cancer [388].  
2.1.1 Physiological functions of HDAC4 
HDAC4 regulates the expression of genes involved in cell growth, survival and 
proliferation, with abnormal expression resulting in aberrant physiology and death. 
HDAC4 is most well characterized for its role in regulating chondrocyte hypertrophy and 
endochondral bone formation through inhibiting the activity of MEF2C and Runx2 [283, 
389]. MEF2C regulates the expression of extracellular matrix proteins including collagen 
type X alpha 1 and vascular endothelial growth factor which are both important for the 
late stages of chondrocyte development [390-392]. Runx2 is important in the expression 
of the secreted growth factor Indian hedgehog which is important in enhancing 
chondrocyte proliferation, especially during endochondral ossifications [393, 394]. In the 
absence of HDAC4, transcriptional activation of MEF2C and Runx2 is uncontrolled 
leading to excessive bone formation. Thus, HDAC4 is able to delay the expression 
chondrocyte hypertrophy and thereby control the timing and extent of ossification of 
endochondral bones through regulation of Runx2 and MEF2C.  
HDAC4 also plays an important role in muscle development through the regulation of 
MEF2C, particularly in cardiac muscle growth. HDAC4 binds directly to and represses 
MEF2 function, thereby controlling the diversification of mesoderm cells into 
cardiomyoblasts through inhibition of GATA4 and Nkx2-5 expression [395]. Inhibition of 
HDAC4 activity induces the specification of mesodermal cells into cardiac-muscle linage, 
as GATA4, Nkx2-5, MEF2C and cardiac alpha-actin are all upregulated [395]. The 
repression of these genes through the MEF-2/HDAC4 complex is relieved through CaMK 
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phosphorylation of HDAC4, inducing its translocation into the cytoplasm [396]. An 
overabundance of CaMK expression induces cardiac hypertrophy as cardiomyocytes 
undergo hypertrophic growth of due to increased MEF2C activity [397]. A number of 
cardiovascular disorders arise as a result of cardiac hypertrophy including myocardial 
infection, arterial hypertension and altered contractility. 
HDAC4 expression is also highly enriched in the brain and nervous tissue where it is 
predominantly expressed in the cytoplasm [398]. Depletion of HDAC4 in the forebrain of 
mice results in the impairment of memory, behavioural learning and long-term synaptic 
plasticity [399]. Additionally, overabundance of HDAC4 within the nucleus of neurons 
affects gene transcription profile of the central synapsis, directly affecting information 
processing in the brain [400]. Abnormalities of HDAC4 expression have been linked with 
several neurological disorders in human patients too. HDAC4 locus has been observed to 
be mutated in patients with brachydactyly mental retardation (BDMR) syndrome which is 
characterised by intellectual disabilities, development delays and behavioural abnormalities 
[401]. In patients with ataxia telangiectasia, a neurodegenerative disease, HDAC4 is highly 
localized to the nucleus of neurons [402]. In the nucleus, HDAC4 interacts with the 
transcription factors MEF2A and cAMP response element binding protein. This results in 
altered gene expression programs associated with neuronal degeneration [403]. 
Additionally, HDAC4 has been implicated in the pathogenesis of Huntington’s disease 
(HD) where HDAC4 associates with huntingtin and co-localises with cytoplasmic 
inclusions. The reduction of HDAC4 in HD mouse models delayed the formation of 
cytoplasmic aggregates and rescued neuronal synaptic function [404]. 
2.1.2 HDAC4 and cancer 
HDAC4 has also been shown to be involved in the development of several forms of 
cancer. Increased HDAC4 expression has been linked to promotion of cell growth and 
proliferation of various cancers, including gastric cancer, ovarian cancer, lung cancer, head 
and neck cancer, colon cancer, glioblastoma and oesophageal carcinoma [286, 405-409]. 
This occurs through nuclear accumulation of HDAC4 which is linked to repression of 
many genes, in particular p21, which is important in promoting cell cycle arrest. 
Additionally, the downregulation of a number of different miRNAs that specially target 
HDAC4 has also been found in many different cancer types [408, 410]. Furthermore, 
inhibition of HDAC4 has been shown to make certain cancer types more sensitive to anti-
cancer drugs. For example, inhibition of HDAC4 has been found to decrease HIF-1 
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transcriptional activity resulting in the reduction of resistance to docetaxel chemotherapy 
in prostate and liver cancers [411]. Additionally, increased HDAC4 expression has been 
identified in patients with platinum-resistant ovarian cancer [412]. Furthermore, elevated 
levels of HDAC4 have also been identified in bladder tumour tissues as compared to 
healthy bladder tissues [413].  
2.1.3 The role of HDAC4 in virus infection 
HDAC4 has been reported to be involved in several different latent viral infections, the 
most characterised of which is HIV-1. HDAC4 has been shown to be important in 
maintaining HIV-1 latency. Both the downregulation of HDAC4 and the pharmacological 
inhibition of HDAC4 are shown to promote reactivation of HIV-1 transcription and 
reverse transcriptase activity [338, 414-416]. HDAC4 has also been shown to be involved 
in maintaining the latency of several gammaherpesvirus, such as EBV. It has been 
proposed that HDAC4 inhibits the expression of the EBV BZLF1 gene which is an 
important transcription factor that mediates the switch from latency to the productive 
cycle. The inhibition appears to be induced through recruitment of HDAC4 to the BZLF1 
gene promoter via DNA-bound MEF2 proteins [417]. Additionally, HDAC4 has been 
shown to inhibit the expression of the murine gammaherpesvirus 68 (MHV68) gene, gene 
50, which is involved in the switch from latent gene expression to lytic replication. 
Downregulation of HDAC4 in murine macrophages infected with MHV68 was sufficient 
to promote active viral replication [418]. Human papillomavirus is able to manipulate 
tumour angiogenesis through dissociation of HDAC4 from HIF-1α via its E7 oncoprotein 
[419]. HDAC4 also plays a role in herpes simplex virus 1 (HSV-1) infection and appears 
to be an important target to mediate the switch from the latent cycle to lytic cycle. The 
HSV-1 gene ICP0 has been shown to interact with, and localises HDAC4 to the cytoplasm, 
alleviating its transcription repressive properties [420]. Interestingly, HDAC4 appears to 
be an important gene in the active replication of HSV-1, as cells lacking HDAC4 produce 
significantly less HSV-1 than normal expressing cells [421]. Contrastingly, a recent study 
showed that HDAC4 enhances the type I IFN response during infection with HSV-1 and 
vaccinia virus (VACV) infection. Mechanistically, HDAC4 interacts with STAT2 and is 
then recruited to IFN-stimulated response element (ISRE)-containing promoters. As a 
means to counter this type I IFN signalling, VACV C6 protein interacts with HDAC4 to 
induce its degradation via the proteasomal pathway [422]. 
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While HDAC4 appears to benefit chronic viral infections, its role is reversed during 
activley replicating viral infections whereby it inhibits virus replication. For example, in 
cells infected with HBV, the expression of miR-548 is upregulated and targets HDAC4 to 
decrease its expression. HDAC4 is believed to inhibit HBV through deacetylation of the 
HBV covalently closed circular DNA (cccDNA) which subsequently inhibits cccDNA 
transcription. Therefore, HBV replication is promoted through the downregulation of 
HDAC4 via miR-548 [423-425]. Hepatitis C virus (HCV) also targets HDAC4 transcript 
expression through the activity of its core protein, as a means to block HDAC4-induced 
IFN signalling. Additionally, it has been shown that ectopic expression of HDAC4 
promotes resistance in hepatocellular carcinoma cells to infection with VSV through 
enhancement of the IFN response [426]. Finally, a recent study showed that influenza 
promotes the expression of miR-22 in primary bronchial epithelial cells (pBECs) which 
goes on to downregulate the expression of HDAC4 [427]. 
Previously, it has been reported that other HDACs play an antiviral role during infection 
with IAV. At least one member of each class has been reported to possess anti-IAV 
properties, including HDACs, 1, 2, 6, all of the sirtuins, and the sole member of the class 
IV family, HDAC11 [79, 224-226, 352]. Therefore, the purpose of this chapter is to 
determine if, like the other previously reported HDACs, HDAC4 possesses antiviral 
properties in the context of IAV infection. The outcomes from this chapter reveal that 




In order to determine the potential antiviral role of HDAC4 in IAV infection, 2 approaches 
were used. The first was to use siRNA to knockdown HDAC4 expression and determine 
if this enhanced IAV replication. The second approach was to determine if overexpression 
of HDAC4 from a plasmid inhibited IAV replication. 
2.2.1 Efficiency of HDAC4-targeting siRNA and its effect on IAV infection 
First, we wanted to optimize a concentration of siRNA to effectively knockdown HDAC4 
expression in human lung alveoli (A549) cells. Therefore, different concentrations (1, 5, 
10, 20 nM) of siRNA targeting human HDAC4 and 20 nM of a non-targeting control (CT) 
siRNA were transfected in A549 cells. After 72 hours, the total cell lysates were prepared 
and resolved by SDS-PAGE. The level of HDAC4 polypeptide was measured by western 
blotting (WB) and protein disulphide isomerase (PDI) was detected as a loading control as 
its levels are unaffected during IAV infection [225, 226]. Each of the different 
concentrations tested resulted in almost complete depletion of the HDAC4 polypeptide 
which was barely detectable by WB (Figure 5A). Protein bands were visualized by Odyssey 
Fc imaging system (Li-COR) and the HDAC4 and PDI bands were quantified using Image 
Studio Lite V5.2 software (Li-COR). HDAC4 was normalized to PDI and the normalized 
amount of HDAC4 in the control siRNA-treated sample was considered 100% for 
comparisons to the HDAC4 siRNA-treated samples. The lowest concentration (1 nM) 
used was sufficient to reduce the HDAC4 polypeptide level by 98% (Figure 5B). 
Additionally, this siRNA concentration had a negligible cytotoxic effect as compared to 
the control siRNA (Figure 5C). This led us to use 1 nM of HDAC4-targeting siRNA for 
all subsequent experiments to deplete HDAC4 expression.  
Additionally, we wanted to confirm that the knockdown of HDAC4 had no substantial 
effect on the ability of IAV to infect the HDAC4-depleted cells. Here, cells were 
transfected with control siRNA and HDAC4-targeting siRNA. The cells were then 
infected at 1.0 MOI for 8 hours after which, immunofluorescent staining of viral NP was 
done. Briefly, cells were fixed in 4% paraformaldehyde (Sigma) and then were 
permeabilized using 0.2% TritonX-100. An antibody targeting viral NP was then added, 
followed by a fluorescent secondary antibody. Finally, Hoechst dye (Invitrogen) was added 
to stain the nucleus. The cells were observed using fluorescent microscopy in order to 
determine the percentage of IAV-infected cells. To determine this, the total number of NP 
positive cells was divided by the total number of cells present in the field of view. This 
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number was then compared between HDAC4-depleted cells and control cells. Here we 
were able to determine that approximately 70% of HDAC4-depleted cells and 
approximately 72% of the cells treated with the control siRNA were infected, thus, 
indicating that the knockdown HDAC4 had no significant effect on the efficiency of virus 







Figure 5. Knockdown efficiency and cytotoxic effect of HDAC4-targeting siRNA. (A) A549 
cells were transfected with indicated concentrations of non-targeting control (CT) siRNA or 
targeting (HD4) siRNA for 72 hours. Total cell lysates were prepared and HDAC4 (140 kDa) and 
protein disulphide isomerase (PDI) (57 kDa) polypeptide levels were measured by WB. (B) The 
HDAC4 and PDI bands from the 1 nM sample in panel (A) blot were quantified using Image 
Studio Lite software (li-Cor). The level of HDAC4 in each sample was then normalized with the 
corresponding PDI levels. Finally, the normalized level of HDAC4 in CT siRNA transfected cells 
was considered 100% to compare its level in HD4 siRNA transfected cells. (C) A549 cells were 
transfected with Lipofectamine (LF) only or in a complex with CT or HD4 siRNA. After 72 hours, 
the viability of the cells was determined by MTT assay. Then, the viability of LF only transfected 
cells was considered 100% to compare the viability of CT and HD4 siRNA transfected cells. Error 
bars represent means ± standard errors of the means of three independent experiments (B) or 
technical replicates (C). P value calculated using unpaired t test. MW, molecular weight.  
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Figure 6. Equal numbers of cells were infected in both CT and HD4 siRNA treated cells. 
(A) A549 cells were transfected with 1 nM of CT siRNA or HD4 siRNA for 72 hours. Cells were 
then infected with PR8 at an MOI of 1.0. After 8 hours the cells were fixed, permeabilized, and 
then stained with mouse anti-viral NP followed by Alexa 488-conjugated rabbit anti-mouse IgG 
antibody. DNA binding dye Hoechst was used for nuclear staining and then analysed by fluorescent 
microscopy. (B) Total numbers of NP positive cells were counted in HD4 and CT siRNA-treated 
cells. This number was then divided by the total number of cells counted in the same field using 
the Hoechst nuclear stain to count individual cells. Percentage of infected cells were then compared 
between CT and HD4 siRNA-treated cells. Error bars represent means ± standard errors of the 




2.2.2 The knockdown of HDAC4 expression promotes IAV infection 
Next, we wanted to determine if, like the other previously reported HDACs, HDAC4 
possesses antiviral property against IAV. To achieve this, we depleted A549 cells of 
HDAC4 using the transfection conditions that were optimized above (Figure 5). Here, 
the cells were transfected with control or HDAC4 siRNA for 72 hours and were then 
infected with influenza virus strain A/PR/8/34 (H1N1) (hereafter referred to as PR8) at 
1.0 multiplicity of infection (MOI) for 24 hours. Following this, the culture media was 
collected to be titrated by plaque assay in order to determine the amount of infectious virus 
progeny released in HDAC4-depleted cells versus cells expressing HDAC4 at normal 
levels. Meanwhile, RNA from the cell lysates was extracted in order to analyse the level of 
viral mRNA expression. Additionally, some cell lysates were harvested for WB analysis in 
order to confirm the successful knockdown of HDAC4. The outcome from the plaque 
assay revealed that IAV was able to replicate more efficiently in cells depleted of HDAC4 
as these cells produced approximately 2.6 fold more infectious progeny than the control 
siRNA-treated cells (Figure 7A). Furthermore, in HDAC4-depleted cells, the mRNA 
levels of the viral NP gene was found to be 1.9-fold higher and the M gene was 3.9-fold 
higher compared to the control siRNA-treated cells (Figure 7B). WB analysis of the cell 
lysates revealed that the knockdown of HDAC4 was successful, but also revealed that in 
control siRNA-treated infected cells, HDAC4 polypeptide appeared to be downregulated 
(Figure 7C). This phenotype is similar to what we have previously reported for some other 
HDACs [224-226, 369] and will be further explored in Chapter IV. The intracellular viral 
NP polypeptide expression was also quantified and found to be 1.9 fold greater in 
HDAC4-depleted cells (Figure 7D). 
Next, we wanted to determine how the depletion of HDAC4 effects the growth kinetics 
of IAV. A549 cells were transfected with control and HDAC4 siRNA as described 
previously and were then infected with PR8 at an MOI of 0.1. Here, a lower MOI was used 
in order to reduce the level of dysregulation of HDAC4 during IAV infection in control 
siRNA-treated cells. Theoretically, this would allow HDAC4 to exert its antiviral potential 
for a longer period of time and therefore result in a greater observable difference in viral 
replication between control and HDAC4 siRNA-treated cells. The culture medium and 
infected cells were harvested separately at 0, 6, 12 and 24 hours post-infection. The culture 
media was divided into two parts, one part was analysed by WB to measure the total virus 
progeny release, while the other part was titrated by plaque assay to measure the infectious 
virus progeny release. The infected cell lysates were harvested and analysed by WB in order 
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to confirm the successful depletion of HDAC4 polypeptide. Knockdown of HDAC4 was 
confirmed and once again the IAV-induced dysregulation was observed with a noticeable 
decrease between 6 and 12 hours of infection (Figure 8A). Additionally, a greater 
difference in infectious virus release was measured where HDAC4-depleted cells produced 
approximately 4.4 fold more infectious virus than control siRNA-treated cells (Figure 8B). 
Furthermore, after 6, 12 and 24 hours of infection, the cells transfected with HDAC4-
targeting siRNA released more total virions (replicative competent and incompetent virus 
in the culture medium) than the cells transfected with control siRNA (Figure 8C).  
Lastly, we infected A549 cells depleted of HDAC4 expression with influenza 
A/California/07/2009(H1N1) strain (henceforth referred to as CA09) to determine if a 
recent clinical isolate would also replicate to higher titres in HDAC4 depleted cells. Again, 
A549 cells were transfected with either control or HDAC4 siRNA for 72 hours, following 
which, the cells were infected with CA09 at 1.0 MOI for 24 hours. Once again the culture 
media was collected to be titrated by plaque assay to determine the infectious virus release 
while the cell lysates were harvested for total RNA to analyse the viral gene mRNA 
expression. Consistent with the previous results, cells depleted of HDAC4 produced 2.7 
fold more infectious viral progeny compared to cells expressing normal levels of HDAC4 
(Figure 9A). The mRNA level of viral NP and M and cellular actin mRNA was measured 
by qPCR and the threshold cycle (Ct) values were determined. The Ct values of the viral 
genes were normalized using the actin value. The mRNA level of the viral mRNA in CT 
siRNA-treated cells was considered 1 fold for comparison with HD4 siRNA-treated cells. 
This analysis revealed that the mRNA expression of the viral genes NP and M was 

















Figure 7. Depletion of HDAC4 promotes PR8 replication. (A-D) A549 cells were transfected 
with 1 nm of CT siRNA or HD4 siRNA for 72 hours. Cells were then infected with PR8 at an 
MOI of 1.0 for 24 hours, after which, the culture media and the cells were harvested separately. 
(A) The culture media was titrated on MDCK cells by plaque assay in order to determine the total 
infectious virus released. Then, the amount of virus released from CT siRNA-treated cells was 
considered 1 fold to compare the amount of virus released from HD4 siRNA-treated cells. (B) 
The total RNA content from infected CT and HD4 siRNA-treated cells was processed and the 
levels of viral NP, M and cellular actin mRNA were detected by qPCR. Then, the NP and M mRNA 
levels were normalized with corresponding actin mRNA levels. Finally, the normalized levels of 
each viral mRNA in CT siRNA-treated cells were considered 1 fold to compare their levels in HD4 
siRNA-treated cells. (C) Total cell lysates of uninfected (UNI) and PR8-infected (INF) cells 
transfected with CT or HD4 siRNA were prepared and HDAC4, PDI and viral NP (56 kDa) 
polypeptides were detected by WB. (D) The NP and PDI bands in panel (C) blots were quantified 
and normalized as was done previously. Then, the normalized level of NP in CT siRNA-treated 
cells was considered 1 fold to compare its levels in HD4 siRNA-treated infected cells. Error bars 
represent means ± standard errors of the means of three independent experiments. P value 
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Figure 8. PR8 replication kinetics are enhanced in HDAC4-depleted cells. (A-D) A549 cells 
were transfected with 1nm of CT or HD4 siRNA for 72 hours. Cells were then infected with PR8 
at an MOI of 0.1 and the cells and culture medium were harvested separately at 0, 6, 12 and 24 
hours post-infection. (A) Total cell lysates were prepared and resolved via SDS-PAGE, and 
HDAC4, PDI and viral NP were detected by WB. (B) The culture media was titrated on MDCK 
cells by plaque assay in order to determine the amount of infectious virus progeny released. (C) 
Total culture media from CT and HD4 siRNA-treated cells were concentrated by trichloroacetic 
acid precipitation, and the levels of viral HA (68 kDa) and viral NP were compared by WB. Error 
bars represent means ± standard errors of the means of three independent experiments. P value 




Figure 9. CA09 replication is enhanced in HDAC4-depleted cells. (A-B) A549 cells were 
transfected with 1 nm of CT siRNA or HD4-targeting siRNA for 72 hours. Cells were then infected 
with CA09 at an MOI of 1.0 for 24 hours and then the cells and culture media were harvested 
separately. (A) The culture media was titrated on MDCK cells by plaque assay in order to determine 
the amount of infectious virus progeny released. Then, the amount of virus released from CT 
siRNA-treated cells was considered 1 fold to compare the amount of virus released from HD4 
siRNA-treated cells. (B) The total RNA content from infected CT and HD4 siRNA-treated cells 
was processed and the levels of viral NP, M and cellular actin mRNA were detected by qPCR. 
Then, the NP and M mRNA levels were normalized with corresponding actin mRNA levels. 
Finally, the normalized levels of each viral mRNA in control siRNA-treated cells were considered 
1 fold to compare their levels in HDAC4 siRNA-treated cells. P value calculated using unpaired t 




2.2.3 Overexpression of HDAC4 inhibits IAV replication 
The knockdown of HDAC4 indicated that endogenously expressed HDAC4 plays an 
antiviral role during IAV infection. IAV replication and total virion release was observed 
to be greater in A549 cells depleted of HDAC4. Therefore, the next step was to determine 
if transfection of a plasmid containing the human HDAC4 gene would have an opposite 
effect and inhibit IAV replication.  
First of all, the transfection conditions were optimized in order to ascertain a suitable 
plasmid concentration and lipofectamine 2000 (LF) volume for use in subsequent 
experiments. A549 cells were transfected with either an empty plasmid (peGFP) or an 
HDAC4-expressing plasmid (HD4-GFP) (~149 kDa) with various ratios of plasmid 
concentrations (1, 2 and 3 µg) and LF volumes (1, 2 and 3 µL). After 48 hours the cell 
lysates were harvested and analysed by WB. It was found that the lowest concentration of 
plasmid required for sufficient HDAC4 expression was with 1 µg of DNA combined with 
3 µL of LF (Figure 10A). Next, we wanted to compare the expression capabilities of a 
second HDAC4 expressing plasmid (HD4-FLAG) (~120 kDa) with the previously used 
HD4-GFP plasmid. A549 cells were transfected with either 1 µg or 2 µg of peGFP plasmid 
or two HDAC4 plasmids using 3 µL of LF for 48 hours. Once again the cell lysates were 
harvested for analysis by WB which revealed that there was no major difference in the level 
of HDAC4 expression between the two plasmids (Figure 10B). However, we chose HD4-
FLAG for all subsequent overexpression experiments because the HDAC4 polypeptide is 
of a similar size as the endogenous HDAC4 on an SDS-PAGE. Furthermore, the FLAG 
tag is fused to the C-terminus of the HDAC4 gene whereas the HDAC4 antibody 
recognises the N terminus of HDAC4. This allows for detection of HDAC4 from both 
ends of the polypeptide, which could be useful for future analysis into the dysregualtion of 
HDAC4 by IAV.  
Next, we wanted to determine if, like endogenously expressed HDAC4, overexpressed 
HDAC4 is also severely dysregulated by IAV. To do this, A549 cells were transfected with 
either HD4-GFP or HD4-FLAG using the aforementioned transfection conditions for 48 
hours. Next, the cells were either infected with PR8 at 1.0 MOI or were left uninfected for 
24 hours, following which the cell lysates were harvested for WB analysis. Interestingly, 
even in cells overexpressing HDAC4, IAV infection was able to significantly decrease the 
levels of HDAC4 polypeptide as compared to uninfected cells (Figure 11A). Because the 
effect on HDAC4 polypeptide overexpression was so profound in A549 cells, we decided 
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to try another cell line, human embryonic kidney 293T (HEK293T) cells. Therefore, 
HEK293T cells were transfected with both HD4-GFP and HD4-FLAG in exactly the 
same manner as was performed in the A549 cells. After 48 hours, the cell lysates were 
prepared and analysed by WB, which revealed that, unlike A549 cells, HEK293T cells 
maintained HDAC4 overexpression, even in the presence of IAV infection (Figure 11B). 
Detection of intracellular viral NP revealed that IAV was able to successfully replicate in 
these cells. Lastly, we wanted to determine the efficiency of transfection between A549 
and HEK293T cells by fluorescent microscopy. Both cell lines were transfected with HD4-
FLAG using the same transfection conditions as used previously. After 48 hours of 
transfection, the cells were stained as described above using an HDAC4 antibody and 
visualised using immunofluorescence. This revealed that HEK293T cells were transfected 
at far greater efficiency than A549 cells (Figure 11C-D) and thus HEK293T cells were 
chosen for subsequent HDAC4 overexpression experiments.  
To determine if ectopically-expressed HDAC4 inhibits IAV infection, HEK293T cells 
were transfected with either the empty plasmid, pcDNA3.1(-) or HD4-FLAG plasmid, 
using the transfection conditions described previously. After 48 hours of transfection, the 
cells were infected with PR8 for 24 and 48 hours at either 0.1 or 1.0 MOI. Some of the 
cells were harvested for WB analysis to confirm the overexpression of HDAC4 and that 
HDAC4 polypeptide expression was maintained throughout the course of infection 
(Figure 12A). Meanwhile, the culture media was harvested for plaque assay analysis to 
determine infectious virus release. Compared to cells transfected with pcDNA3.1(-) 
plasmid, HDAC4 overexpressing cells infected with PR8 at 0.1 MOI released 49% and 
46% less infectious virus progeny after 24 and 48 hours of infection respectively (Figure 
12B). Similar results were obtained in HEK293T cells infected with PR8 at 1.0 MOI. 
HDAC4 overexpressing cells released 42% less infectious viral progeny at 24 hours post-
infection and 46% less at 48 hours post-infection as compared to cells expressing normal 
HDAC4 levels (Figure 12C). Finally, to determine if the levels of infectious virus progeny 
measured correlated to the level of virus replication inside the cells, a qPCR was performed 
exactly as above on RNA extracted from the cell lysates infected with PR8 at 1.0 MOI. 
The qPCR analysis revealed that the mRNA level of the viral NP and M genes were 
decreased by 41% and 50% respectively, when normalized to the actin mRNA level and 
48% and 44% respectively, when normalized to 18SRNA level (Figure 12D).
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Figure 10. Transfection efficiency of HDAC4-expressing plasmids. (A) A549 cells were 
transfected with either peGFP or HD4-GFP using the indicated concentrations of plasmid DNA 
and volumes of LF for 24 hours. Total cell lysates were then prepared and HDAC4 and PDI were 
detected by WB. (B) A549 cells were transfected with 1 or 2 µg of an empty pcDNA3.1(-) plasmid 
(pc), HD4-GFP or pcDNA3.1(-) plasmid containing HDAC4 (HD4-FLAG) using 3 µL of LF for 















Figure 11. HDAC4 overexpression is enhanced in HEK293T cells compared to A549 cells. 
A549 cells (A-B) or HEK293T cells (C-D) were transfected with 1 µg of HD4-GFP or HD4-
FLAG with 3 µL of LF for 24 hours. (A and C) The cells were then infected with PR8 at 1.0 MOI 
or left uninfected for 24 hours. Total cell lysates were prepared and HDAC4, PDI and viral NP 
were detected by WB. (B and D) Cells transfected with the HD4-FLAG plasmid were fixed with 
4% paraformaldehyde. Next, 0.2% TritonX-100 was added to permeabilize the cells. Next HDAC4 
antibody was added, followed by anti-rabbit secondary Alexa flour 594 dye. The cells were then 
viewed and imaged under an inverted fluorescence microscope (Olympus) at magnification of 10X. 







Figure 12. Overexpression of HDAC4 restricts IAV replication. (A-D) HEK293T cells were 
transfected with 1 µg of either pcDNA3.1(-) (pc) or HD4-FLAG (HD4) with 3 µL of LF for 24 
hours. The cells were then infected with PR8 at 1.0 MOI (A and B) or 0.1 MOI (C and D). The 
cell lysates and culture media were harvested separately at 0, 24 and 48 hours post-infection. (A) 
Total cell lysates were prepared and HDAC4, PDI and viral NP were detected by WB. The culture 
media was titrated on MDCK cells by plaque assay in order to determine the amount of infectious 
virus progeny released at 24 hours (B) and 48 hours (C) post-infection. Then, the amount of virus 
released from pc-transfected cells was considered 100% to compare the amount of virus released 
from HD4-transfected cells. (D) The total RNA content from 24 hour infected pc- and HD4-
transfected cells was processed and the levels of viral NP and M and host cell actin and 18SRNA 
mRNA were detected by qPCR. Then, the NP and M mRNA levels were normalized with 
corresponding actin and 18SRNA mRNA levels. Finally, the normalized levels of each viral mRNA 
in pc-transfected cells were considered 100% to compare their levels in HD4-transfected cells. 
Error bars represent means ± standard errors of the means of 3 independent experiments. P value 







The data presented in this chapter demonstrate that HDAC4 plays an antiviral role during 
IAV infection. While others have previously reported anti-IAV roles for other members 
of the HDAC family, the role of HDAC4 in IAV infection has not been described [79, 
224-226, 352]. Here, we show that depletion of HDAC4 in A549 cells results in an increase 
in IAV replication (Figure 7, 8, 9). Additionally, we show that overexpression of HDAC4 
from a plasmid inhibits IAV replication in HEK293T cells (Figure 12). The observations 
were confirmed by analysing several parameters of IAV replication; extracellular (total and 
infectious) virion release and intracellular viral mRNA and protein levels. This was 
confirmed using two IAV H1N1 strains, the lab-adapted strain, PR8 (Figure 7), and the 
clinically relevant strain, CA09 (Figure 9). Ultimately, IAV growth was found to be 2-3 
fold higher in HDAC4-depleted cells when infected at 1.0 MOI. However, one could argue 
while statistically significant, this is only a modest increase in virus growth. This 
discrepancy is made more apparent when comparing the effect of other HDACs on IAV 
growth. For example, HDAC11-depleted cells have been shown to produce up to 1-log 
more infectious IAV virions when compared to cells expressing normal levels of HDAC11 
[224]. However, a likely and simple explanation is due to the profound downregulation of 
the HDAC4 polypeptide in IAV-infected cells. In fact, the antagonism of HDAC4 by IAV 
was found to be so severe that in A549 cells overexpressing HDAC4, the levels of HDAC4 
polypeptide were reduced to barely detectable levels after 24 hours of infection (Figure 
11A). Hence, in control siRNA-treated IAV-infected cells, its expression is reduced to 
similar levels seen in the HDAC4-depleted cells. Therefore, HDAC4 has less time to assert 
its antiviral effect and the resulting difference observed in virus growth cannot be as 
profound. Furthermore, when we infected cells with 0.1 MOI we observed decreased 
HDAC4 antagonism, but a greater difference in virus growth between HDAC4-depleted 
cells and control cells (Figure 8B). Therefore, the decreased level of HDAC4 antagonism 
seen at 0.1 MOI indicates that HDAC4 is able to assert its antiviral effect for a longer 
period of time in the control cells. In addition, a recent study further supports this 
argument where overexpression of HDAC4 induced resistance to infection by VSV, but 
only with infection at low titres [426]. Furthermore, both the HDAC4 mRNA and 
polypeptide have been shown to be highly unstable with their respective half-lives being 
approximately 4 and 8 hours [429]. Finally, functional redundancy has been observed 
between different HDACs within the same class and even outside classes [430]. Therefore, 
in the absence of HDAC4, other HDACs could partially compensate for its antiviral role 
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and hence could be contributing to the modest change observed in viral growth in HDAC4 
depleted cells. The combination of all of these factors suggest that HDAC4 restricts IAV 
replication but is rapidly targeted and dysregulated by IAV, potentially as a means to inhibit 
its antiviral potential. 
Some important considerations to take into account when interpreting this data is that that 
for the depletion of HDAC4, only one siRNA was used. In order to gain greater confidence 
in the result, multiple siRNAs should be utilised in order account for potential off-target 
effects. However, the overexpression data presented in Figure 12 does somewhat alleviate 
this issue. Also, the varying knockdown efficiency of different siRNAs used might correlate 
with the effect on viral replication as reported with HDAC11 where 3 different siRNAs 
were used [224]. Additionally, use of an siRNA-resistant HDAC4 plasmid in combination 
with an HDAC4-targeting siRNA would also give greater confidence in these results. 
Another important experiment that could have been performed was to use an HDAC4-
specific inhibitor and determine its effect on IAV replication. General HDAC inhibitors 
such as TSA, which inhibit the activity of multiple HDACs including HDAC4 have been 
used previously and have been shown to promote the replication of different viruses 
including IAV [225, 226]. An obvious choice for an HDAC4-specific inhibitor would be 
tasquinimod, as this would indicate the importance of the deacetylase activity of HDAC4 
in its antiviral role [521]. Finally, because HDAC4 can shuttle between the cytoplasm and 
the nucleus, it would be interesting to determine how the subcellular distribution of 
HDAC4 changes during IAV infection. This might provide some clues as to how and 











CHAPTER III - RESULTS: 
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The outcomes from Chapter II revealed that host HDAC4 is playing an antiviral role 
during IAV infection. Therefore, the next step was to determine how HDAC4 exerts its 
antiviral function. Previous studies on HDAC4 have revealed that it plays an important 
role in regulating the innate immune response, specifically through enhancement of the 
Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signalling 
pathway. Furthermore, other HDACs namely HDAC1, 2 and 11 have also been implicated 
in the innate immune response during IAV infection [224,-226]. Based upon this 
understanding, an obvious next step was to explore the effect of HDAC4 manipulation on 
the IAV-induced interferon signalling pathway. 
3.1.1 The innate immune response to IAV infection 
When IAV first infects a host cell, conserved products of viral replication known as 
pathogen-associated molecular patterns (PAMPs) are recognised by host pathogen 
recognition receptors (PRRs). PRRs include RIG-I and Toll-like receptors (TLRs) and are 
able to distinguish certain characteristics present on the IAV RNA that are not shared by 
cellular RNAs such as regions of dsRNA or the presence of a 5’-triphosphate group [172, 
173]. Following recognition of IAV PAMPs, RIG-I is activated and its caspase and 
recruitment domains (CARDs) are exposed. The CARD is then dephosphorylated or 
ubiquitinated by E3 ligases which triggers downstream signalling at the mitochondrial 
membrane [431]. Transcription factors including IRF3, IRF7 and NF-KB are activated 
promoting production of type I IFNs and inducing expression of ISGs [432].  
Type I IFNs are key mediators of innate antiviral immune responses and have 3 major 
functions to facilitate this. Firstly, they induce an antiviral state in infected cells as well as 
neighbouring cells, which limits further spread of infectious agents [433]. Secondly, they 
enhance innate immune responses through promotion of antigen presentation and natural 
killer cell functions while inhibiting pro-inflammatory pathways and cytokine production 
[432]. Thirdly, they augment the development of high-affinity antigen-specific T and B cell 
responses [434]. IFNα and IFNβ are the most well characterised type I IFNs and are the 
first signalling molecules of the IFN response which culminates in the activation of 
hundreds of ISGs that are able to restrict viral infection by targeting nearly every stage of 
the virus life cycle. The response begins with the binding of type I IFN to the IFNα 
receptor (IFNAR) which is composed of IFNAR1 and IFNAR2 subunits. This binding 
then activates JAK1 and tyrosine kinase 2 (TYK2) which go on to phosphorylate STAT1 
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and STAT2. Tyrosine-phosphorylated STAT1 and STAT2 dimerize and translocate into 
the nucleus where they form a complex with IFN-regulatory factor 9 (IRF9) to form a 
trimolecular structure called IFN-stimulated gene factor 3 (ISGF3). ISGF3 then binds to 
IFN-stimulated response elements (ISREs) which then directly activates the transcription 
of ISGs. STAT1 can also form homodimers which translocate into the nucleus and bind 
to gamma-activated sequences to induce pro-inflammatory genes [435].  
3.1.2 HDAC4 and the innate immune response 
Several studies have demonstrated the role that HDAC4 plays in regulating the innate 
immune response. Multiple groups have reported on the role HDAC4 plays in promoting 
STAT1 activation to promote the innate immune response. The first study revealed that 
in cisplatin-resistant cancer cells HDAC4 physically interacts with STAT1 which allows 
STAT1 to become activated. Further they showed that overexpression of HDAC4 
promotes STAT1 phosphorylation which allows STAT1 to translocate into the nucleus 
allowing expression of STAT1-inducible genes [412]. Other studies have since reported 
similar findings on the role of HDAC4 in promoting STAT1 activation in other cell lines 
and that STAT1 activity promotes HDAC4 expression [436, 437]. A recent further study 
supported these findings in hepatocellular carcinoma cells, whereby depletion of HDAC4 
decreased STAT1 phosphorylation and as a result decreased type I IFN signalling. 
Consequently, these HDAC4-depleted cells were more susceptible to VSV infection. 
Meanwhile, ectopic expression of HDAC4 enhanced STAT1 activation and type I IFN 
expression, resulting in impaired VSV replication [426]. STAT2 has also been shown to be 
positively regulated by HDAC4 activity as a recent study revealed that HDAC4 
coprecipitates with STAT2 and is recruited to IFN-stimulated response element (ISRE)-
containing promoters following IFN induction. In the absence of HDAC4, STAT2 
binding to these promoters is greatly reduced, leading to enhanced replication of HSV-1 
and vaccinia virus [422].  
Conversely, other studies have reported that HDAC4 plays a role in suppressing the innate 
immune response. Upon being dephosphorylated, HDAC4 localizes to the nucleus where 
it represses the innate immune response in several ways. Firstly, it deacetylates NF-KB 
p65, which results in the repression of many inflammatory genes including TNF-α, IL-6, 
IL-1β, and IL-12 [438]. Secondly, HDAC4 binds with LXRα and promotes its sumoylation 
allowing LXRα to bind nuclear pSTAT1 in a trimeric complex with HDAC4. This complex 
prevents phosphorylated STAT1 (pSTAT1) from binding to the IRF1 promoter 
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preventing IFN production [439]. More recently, a study showed that cytoplasmic HDAC4 
can also interfere with the innate response by preventing the phosphorylation of IRF3 and 
thereby decrease type I IFN production. HDAC4 outcompetes IRF3 as the substrate of 
the kinases TBK1 and IKKε, which normally phosphorylates IRF3 to promote its 
activation [421].  
Previously, it has been reported that HDAC1, 2 and 11 all play a role in promoting the 
innate immune response during IAV infection [224-226]. Furthermore, HDAC4 itself has 
been shown to play roles in enhancing and inhibiting the innate immune response under 
various conditions [436-438]. Taking the outcomes from Chapter II into account, the 
purpose of this chapter was to determine if HDAC4 inhibits IAV replication by enhancing 
the innate immune response.  
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3.2 Results 
3.2.1 Depletion of HDAC4 impairs IFN mRNA expression 
In the light of the involvement of HDAC4 in innate immune response discussed above, 
we wanted to determine the role of HDAC4 in IAV-induced host innate antiviral response. 
For this, A549 cells were transfected with CT or HD4 siRNA as in Chapter II (Figure 5). 
After 72 hours, the cells were infected with PR8 at an MOI of 1.0 for 6 hours. Additionally, 
a control group of CT and HD4 siRNA-treated cells were harvested for WB analysis to 
confirm the knockdown of HDAC4. Following this, the cell lysates were prepared and the 
total RNA was extracted and converted to cDNA for analysis by qPCR. WB analysis of 
the uninfected cells revealed that the knockdown of HDAC4 was successful (Figure 13A). 
The mRNA level of IFNα, IFNβ, IFNγ and actin was measured by qPCR and the ct values 
were determined. The ct values of the IFNs were normalized using the actin value. The 
mRNA level of the IFNs in CT siRNA-treated cells was considered 100% for comparison 
with HD4 siRNA-treated cells. There was a significant 73.8% and 83% decrease in the 
expression of IFNα and IFNβ respectively, in HDAC4-depleted cells compared with the 




Figure 13. HDAC4 depletion decreases IFNα and IFNβ mRNA expression during IAV 
infection. A549 cells were transfected with 1 nM of CT or HD4 siRNA for 72 hours. (A) Total 
cell lysates were prepared and HDAC4 and PDI polypeptide levels were measured by WB. (B) The 
siRNA treated cells were infected with PR8 at 1.0 MOI for 6 hours. The levels of IFNα, IFNβ, 
IFNγ and actin mRNA were detected by qPCR. The levels of IFNα, IFNβ or IFNγ were 
normalised with the levels of the corresponding actin mRNA. Finally, the normalised mRNA level 
of each gene in CT siRNA-treated cells was considered 100% to compare its level in HD4 siRNA-
treated cells. Error bars represents means ± standard errors of the means of three repeats. P value 
calculated using unpaired t test. MW molecular weight.  
A B 
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3.2.2 The depletion of HDAC4 inhibits IAV-induced STAT1 signalling 
The above results revealed that HDAC4 plays a role in the IAV-induced IFN signalling 
pathway. Therefore, the next step was to determine whether HDAC4 is involved in 
promoting the phosphorylation of STAT1. For this, A549 cells were transfected with CT 
siRNA or HD4 siRNA and then infected with PR8 at 1.0 MOI. After 0, 6, 12 and 24 hours, 
cell lysates were prepared and the levels of HDAC4, phosphorylated STAT1 (pSTAT1) 
(87 kDa), total STAT1 (tSTAT1) (87 kDa), PDI and viral NP were detected by WB. The 
tSTAT1 and PDI were used as loading controls and viral NP was detected as an infection 
marker. The analysis revealed that there was a noticeable decrease in pSTAT1 level in the 
cells transfected with HD4 siRNA compared to the cells transfected with CT siRNA, 
particularly at 12 and 24 hours post-infection (Figure 14A). In order to quantify the 
decrease in pSTAT1 levels, the intensity of pSTAT1 and tSTAT1 bands were quantified 
using the Image Studio Lite Software (Version 7.0, LI-COR). The amount of pSTAT1 was 
normalised with the corresponding tSTAT1 amount. Then, the normalised amount of 
pSTAT1 at each time point in CT siRNA-treated cells was considered 100% to compare 
its amount in HD4 siRNA-treated cells. This revealed that there was a significant 54.3% 
and 61.9% decrease in pSTAT1 levels in HDAC4-depleted cells at 12 and 24 hours post 
infection respectively (Figure 14B).  
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Figure 14. HDAC4 is important for IAV-induced phosphorylation of STAT1. A549 cells were 
transfected with 1 nM of CT or HD4 siRNA for 72 hours. Cells were then infected with PR8 at an 
MOI of 1.0 and the cells were harvested separately at 0, 6, 12 and 24 hours post-infection. (A) 
Total cell lysates were prepared and resolved via SDS-PAGE, and the levels of HDAC4, pSTAT1 
(91/84 kDa), tSTAT1 (91/84 kDa), PDI and viral NP were detected by WB. (B) The intensity of 
the pSTAT1 and tSTAT1 bands was quantified using the Image Studio Lite software (LI-COR). 
The levels of pSTAT1 was then normalised with the corresponding tSTAT1 levels. Finally, the 
normalised level of pSTAT1 at each time point in CT siRNA-treated cells was considered 100% to 
compare its amount in HD4 siRNA-treated cells (6, 12, and 24h). Error bar represents means ± 
standard errors of the means of three independent experiments. P value calculated using unpaired 
t test. MW, molecular weight.  
A B 
74 
3.2.3 Depletion of HDAC4 impairs expression of ISGs: IFITM3, viperin and ISG15 
The above observations indicated that HDAC4 is playing a role in regulating the innate 
immune signalling pathway in IAV-infected cells. Therefore, the next step was to 
investigate the effect of decreased IFNα and IFNβ mRNA expression as well as the 
impaired phosphorylation of STAT1 in HDAC4-depleted cells. Hence, the mRNA 
expression of various ISGs (IFITM1, IFITM2, IFITM3, ISG15, viperin, cholesterol-25-
hydroxylase (CH25H), effector mitochondrial antiviral signalling protein (MAVS), 
TRM22, MX1 and OAS3) was investigated in HDAC4-depleted cells, because their 
previously reported roles in IAV infection [435, 440, 441]. While the mRNA expression of 
most of the genes tested did not appear to change in the absence of HDAC4, ISG15 
mRNA expression decreased by 88% and viperin mRNA expression decreased by 70.2% 
in cells depleted of HDAC4 compared to HDAC4 expressing cells (Figure 15). 
In addition, we wanted to determine if a similar phenotype could be observed at the 
polypeptide level of several of the ISGs (IFITM3, viperin and ISG15) in HDAC4-depleted 
cells. Here, IFITM3 was used as a negative control. To assess this, A549 cells were 
transfected with CT or HD4 siRNA and were then infected with PR8 at 1.0 MOI. After 0, 
6, 12 and 24 hours of infection, cell lysates were prepared and the polypeptide levels of 
HDAC4, IFITM3, viperin and ISG15 we measured by WB. HDAC4 was confirmed to be 
knockeddown prior to virus infection and remained depleted throughout the entire time 
course. Interestingly, the polypeptide expression of both IFITM3 and viperin were 
massively decreased in HDAC4-depleted cells, whereas ISG15 expression initially 
decreased in HDAC4-depleted cells but seemed to recover after 24 hours of infection 
(Figure 16A). Analysis of three independent experiments revealed that in HDAC4-
depleted cells, IFITM3 polypeptide expression decreases significantly by 49.3% at 12 hours 
post infection and 59.7% at 24 hours post-infection (Figure 16B). HDAC4 depletion 
results in viperin polypeptide expression to decrease by 70% and 76.7% at 12 and 24 hours 
post-infection, respectively (Figure 16B). Interestingly, in cells depleted of HDAC4, 
ISG15 polypeptide expression initially decreases by 56.7% at 12 hours post infection. 
However, after 24 hours, the expression of ISG15 recovers back to similar levels observed 
in the control (Figure 16C).   
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Figure 15. Depletion of HDAC4 impairs mRNA expression of ISG15 and viperin during 
IAV infection. A549 cells were transfected with 1 nM of CT or HD4 siRNA for 72 hours 
following which the cells were infected with PR8 at 1.0 MOI for 6 hours. The mRNA levels of 
actin and the indicated ISGs were detected by qPCR and normalised and presented as was done in 
figure 12. Error bars represents means ± standard errors of the means of three repeats. P value 




















Figure 16. Depletion of HDAC4 impairs ISG polypeptide expression. (A) A549 cells were 
transfected with 1 nM of CT siRNA or HD4-targeting siRNA for 72 hours. Cells were then 
infected with PR8 at an MOI of 1.0 and the cells were harvested separately at 0, 6, 12 and 24 hours 
post-infection. Total cell lysates were prepared and resolved via SDS-PAGE, and HDAC4, 
IFITM3 (15 kDa), viperin (42 kDa), ISG15 (18 kDa), PDI and viral NP were detected by WB. The 
IFITM3 (B), viperin (C) or ISG15 (D) bands were quantified and normalized to the corresponding 
PDI bands.  Then, the normalized levels of IFITM3, viperin and ISG15 at each time point in CT 
siRNA-treated cells was considered 100% to compare their levels in HD4 siRNA-treated cells at 
the respective time points. Error bars represent means ± standard errors of the means of three 






3.2.4 Overexpression of HDAC4 promotes IAV-induced innate antiviral signalling 
The above results demonstrated that depletion of HDAC4 impairs IAV-induced pSTAT1 
activation and the downstream signalling of antiviral ISGs at both mRNA and polypeptide 
levels. Therefore, the next step was to determine if the opposite effect could be observed 
when overexpressing HDAC4, whereby the IAV-induced immune response would be 
enhanced. As was done above, the effect of HDAC4 overexpression was examined in the 
context of IFN mRNA expression. First, HEK293T cells were transfected with  HD4-
FLAG plasmid or the empty vector pcDNA3.1(-) for 24 hours. Following this, some of 
the cells were harvested for WB analysis in order to confirm the overexpression of HDAC4 
(Figure 17A). Meanwhile, the remaining cells were infected with PR8 at 1.0 for 6 hours, 
after which, the cells were harvested and total RNA was extracted. The mRNA expression 
of IFNα, IFNβ, IFNγ and actin was measured by qPCR in HD4-FLAG transfected cells 
and compared to pcDNA3.1(-) transfected cells. Consistent with the knockdown data, 
IFNα mRNA expression increased by 3.3 fold in cells overexpressing HDAC4 during 
IAV-infection. Consistent with the knockdown data, IFNγ mRNA expression was not 
affected in response to HDAC4 overexpression (Figure 17B). Interestingly, IFNβ mRNA 
did not appear to be affected by the overexpression of HDAC4 despite its decreased 
expression in the absence of HDAC4. 
The above data indicated a clear link between HDAC4 expression and IFNα mRNA 
expression. Therefore, it was likely that the mRNA level of one or more of the downstream 
ISGs would also be promoted in HDAC4 overexpressing cells. HEK293T cells were 
transfected with HD4-FLAG or pcDNA3.1(-) exactly as was performed above. The cells 
were then infected for 6 hours with PR8 at 1.0 MOI, after which, the cells were harvested 
for RNA. The mRNA levels of IFITM1, IFITM 2, IFITM3, ISG15, viperin, CH25H, 
MAVS, TRM22 and actin were analysed by qPCR. The IAV-induced mRNA expression 
of the ISGs in HDAC4 overexpressing cells was compared with cells expressing normal 
levels of HDAC4. Once again, the mRNA levels of most of the ISGs observed did not 
significantly alter in response to the overexpression of HDAC4. However, ISG15 mRNA 
expression increased significantly by 8.2 fold in HDAC4 overexpressing cells. Likewise, 
viperin mRNA expression increased significantly by 3.66 fold in cells overexpressing 
HDAC4 (Figure 18). The complementary data obtained from the knockdown 
experiments indicate that the mRNA expression of both of these genes is regulated by 
HDAC4. 
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Next, we wanted to determine if the overexpression of HDAC4 affected the polypeptide 
expression of these ISGs in a complementary pattern to the HDAC4 knockdown data. 
Therefore, the IAV-induced activation of STAT1 and subsequent polypeptide expression 
of the downstream ISGs in HDAC4 overexpressing cells was compared to cells expressing 
normal levels of HDAC4. Here, HEK293T cells were transfected with HD4-FLAG or 
pcDNA3.1(-) for 24 hours. Next, the cells were infected with PR8 at 1.0 MOI and the cells 
were harvested at 0, 6, 12 and 24 hours post infection. The cell lysates were prepared and 
HDAC4, pSTAT1, tSTAT1, viperin, ISG15, PDI and viral NP were detected by WB. 
tSTAT1 and PDI were used as loading controls and viral NP as an infection marker. 
Consistent with the above mRNA data (Figure 15), the overexpression of HDAC4 
appeared to induce an opposite effect on the activation of STAT1 and polypeptide 
expression of the examined ISGs. Phosphorylation of STAT1 was increased in cells 
overexpressing HDAC4 while the polypeptide expression of viperin and ISG15 increased, 
at least at 24 hours post infection (Figure 19). Interestingly, STAT1 phosphorylation 
induction was greatest at 0 hours, suggesting that plasmid transfection alone is sufficient 
to induce the innate immune response.  
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Figure 17. Overexpression of HDAC4 promotes IFNα mRNA expression. HEK293T cells 
were transfected with either an empty pcDNA3.1(-) or HD4-FLAG plasmid using 1 µg of DNA 
and 3 µL of LF for 24 hours. (A) Cells were harvested and total cell lysates were prepared. The 
samples were run on a 10% SDS-PAGE and HDAC4 and PDI were detected by WB. (B) Cells 
were infected with PR8 at 1.0 MOI for 6 hours, following which the levels of IFNα, IFNβ, IFNγ 
and actin mRNAs were detected by qPCR. Then, the IFNα, IFNβ and IFNγ levels were normalized 
to the corresponding actin mRNA levels. Finally, the normalized levels of each IFN mRNA in 
pcDNA plasmid transfected cells was considered 1-fold to compare their levels to HD4-FLAG 
transfected cells. Error bars represent means ± standard errors of the means of three repeats. P 




Figure 18. HDAC4 overexpression increases ISG15 and viperin mRNA expression. 
HEK293T cells were transfected with 1µg pcDNA3.1(-) or HD4-FLAG with 3µL of LF for 24 
hours. The cells were then infected with PR8 at 1.0 MOI for 6 hours. Next, the mRNA levels of 
actin and the indicated ISGs were detected by qPCR and normalised and presented as was done in 
the previous figure. Error bars represent means ± standard errors of the means of three repeats. P 



















Figure 19. Overexpression of HDAC4 promotes phosphorylation of STAT1 and expression 
of viperin and ISG15 during IAV infection. HEK293T cells were transfected with 1 µg of either 
pcDNA3.1(-) or HD4-FLAG with 3 µL of LF for 24 hours. The cells were then infected with PR8 
at 1.0 MOI and the cells were harvested following 0, 6, 12 and 24 hours post infection. Total cell 
lysates were prepared and HDAC4, pSTAT1, tSTAT1, viperin, ISG15, PDI and viral NP were 
detected by WB. Data is representative of a single experiment. MW, molecular weight. 
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3.2.5 HDAC4 enhances STAT1 activation and IFITM3 expression, independent of 
IAV 
Based upon the above data where IFNα mRNA expression was decreased in HDAC4-
depleted cells and increased in HDAC4 overexpressing cells, we wanted to determine 
whether HDAC4 is involved in the IFNα mediated antiviral response. For this, A549 cells 
were transfected with CT or HD4 siRNA for 72 hours. Next, the cells were treated with 
IFNα (10 IU/mL) and the cells were harvested after 0, 2, 4 and 6 hours of treatment. Total 
cell lysates were prepared and HDAC4, pSTAT1, tSTAT1 and PDI polypeptide levels were 
analysed by WB. Under these conditions, pSTAT1 levels appeared rapidly within the first 
2 hours of treatment then subsided to barely detectable levels by 6 hours post-treatment. 
Consistent with the previous observations on the role of HDAC4 and the activation of 
STAT1, the IFNα-induced phosphorylation of STAT1 in HDAC4 depleted cells was 
impaired (Figure 20A). The initial phosphorylation of STAT1 at 2 hours post-treatment 
is similar between CT and HD4 siRNA-treated cells. However, in the HDAC4-depleted 
cells, the level of STAT1 phosphorylation diminishes rapidly when compared to cells 
expressing normal levels of HDAC4. In fact, by 6 hours post-treatment, there is a 
significant 50.6% decrease in STAT1 phosphorylation in HD4 siRNA-treated cells as 
compared to CT siRNA-treated cells (Figure 20B). 
Additionally, the IFNα-induced expression of IFITM3, viperin and ISG15 were 
investigated and compared in HD4 siRNA-treated cells to CT siRNA-treated cells. A549 
cells were transfected with CT or HD4 siRNA for 72 hours, after which, the cells were 
treated with IFNα (10 IU/mL). The cells were harvested at 0, 2, 4, 6 hours post-treatment 
and total cell lysates were prepared for each time point and HDAC4, IFITM3, viperin, 
ISG15 and PDI were detected by WB. Detection of HDAC4 revealed that the knockdown 
was successful, however, both viperin and ISG15 were undetectable even 6 hours post-
treatment. IFITM3 was detectable even without IFNα induction due to its basal 
expression. Consistent with the previously observed results, IFNα-induced expression of 
IFITM3 was decreased in cells depleted of HDAC4 (Figure 21A). At 6 hours post-
treatment, the expression of IFITM3 polypeptide in HDAC4 depleted cells was reduced 
by 50.1% when normalized with PDI (Figure 21B). 
Collectively these results demonstrate that HDAC4 plays a role as part of the host innate 
antiviral response against IAV, through activation of STAT1, and promotion of the 
downstream ISGs including IFITM3, viperin and ISG15.   
83 
Figure 20. IFNα-induced phosphorylation of STAT1 is impaired in HDAC4 –depleted 
cells. A549 cells were transfected with 1 nM of CT or HD4 siRNA for 72 hours, following which 
the cells were treated with IFNα (10 IU/mL). (A) After 0, 2, 4 and 6 hours of treatment the cells 
were harvested and the levels of HDAC4, pSTAT1, tSTAT1 and PDI polypeptides were analysed 
by WB. The knockdown of HDAC4 was confirmed at the 0h time point where no polypeptide can 
be detected in the HD4 sample. (B) The intensity of the pSTAT1 and tSTAT1 bands was 
quantified using Image Studio Lite software (LI-COR). The levels of pSTAT1 was then normalised 
with the corresponding tSTAT1 levels. Finally, the normalised level of pSTAT1 at each time point 
in CT siRNA-treated cells was considered 100% to compare its amount in HD4 siRNA-treated 
cells. Error bars represents means ± standard errors of the means of three biological replicates. P 
value calculated using unpaired t test. MW, molecular weight.  
A B 
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Figure 21. IFNα-induced expression of IFITM3 is decreased in HDAC4-depleted cells. 
A549 cells were transfected with 1 nM of CT or HD4 siRNA for 72 hours, following which the 
cells were treated with IFNα (10 IU/mL). (A) After 0, 2, 4 and 6 hours of treatment the cells were 
harvested and the levels of HDAC4, IFITM3 and PDI polypeptides were analysed by WB. The 
knockdown of HDAC4 was confirmed at the 0h time point where no polypeptide can be detected 
in the HD4 sample. (B) The intensity of the IFITM3 and PDI bands was quantified using Image 
Studio Lite software (LI-COR). The levels of IFITM3 was then normalised with the corresponding 
PDI levels. Finally, the normalised level of IFITM3 at the 6h time point in CT siRNA-treated cells 
was considered 100% to compare its amount in HD4 siRNA-treated cells. Error bars represents 
means ± standard errors of the means of three biological replicates. P value calculated using 





In chapter II, we were able to demonstrate that host HDAC4 plays an antiviral role in IAV 
infection. The aim of this chapter was to elucidate the mechanism by which HDAC4 is 
exerting its antiviral function. The data presented here indicate that HDAC4 plays an 
important role as a component of type I interferon signalling. 
HDAC4 regulates the type I interferon signalling pathway at several levels. In IAV-infected 
HDAC4-depleted cells, the mRNA level of IFNα is reduced, whereas in HDAC4-
overexpressing cells, the level is enhanced (Figure 13, 17). It should be noted that we 
assumed IFN expression was induced as a result of IAV infection as we did not actually 
confirm the induction by using an uninfected control. Regardless, this is a reasonable 
assumption to make given the link between viral infection and IFN expression. 
Interestingly, this data directly contrasts with a study which reported that HDAC4 
decreases type I IFN production during virus infection by preventing phosphorylation of 
IRF3 [421]. However, in this study, only the expression of IFNβ was examined and only 
in response to infection with Sendai virus, VSV and HSV-1. Furthermore, the results were 
obtained in HEK293T cells, which are not natural infection models of these viruses or 
IAV. Given the diversity of heterogeneous phenotypes within mammalian cell lines, it is 
possible that HDAC4 might both promote and inhibit the antiviral response against 
different viruses in different cell lines. In addition, another Class II HDAC, HDAC6, 
promotes the phosphorylation of IRF3 and type I IFN production during RNA virus 
infection, including IAV [366]. Being from the same class, HDAC4 and HDAC6 might 
possess similar functionality and appear to be involved in similar cellular processes [367]. 
Nevertheless, it would be interesting to determine how the depletion and overexpression 
of HDAC4 effects the phosphorylation of IRF3 during IAV infection and how this 
correlates with downstream type I IFN production. 
This data also reveals that HDAC4 is important in promoting the phosphorylation of 
STAT1 during IAV infection. Decreased HDAC4 expression corresponded with a 
decrease in IAV-induced STAT1 phosphorylation (Figure 14). Subsequently, the 
downstream effect of decreased STAT1 phosphorylation was observed in the decreased 
polypeptide expression of ISGs – IFITM3, ISG15 and viperin (Figure 16), all of which 
have been previously reported to restrict the IAV infection [441]. Consistently, 
overexpression of HDAC4 promoted STAT1 phosphorylation and ISG expression during 
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IAV infection. However, the transfection of large DNA structures such as the plasmids 
that were used here induced the innate immune response. This is evident as STAT1 was 
phosphorylated even before infection with IAV (Figure 19). Regardless, the polypeptide 
levels of pSTAT1, viperin and ISG15 were all found to be increased in HDAC4 
overexpressing cells as compared to control cells (Figure 19). Others have previously 
reported that HDAC4 physically interacts with STAT1 to promote its phosphorylation and 
subsequent nuclear import [412, 426, 436]. However, none of these studies observed this 
phenomenon in the context of IAV infection and only 1 study focused on the HDAC4-
STAT1 interaction in response to a virus infection –VSV. In this study they were able to 
show that HDAC4 depletion decreased STAT1 phosphorylation and type I IFN signalling 
while overexpression of HDAC4 activated STAT1 inducing resistance to VSV infection 
[426]. Additionally, HDAC4 is also known to activate STAT2 during infection with HSV-
1 and vaccinia virus to promote type I IFN signalling [422]. Furthermore, it has been 
established that HDACs 1, 2, 3, 8 and 11 all play a role in promoting STAT1 activation 
under various conditions [224-226, 442, 443].  
In direct contrast with the data presented here, several studies have reported that HDAC4 
negatively regulates the innate immune response. Recently, 2 findings showed that HDAC4 
depletion inhibits VSV and HSV-1 replication [421, 508]. However, neither study reported 
the effect of HDAC4 overexpression on the growth of these viruses. Furthermore, a 
different cell type, Hep-2 cells were used which have been shown to have differential 
effects on HSV-1 replication where knockdown of STING inhibited HSV-1 replication 
where in other cell lines STING depletion promotes HSV-1 replication [444]. Another 
group reported that nuclear localized HDAC4 present prevents phosphorylated STAT1 
from binding to its target promoters by forming a complex with LXRα, HDAC4 and 
pSTAT1 [439]. Interestingly, this inhibitory activity is a result of HDAC4 sumoylation and 
not its deacetylase activity. This is in line with the data showing HDAC4 regulates STAT1 
in the cytoplasm through its deacetylase activity which promotes STAT1 phosphorylation 
and translocation into the nucleus to induce the type I IFN response. Thus, it seems that 
HDAC4 can play a dual role in both promoting and inhibiting the type I IFN signalling 
pathway. However, as mentioned above, this is highly dependent upon the cell line and 
conditions under which the type I IFN pathway is stimulated. Even so, in the context of 
IAV infection, it is apparent that HDAC4 promotes type I IFN signalling in order to 
restrict viral replication. The targeting of HDAC4 by IAV observed here and in another 
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study [427] provides further evidence towards the importance of HDAC4 as an anti-IAV 
host factor.  
We also investigated the effect on the JAK/STAT pathway in HDAC4-depleted cells after 
stimulation with IFNα. Here we found that the JAK/STAT signalling cascade was 
impaired in HDAC4-depleted cells, indicating that the antiviral role of HDAC4 is not 
specific to IAV, but a general response to viral infection (Figure 20). Here, 
phosphorylation of STAT1 was greatest at 2 hours post-treatment, indicating that IFN-α-
induced induction of STAT1 phosphorylation occurs sooner than this. Interestingly, the 
level of pSTAT1 is only slightly less in the HDAC4-depleted cells, however the levels 
diminish at a faster rate when compared to the HDAC4-expressing cells (Figure 20B). 
This is potentially due to the acetylation-phosphorylation switch previously observed in 
STAT1 signalling [445]. The acetylation of phosphorylated STAT1 at lysine residues K410 
and K413 induce a conformational change in the structure of phosphorylated STAT1. This 
exposes the phosphorylated tyrosine residue Y701 to the phosphatase T cell protein 
(TCP45) which then dephosphorylates STAT1 [513, 514]. Upon being dephosphorylated, 
STAT1 becomes inactive and translocates to the nucleus where it remains in a latent state 
[445]. Deacetylation of STAT1 by HDACs then allows STAT1 to become phosphorylated 
once more, allowing it to translocate back into the nucleus to promote the expression of 
immune genes (Figure 33). Hence, in HDAC4-depleted cells, STAT1 is dephosphorylated 
at a faster rate (Figure 16) and in cells overexpressing HDAC4, STAT1 remains 
phosphorylated for longer (Figure19). However, it still remains to be determined if 
HDAC4 actively deacetylates STAT1 as this has not been experimentally shown here. 
Furthermore, there is still some uncertainty within the literature regarding the acetylation-
phosphorylation switch of STAT1 as 1 study as suggested that STAT1 is not regulated by 
such a mechanism [515]. Nevertheless, it is clear that further investigations into the 
interaction between HDAC4 and STAT1 are necessary in order to understand how 
HDAC4 affects STAT1 phosphorylation in IAV-infected cells. Regardless, the 
downstream response to STAT1 phosphorylation had a consistent effect on the expression 
of the STAT1-regualted ISGs – viperin, ISG15 and IFITM3. 
However, there was an interesting discrepancy observed between the levels of IFITM3 
mRNA and polypeptide in IAV-infected, HDAC4 depleted cells. Here, the mRNA of 
IFITM3 was unchanged in response to HDAC4 knockdown (Figure 15), however, there 
was an obvious decrease in the polypeptide expression as compared to normal expressing 
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cells (Figure 16). A possible explanation for this is that HDAC4 does not promote the 
mRNA expression of IFITM3 but rather, indirectly enhances the stability of the IFITM3 
polypeptide. The stability of the IFITM3 polypeptide is known to be mediated by the E3 
ubiquitin ligase NEDD4 [446]. Ubiquitination of IFITM3 is primarily mediated by 
NEDD4 and results in the degradation of the IFITM3 polypeptide. As such, mutation of 
the ubiquitination sites on IFITM3 or knockdown of NEDD4 results in an increase in 
IFTIM3 stability [446, 447]. Previously, it has been shown that some members of the 
HDAC family including the Class IIa HDAC, HDAC5, repress NEDD4 gene expression 
[448, 449]. Therefore, it is possible that HDAC4 may also play a similar role in repressing 
NEDD4 expression and in its absence, NEDD4 expression is increased, leading to 
increased degradation of the IFITM3 polypeptide. Examining the effect of NEDD4 
expression in response to HDAC4 knockdown and overexpression would provide insight 
into this potential mechanism of IFITM3 regulation. An alternative explanation could be 
that the primers used to detect IFITM3 mRNA could be giving a false reading given that 
these primers were not tested in uninfected cells. Testing these primers in uninfected cells 
and using different primers to detect IFITM3 might resolve this discrepancy. Another 
limitation of the experiments performed pertains to the lack of mock infected cells in the 
experiments examining the mRNA levels of different ISGs in response to IAV infection 
(Figure 13, 15, 17, 18). The lack of mock infected controls for these experiments means 
that there is no discernible induction of these ISGs as a result of IAV infection. 
Furthermore, because the data is presented as percentages, it means the observations could 
be a result of background readings as opposed to an actual effect on the ISG mRNA 
expression in response to HDAC4 expression. This might further elucidate the 
inconsistency between the IFITM3 mRNA and polypeptide expressions. It might also be 
prudent to use antibodies to probe for any of the other ISGs whose mRNA levels did not 










CHAPTER IV - RESULTS: 
 
 THE ANTAGONISM OF HOST HISTONE 






The data presented in chapter II and III clearly demonstrate that host HDAC4 possesses 
anti-influenza properties and exerts its antiviral effect through being a component of host 
innate immune response against IAV. While obtaining these data, it became apparent that 
during the course of IAV infection, the polypeptide expression level of HDAC4 was being 
dramatically reduced. In fact, after 24 hours of infection with 1 MOI, HDAC4 polypeptide 
would often be undetectable. This level of antagonism indicated that IAV might be 
targeting HDAC4 to decrease its expression within the cell in order to disrupt its antiviral 
function, thereby allowing the virus to replicate more efficiently. Therefore, the purpose 
of this chapter is to identify the mechanism(s) that IAV employs to dysregulate HDAC4 
expression so effectively. Previous studies have shown that IAV dysregulates the 
polypeptide expression of other HDACs (HDAC1, 2 and 6) during the course of infection 
and this appears to be important in promoting viral replication. However, none of these 
HDACs appear to be antagonized as profoundly as has been observed here with HDAC4. 
This chapter explores the precise nature of HDAC4 dysregulation as a result of IAV 
infection including identifying the importance of viral dose and strain as well as the overall 
dysregulation kinetics over time. Furthermore, it looks into the role of some the common 
host mechanisms that regulate protein expression in the context of IAV-induced HDAC4 
dysregulation. Finally, this chapter aims to identify the specific IAV gene(s) that are 
responsible for inducing the dysregulation of HDAC4 during infection. 
4.1.1 IAV mechanisms of host manipulation that promote virus replication  
Many of the IAV proteins play a multifunctional role during infection where they are able 
to interact with specific host proteins in order to dysregulate the antiviral response and 
influence the cell physiology to be optimal for virus replication. NS1 is the most well 
characterised IAV protein in this regard and has been shown to be involved in host innate 
immune defence, host and viral mRNA expression, apoptosis, viral RNA splicing and 
morphogenesis. NS1 is able to bind with the host cell double-stranded RNA sensors such 
as protein kinase R (PKR), RIG-I, and 2’-5’ oligoadenylate synthetase [450-454]. The 
binding of NS1 to these sensors interferes with their function and prevents them from 
activating the innate immune response. Furthermore, NS1 is also able to interact with some 
of the regulators of these sensors such as the protein activator EIF2AK2, TRIM25 and 
NF90 [455-457]. For example, NS1 binds to the coiled-coil domain of TRIM25, blocking 
TRIM25-mediated activation of RIG-I [456]. NS1 also plays a role in suppression of 
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cellular mRNA nuclear export and subsequent expression, including the expression of type 
I interferon genes. NS1 achieves through interaction with poly(A)-binding protein II 
(PABII) as well as the host export machinery, thereby blocking the nuclear export of fully 
processed host mRNAs [39, 458]. Additionally, NS1 can also manipulate the cell cycle 
progression and delay virus-induced apoptosis through activation of the phosphoinositide 
3-kinase (PI3K)/AKT serine/threonine kinase 2 (AKT) pathway and interaction with p53 
[459, 460]. This prolongs the period of time which the cell is able to produce viral progeny 
and prolong the infection cycle. Conversely, NS1 has been shown to interact with heat 
shock protein 90 and alpha tubulin to promote apoptosis [461, 462]. Finally, NS1 promotes 
viral replication, RNA splicing and viral morphogenesis through utilization of several host 
factors. Translation of viral mRNA is enhanced by NS1 through interaction with eIF4GI 
and PABPI. Regulation of viral M1 RNA splicing is also mediated by NS1-binding protein, 
as it forms a complex with heterogeneous nuclear ribonucleoproteins [463]. In the late 
stages of infection, NS1 is believed to involved in the morphogenesis of the viral particle 
by binding with the Staufen protein [464, 465]. 
IAV NP is also known to interfere with cellular responses and suppresses the immune 
response. NP is able to interact with the DExD-box helicase 39B and high mobility group 
box 1 (HMGB1) which promotes viral RNA synthesis and viral replication. Additionally, 
NP has been found to interact with the chaperone protein heat shock protein 40 (Hsp40). 
This interaction is thought to prevent the phosphorylation of PKR and the subsequent 
activation of the downstream antiviral IFN response [44, 466, 467]. 
The IAV RdRp is the key enzyme that drives the virus replication cycle and consists of 
three individual polypeptides, PB1, PB2 and PA. While the primary role of the RdRp is to 
carry out the transcription of viral genes, it has also been shown to antagonise cellular 
processes too. For example, RdRp can inhibit RNA Pol II transcription by inducing the 
degradation of Pol II via the ubiquitin-proteasome system [468]. Additionally, it is believed 
that because of its cap-snatching activity, RdRp can promotes the degradation of nasecent 
RNAs through the activity of host exonucleases such as Xrn1 and Xrn2 [469].  
The PB1 gene segment also encodes a variant of the PB1 protein known as PB1-F2 which 
is encoded by an alternate (+1) reading frame within the Pb1 gene. PB1-F2 has been 
described as another IAV protein that is involved in blocking the host immune response. 
PB1-F2 is able to interact with MAVS and other components of the RIG-I/MAVS system 
which leads to a decreased production of cytokines such as IFN-β, IL-6, IL-8, and IL-1β 
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[470-472]. Additionally, PB1-F2 is able to interfere with some of the downstream pathways 
of the RIG-I/MAVS including the IRF3, the NF-ΚB and the TBK1 pathways to further 
dysregulate the IFN signalling [473-475]  
PA-X is a recently discovered protein that is derived as a result of ribosomal frameshifting 
during translation and has been well characterised for its role in host shutoff activity 
through host RNA degradation. PA-X has been found to preferentially destabilise host 
mRNA synthesised by cellular Pol II, which is responsible for transcribing all host mRNA 
and many non-coding RNAs in the cell. This preferentially targeting of RNA transcribed 
by Pol II means that viral RNAs are spared from PA-X mediated degradation as these are 
transcribed by the viral RdRp. Pol II-transcribed mRNAs undergo PA-X-mediated 
endonucleolytic cleavage which then allows the host 5’-3’-exonuclease Xrn1 to complete 
the degradation of the RNA [48].  
4.1.2 Mechanisms of cellular HDAC4 regulation 
Appropriate regulation of HDAC4 is highly important for healthy development, therefore, 
it is unsurprising that there several layers of regulation within the cell that control when, 
and where HDAC4 is expressed. MicroRNAs (miRNAs) are a class of regulatory RNAs 
that have been shown to modulate HDAC4 expression which include miR-1, miR-29, miR-
140, miR-155, miR-200a, miR-206, and miR-365 in a variety of different cell types [388]. 
These miRNAs target GC regions in the 3’ UTR region of the HDAC4 mRNA and thereby 
repress its expression.  
HDAC4 is able to shuttle between the cytoplasm and the nucleus in response to various 
stimuli [476]. This change in HDAC4 subcellular distribution has been identified as a key 
way in which the cell is able to rapidly modulate HDAC4-controlled gene expression. Post-
translational modifications have been identified has key regulators that determine where 
HDAC4 localises, which can have a profound effect on a number of cellular responses. 
Recent evidence has shown that HDAC4 is subject to phosphorylation, sumoylation, 
ubiquitination as well proteolytic cleavage, all of which control HDAC4 distribution and 
function. Phosphorylation/dephosphorylation is an important regulatory mechanism of 
HDAC4 as it efficiently and rapidly couples the repression of HDAC4 to environmental 
signals. Phosphorylation of HDAC4 is carried out by calcium/calmodulin-dependent 
protein kinase (CaMK), extracellular signal-regulated kinases 1 and 2 (EPK1/2), protein 
kinase A (PKA) and glycol synthase kinase 3 (GSK3). HDAC4 contains phosphoserine 
binding sites that, upon being phosphorylated, allow for binding with the 14-3-3 chaperone 
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protein. This interaction occurs within in the nucleus and results in the escort of HDAC4 
into the cytoplasm leading to the activation of HDAC4-target genes [477-479]. CaMK 
phosphorylation of HDAC4 promotes myogenesis through disruption of MEF2-HDAC4 
complexes and induction HDAC4 nuclear export [480]. Phosphorylation by PKA induces 
the proteolytic cleavage of HDAC4 at tyrosine 207 by some unknown protease which leads 
to a nuclear accumulation of the generated N-terminal fragment of HDAC4 capable of 
selectively inhibiting MEF2, but not other HDAC4 target genes [481]. Additionally, GSK3 
can phosphorylate HDAC4 at position 298 and 302 to induce proteasome-mediated 
degradation which shown to be important in regulating random cell motility [482]. HDAC4 
is also known be dephosphorylated by protein phosphatase 2A (PP2A) at multiple serine 
residues on the polypeptide including at the 14-3-3 binding sites. This induces its nuclear 
import and subsequent reinstatement of its transcriptional repression activity [483]. 
Sumoylation has also been reported to be important for the enzymatic functionality of 
HDAC4. Specifically, SUMO-1 recognises HDAC4 at a single lysine residue (lysine599) 
which does not affect the subcellular distribution, but seems to be important in promoting 
the transcriptional repression and enzymatic activities of HDAC4 [484, 485]. Finally, direct 
proteolytic cleavage of HDAC4 has been shown to be a highly important mechanism for 
regulating HDAC4 activity and promoting apoptosis. Caspase-mediated cleavage of 
HDAC4 polypeptide has been shown to occur at aspartic acid 289 which generates a small 
N terminal fragment. This N-terminal fragment possesses a nuclear localization sequence 
and after cleavage is translocated into the nucleus where it inhibits transcription, induces 




4.2.1 HDAC4 polypeptide expression is downregulated in a cell line independent 
manner 
In order to further understand the IAV-induced downregulation of HDAC4 polypeptide, 
several experiments were performed. Firstly, the effects of varying IAV doses was explored 
to determine if there was a correlation between IAV dose and HDAC4 antagonism. A549 
cells were infected with PR8 at an MOI of 0.5 or 5.0 for 24 hours. The total cell lysates 
were prepared and HDAC4, actin and viral NP were detected by WB. The protein bands 
were visualised using the Odyssey Fc imaging system (LI-COR) and the HDAC4 and actin 
bands were quantified using Image Studio Lite software. HDAC4 was normalized to actin, 
then the normalized amount of HDAC4 in the uninfected sample was considered 100% 
in order to compare it to the infected, 0.5 and 5.0 MOI samples. The WB analysis revealed 
that the IAV-induced downregulation of HDAC4 was a dose-dependent response, with 
greater HDAC4 antagonism occurring at higher doses (Figure 22A). Quantitation of 3 
independent experiments revealed the IAV-induced antagonism of HDAC4 reduced the 
polypeptide by 36.5% at 0.5 MOI and 52% at 5.0 MOI when compared to uninfected cells 
harvested at the same time (Figure 22B). 
Additionally, IAV-induced antagonism of the HDAC4 polypeptide was also analysed in 
MDCK cells. Despite these cells not being physiologically relevant, MDCK cells are 
conducive to IAV infection and have been extensively used to study IAV biology. MDCK 
cells were infected for 24 hours with PR8 at either 0.5 or 5.0 MOI or were left uninfected. 
Following this, the cells were harvested and whole cell lysates were analysed by WB. Once 
again, WB analysis revealed a dose-dependent downregulation of the HDAC4 polypeptide 
after IAV infection. Furthermore, the antagonism was enhanced in MDCK cells as 
compared to A549 cells (Figure 23A). Quantitation of 3 independent experiments 
revealed the HDAC4 polypeptide was downregulated by 57.9% and 86.8% after infection 
at 0.5 and 5.0 MOI respectively, as compared to uninfected cells (Figure 23B).  
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Figure 22. IAV downregulates HDAC4 polypeptide level in A549 cells. A549 cells were 
infected with PR8 at 0.5 MOI or 5.0 MOI. (A) After 24 hours, the UNI and infected (0.5 and 5.0) 
cells were harvested, total cell lysates were prepared, and HDAC4, actin (42 kDA) and viral NP 
polypeptides were detected by WB. (B) The HDAC4 and actin bands in panel (A) blot were 
quantified using Image Studio Lite software (LI-COR). The levels of HDAC4 in each sample was 
then normalized with the corresponding actin levels. Finally, the normalized level of HDAC4 in 
UNI sample was considered 100% to compare its level in infected (0.5 or 5.0) cells. Error bars 
represent means ± standard errors of the means of 3 independent experiments. P value calculated 











Figure 23. IAV downregulates HDAC4 polypeptide level in MDCK. MDCK cells were 
infected with PR8 at 0.5 MOI or 5.0 MOI. (A) After 24 hours, the UNI and infected (0.5 and 
5.0) cells were harvested, total cell lysates were prepared and HDAC4, actin and viral NP 
polypeptides were detected by WB. (B) The HDAC4 and actin bands in panel (A) blot were 
quantified using Image Studio Lite software (LI-COR). The levels of HDAC4 in each sample was 
then normalized with the corresponding actin levels. Finally, the normalized level of HDAC4 in 
UNI sample was considered 100% to compare its level in infected (0.5 or 5.0) cells. Error bars 
represent means ± standard errors of the means of 3 independent experiments. P value calculated 
using unpaired t test. MW, molecular weight.  
A B 
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4.2.2 IAV-induced antagonism of HDAC4 polypeptide is strain-independent  
Next, we wanted to determine if the IAV-induced antagonism of HDAC4 is strain-
independent. Here, A549 cells were infected for 24 hours with the clinically relevent strain 
CA09 (at 0.5 or 5.0 MOI) or another lab-adapted strain, WSN (at 1.0 or 3.0 MOI). The 
cells were then harvested and whole cell lysates were used to detect the polypeptide 
expression of HDAC4, actin and viral NP by WB. Consistent with the previous 
observations using PR8, both CA09 (Figure 24A) and WSN (Figure 24B) downregulated 
the HDAC4 polypeptide expression in a dose-dependent manner. 
Additionally, a further experiment was performed using UV-irradiated IAV to ascertain if 
a productive infection is required to antagonise the HDAC4 polypeptide. For this, A549 
cells were infected for 24 hours with either UV-irradiated PR8, or ‘live’ PR8, or left 
uninfected. UV-irradiation inactivates the genetic material of the virus, rendering it unable 
to replicate. However, the virus still retains its antigenic nature, capable of eliciting and 
immune response [490]. WB analysis revealed that the HDAC4 polypeptide expression in 
cells infected with UV-irradiated virus was comparable in uninfected cells (Figure 24C). 
Absence of viral NP confirmed that the UV-irradiated virus was unable to replicate. 
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Figure 24. Downregulation of HDAC4 polypeptide is strain-independent. (A and B) 
MDCK cells were infected for 24 hours with (A) CA09 (at MOI of 0.5 or 5.0) or (B) WSN (at 
MOI 1.0 or 3.0). The UNI and infected (0.5, 1.0, 3.0 and 5.0) cells were harvested, total cell lysates 
were prepared and HDAC4, actin and viral NP polypeptides were detected by WB. (C) MDCK 
cells were infected with ‘live’(INF) or UV-irradiated (INFUV) PR8 at an MOI of 0.5 for 24 hours. 
Total cell lysates were prepared, and HDAC4, actin and viral NP polypeptides were detected by 
WB. Data is representative of a single repeat. MW, molecular weight.  
A C B 
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4.2.3 IAV-induced antagonism of the HDAC4 polypeptide is time-dependant  
The above results were observed 24 hours post-infection, however, the antagonism of 
HDAC4 was likely occurring much earlier. Therefore, we wanted to understand the 
antagonism kinetics of the HDAC4 polypeptide over the 24-hour infection period. Due to 
the greater level of IAV-induced antagonism of HDAC4 observed above, MDCK cells 
were chosen for these experiments. For this, MDCK cells were infected with PR8 at 1.0 
MOI and were harvested after 2, 6, 12 and 24 hours of infection. The total cell lysates were 
prepared and resolved on a 7-12% gradient SDS-PAGE and HDAC4, PDI and viral NP 
were detected by WB (Figure 25A). Intriguingly, use of a gradient gel revealed 2 smaller 
HDAC4 fragments of approximately 90 kDa and 30 kDa in size. These fragments first 
appeared around 12 hours post- infection and intensified at 24 hours. This indicated that 
the IAV-induced antagonism of HDAC4 was occurring as result of the polypeptide 
undergoing proteolysis. Previously, it has been reported that another class II HDAC, 
HDAC6 is also cleaved during IAV infection as a result of the activity of caspase 3 [369]. 
Additionally, the first signs of HDAC4 cleavage occur around the same time that viral NP 
is cleaved, which is also cleaved by caspase 3 [79]. Therefore, the same samples were 
probed with caspase 3 antibody to determine if the inactive form (Cas3-FL) was being 
cleaved into the active form (Cas3-CL) at a similar time. Interestingly, WB analysis revealed 
a significant accumulation of the Cas3-CL by 12 hours post infection, indicating that 
activated caspase 3 could be cleaving the HDAC4 polypeptide. Visualisation of HDAC4 
full length polypeptide revealed that IAV-induced antagonism was most profound within 
the 12- to 24-hour time period. The HDAC4 and PDI protein bands from panel (A) blot 
were quantified using Image Studio Lite software (LI-COR). Full length HDAC4 was 
normalized to the corresponding PDI. Then, the normalized amount of HDAC4 at the 2-
hour time point was considered 100% for comparisons to the 6, 12 and 24-hour time 
points. This analysis revealed no significant change in HDAC4 polypeptide level at 6 hours 
and widely variable levels at 12 hours post-infection. However, at 24 hours postinfection, 
there was a significant 82% reduction in HDAC4 full length polypeptide (Figure 25B). 
















Figure 25. IAV-induced HDAC4 polypeptide downregulation occurs in a time-dependent 
manner. (A) MDCK cells were infected with PR8 at an MOI of 1.0, and harvested after 2, 6, 12 
and 24 hours. Total cell lysates were prepared and resolved on a 7-12% gradient SDS-PAGE, and 
HDAC4, PDI, viral NP, full length caspase 3 (Cas3-FL) (35 kDa) and cleaved caspase 3 (Cas3-CL) 
(17 kDa) were detected by WB. Arrows indicate the HDAC4 polypeptide cleavage products. MW 
lane was combined with the rest of the lanes after removing an unwanted middle lane. (B-D) The 
intensity of the full length HDAC4 (B), NP (C), and Cas3-CL (D) bands in panel (A) were 
quantified and then normalized with the corresponding PDI levels or Cas3-FL for (D). Finally, the 
normalized level of HDAC4, NP or Cas3-CL in the 2-hour time point (2 h) was considered 100% 
or 1 fold to compare the amount to the other time points. The HDAC4 blot is the upper and lower 
half of the same blot as is the caspase 3 blot. Error bars represent means ± standard errors of the 





4.2.4 Lysosomally-associated caspase 3 cleaves HDAC4 polypeptide in IAV-
infected cells 
The above data revealed the IAV-induced antagonism of HDAC4 involved proteolytic 
cleavage of the HDAC4 polypeptide. Therefore, the next step was to identify the 
degradation pathway responsible for the IAV-induced cleavage of the HDAC4 
polypeptide. In mammalian cells two main pathways exist that facilitate the degradation of 
polypeptides; the lysosome-mediated and proteasome-mediated pathways. The lysosome 
pathway is the major pathway involved in the turnover of cytosolic proteins. Lysosomes 
are acidic membrane-bound vesicles which contain a variety of hydrolytic enzymes used to 
break down macromolecules within the cell. The proteasome pathway is able to degrade 
both cytosolic and nuclear associated proteins. This pathway involves the tagging of 
unwanted or damaged proteins through the small protein called ubiquitin. Upon being 
tagged, the proteasome, a large protein complex, is able to recognise and subsequently 
degrade the protein. Previously, our lab has shown that during IAV infection, both 
HDAC1 and HDAC2 polypeptides are degraded via the proteasome pathway [225, 226]. 
Therefore, it is likely that the proteasome pathway is degrading the HDAC4 polypeptide 
during IAV infection. However, as mentioned above, caspases are also likely candidates. 
In order to identify which of these pathways might be involved, we perturbed each using 
the lysosome inhibitor NH4Cl and the proteasome inhibitor MG132. Additionally, we used 
a caspase 3 inhibitor (Cas3-I) to determine if caspase 3 was involved. For this, half of a set 
of MDCK cells were infected with PR8 at 1.0 MOI for 24 hours while the other half were 
left uninfected. After 1 hour, the culture media was replaced with SF-MEM containing 
NH4Cl (10 mM), MG132 (20 µM) or Cas3-I (40 µM) as these concentrations of the 
inhibitors have been shown to inhibit the respective pathways [491, 492]. Additionally, an 
untreated mock set of cells were infected or left uninfected exactly as described above. 
After 24 hours, the cells were harvested and whole cell lysates were prepared the levels of 
HDAC4, PDI, viral NP and caspase 3 were detected by WB. The analysis revealed the 
treatments of NH4Cl and Cas3-I rescued the full length HDAC4 polypeptide in IAV-
infected cells. Additionally, the recovery of the HDAC4 polypeptide in the Cas3-I samples 
coincided with the inhibited activation of caspase 3 in infected cells. Caspase 3 activation 
was determined by conversion of the inactive, full length form (Cas-FL) into the active, 
cleaved form (Cas-CL). Further, caspase 3 activation in NH4Cl-treated infected cells was 
partially inhibited (Figure 26A). Compared to 81% reduction of the full length HDAC4 
polypeptide level in mock-treated cells, there was only a 54% and a 46% reduction in cells 
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treated with NH4Cl and Cas3-I, respectively. In other words, HDAC4 polypeptide levels 
recovered from 19% to 46% and 54% in NH4Cl and CAS3-I-treated infected cells, 
respectively (Figure 26B). Interestingly, MG132 treatment actually enhanced HDAC4 
cleavage in infected cells and even induced cleavage in uninfected cells (Figure 26A). 
Quantitation of the infected, MG132-treated cells revealed a 94.4% reduction in the 
HDAC4 full length polypeptide (Figure 26B). The effect of MG132 treatment on 
HDAC4 polypeptide levels, both in uninfected and infected cells, further indicated 
caspases are responsible for cleaving HDAC4. MG132 treatment is known to induce 
apoptosis (hence caspase activation) in mammalian cells [509].  
The above data indicated that caspase 3 cleaves HDAC4 during IAV infection, however, 
the caspase inhibitor used is also known to inhibit the other executioner caspases; 6 and 7. 
This meant that other caspases might also play a role in the IAV-induced cleavage of 
HDAC4. Caspase 3, 6 and 7 are the executioner caspases that are involved in apoptotic-
mediated protein cleavage. The other members of the caspase family are known as the 
initiator caspases, which are upstream activators of the executioner caspases. The initiator 
caspases cleave the procaspase form of the executioner caspase into a smaller, activated 
form. Therefore, we wanted to identify specific which executioner caspase(s) cleaves 
HDAC4 during IAV infection so we decided to conduct a knockdown screen of the 
executioner caspases. Here, two sets of A549 cells were transfected with 10 nM of CT 
siRNA or siRNA targeting caspase 3 (Cas3), caspase 6 (Cas6) or caspase 7 (Cas7) for 72 
hours. Then, the first set of cells were harvested immediately and the total RNA was 
extracted to confirm the knockdown of each caspase via qPCR. Meanwhile, the second set 
of cells were either infected for 24 hours with PR8 at 1.0 MOI or were left uninfected. The 
cells were then harvested and total cell lysates were prepared and HDAC4, PDI and viral 
NP were detected by WB. The WB analysis revealed that caspase 3 knockdown recovered 
the full length HDAC4 polypeptide in infected cells, whereas knockdown of caspase 6 and 
caspase 7 did not (Figure 27A). qPCR analysis of the uninfected caspase siRNA-treated 
cells revealed that all 3 caspases were successfully knocked down. Specifically, there was a 
90.6%, 96.1% and 94.6% reduction in caspase 3, 6 and 7 mRNA expression, respectively 
(Figure 27B).  
Knockdown of the executioner caspase revealed that only caspase 3 was involved in the 
IAV-induced cleavage of HDAC4. Therefore, a further knockdown experiment was 
performed solely on caspase 3, in order to quantify the recovery of the full length HDAC4 
polypeptide in caspase 3 depleted, IAV-infected cells. In addition, the effect of caspase 3 
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depletion on the HDAC4 cleavage products was also investigated. Again, A549 cells were 
treated with CT or Cas3 siRNA as described above. Next, an uninfected subset of the cells 
was harvest for WB to determine the level of caspase 3 polypeptide in CT and Cas3 siRNA-
treated cells. Meanwhile, the other set of cells were infected for 24 hours with PR8 at 1.0 
MOI, or were left uninfected. Cells were harvested and total cell lysates were prepared and 
HDAC4, actin, viral NP and caspase 3 were detected by WB. Again, the analysis revealed 
that caspase 3 was sufficiently depleted in the cas3 siRNA-treated cells. Additionally, the 
full length HDAC4 polypeptide was restored in caspase 3 depleted, IAV-infected cells. 
However, the HDAC4 cleavage products remained in the Cas3 siRNA-treated cells, albeit 
at decreased levels as compared to CT siRNA-treated cells. Interestingly, in the Cas3 
siRNA-treated cells, the HDAC4 cleavage product (denoted c) disappeared entirely, 
however a new product (denoted a) appeared slightly above cleavage product b (Figure 
28A). Quantitation of the full length HDAC4 bands revealed that, consistent with the 
previous observations, knockdown of caspase 3 expression rescued the full length HDAC4 
polypeptide in IAV-infected cells. Specifically, IAV infection induced a 77% reduction in 
the full length HDAC4 polypeptide level in CT siRNA-treated cells, whereas there was 
only a 29.4% reduction in Cas3 siRNA-treated cells. In other words, the full length 
HDAC4 polypeptide level in infected cells depleted of caspase 3, recovered to 70.6% from 
its level at 23.5% in infected cells expressing normal levels of caspase 3 (Figure 28B). 
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Figure 26. NH4Cl and caspase inhibitor treatments recover full length HDAC4 polypeptide 
in infected cells. (A) MDCK cells were infected with PR8 at an MOI of 1.0 and, after removing 
the virus inoculum, were treated with NH4Cl (10 mM), MG132 (20 µM), or caspase 3 inhibitor 
(Cas3-I; 40 µM). After 24 hours, the uninfected (UNI) and infected (INF) cells were harvested, 
total cell lysates were prepared, and HDAC4, PDI, viral NP, Cas3-FL and Cas3-Cl were detected 
by WB. The arrows and letters indicate the different cleavage products detected. (B) The intensity 
of the full length HDAC4 bands were quantified and then normalized to the corresponding PDI 
levels. The normalized levels of HDAC4 for each treatment in the UNI cells was considered 100% 
to compare its amount to the respective treatment in the INF cells. The HDAC4 blot is the upper 
and lower half of the same blot as is the caspase 3 blot. Error bars represent means ± standard 
errors of the means of 3 independent repeats. P value calculated using unpaired t test. MW, 






Figure 27. Caspase 3, not caspase 6 or 7 cleaves HDAC4 polypeptide in IAV-infected cells. 
(A) A549 cells were transfected in duplicates with 10 nM of CT, caspase 3 (Cas3), caspase 6 (Cas6) 
or caspase 7 (Cas7) siRNA for 72 hours. One set of the cells were infected with PR8 at an MOI of 
1.0. After 24 hours the cells were harvested and HDAC4, PDI and viral NP were detected by WB. 
(B) To confirm the knockdown of caspase 3, 6 and 7, the second set of the cells in panel (A) were 
processed to detect levels of caspase 3, 6 or 7 and actin mRNAs by qPCR. Then, the levels of 
caspase 3, 6 or 7 mRNA in CT siRNA-treated cells and caspase siRNA-treated cells was normalized 
to the corresponding actin mRNA levels. Finally, the normalized level of caspase 3, 6 or 7 mRNA 
in CT siRNA-treated cells was considered 100% to compare its level in the corresponding caspase 
siRNA-treated cells. (C) The intensity of the full length HDAC4 bands in panel (A) blot were 
quantified and then normalized with the corresponding PDI levels. Finally, the normalized level of 
HDAC4 in CT siRNA-treated UNI cells was considered 100% to compare its levels in CT, Cas3, 
Cas6 and Cas7 siRNA-treated cells. Error bars represent means ± standard errors of the means of 




Figure 28. Knockdown of caspase 3 expression allows retention of full-length HDAC4 
polypeptide in infected cells. (A) A549 cells were transfected with 10 nM of CT siRNA or cas3 
siRNA for 72 hours. Half of the cells were left uninfected (UNI) while the other half were infected 
(INF) with PR8 at an MOI of 1.0. After 24 hours, both sets of cells were harvested and HDAC4, 
actin, viral NP and caspase-3 were detected by WB. Detection caspase 3 confirmed that the 
knockdown was successful. (B) The intensity of the full length HDAC4 bands in panel (A) blot 
were quantified and then normalized with the corresponding actin levels. Finally, the normalized 
level of HDAC4 in CT siRNA-treated UNI cells was considered 100% to compare its levels in CT 
siRNA-treated INF cells and Cas3 siRNA-treated INF cells. The HDAC4 blot is the upper and 
lower half of the same blot as is the caspase 3 blot. Error bars represent means ± standard errors 
of the means of 3 independent experiments. P value calculated using unpaired t test. MW, 




4.2.5 The IAV protein PA-X is involved in the downregulation of HDAC4  
We also wanted to identify which IAV gene(s) were involved in the IAV-induced 
antagonism of HDAC4. As mentioned above, the IAV genome consists of 8 gene 
segments, each of which encodes at least 1 protein. IAV encodes several non-structural 
genes which aid in viral replication by inhibiting certain host signalling pathways, 
particularly those involved in the immune response. However, studies have also revealed 
that some of the structural genes, namely viral NP and viral HA, can also dysregulate 
certain host responses [466, 493]. Therefore, to identify which IAV gene(s) are responsible 
for the antagonism of HDAC4, we performed an RNAi screen targeting 4 viral gene 
segments: NP, NS, PA, and PB1, using the previously described siRNAs [494]. To 
accomplish this, 50 nM of siRNAs targeting NP, NS, PA, PB1 and the CT siRNA were 
delivered into A549 cells for 24 hours. The cells were then infected for 24 hours with PR8 
at 1.0 MOI. Next, half of the cells were harvested for total RNA content to confirm the 
knockdown, while the other half were harvested and the total cell lysates were prepared. 
HDAC4, PDI and viral NP were detected by WB in order to determine the effect of viral 
gene knockdown on HDAC4 polypeptide expression. Additionally, the culture media was 
titrated by plaque assay to examine the effect of viral gene knockdown on IAV replication. 
The WB analysis revealed that knockdown of the PA gene segment was sufficient to rescue 
the level of the full length HDAC4 polypeptide in infected cells. However, despite the 
recovery in the full length polypeptide, HDAC4 cleavage fragments still remained (Figure 
29A). In addition, quantification of the full length HDAC4 bands in the PA siRNA-treated 
samples revealed the recovery was only partial. Specifically, compared to the 74.1% 
reduction in the full length HDAC4 polypeptide level in CT siRNA-treated cells, there was 
only a 39.9% reduction in PA siRNA-treated cells. In other words, the level of full length 
HDAC4 polypeptide in PA siRNA-treated, infected cells, recovered to 65.8% from its level 
at 25.9% in CT siRNA-treated infected cells (Figure 29B). The depletion of the various 
viral genes was confirmed by qPCR, specifically, NP was depleted by 79.6%, NS1 by 
24.6%, PA by 94.8% PA-X (encoded on the PA gene segment) by 94.2% and PB1 by 86% 
(Figure 29C). Additionally, plaque assay of the culture media revealed that the NP and 
PA siRNAs caused an approximate 1 log reduction in virus titre, whereas the NS and PB1 
siRNAs had minimal effect (Figure 29D). 
The recovery of the full length HDAC4 polypeptide observed in cells transfected with PA 
siRNA indicated that one of the proteins encoded on this segment is involved in the 
antagonism of HDAC4. From the known proteins encoded on PA, we wondered if PA-X 
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was the protein involved in the antagonism of HDAC4. The recently discovered IAV 
protein PA-X is expressed as a result of ribosomal frameshifting during translation of the 
PA gene segment [495]. It is an RNA endonuclease and identified as playing an important 
role in promoting host shutoff activity through selective degradation of host mRNA. 
Therefore, to determine if PA-X was inducing the antagonism of HDAC4, we transfected 
a plasmid containing the PA-X gene into A549 cells. After 48 hours, the cells were 
harvested and total cell lysates were prepared and HDAC4 and PDI were detected by WB. 
Consistent with the above PA knockdown data, expression of PA-X alone was able to 
downregulate the full length HDAC4 polypeptide in A549 cells. However, despite the 
downregulation of the full length HDAC4 polypeptide in PA-X transfected cells, no 
HDAC4 cleavage fragments could be detected (Figure 30A). Importantly, we have 
previously determined that even in the presence of caspase inhibitor, PA-X expression 
alone is still able to downregulate HDAC4 polypeptide expression, suggesting PA-X is 
dysregulating HDAC4 through an alternative alternate mechanism [522]. Quantitation of 
the full length HDAC4 across 3 independent experiments revealed that compared to the 
cells transfected with an empty plasmid, there was a 73.3% reduction in the HDAC4 
polypeptide level in cells transfected with PA-X plasmid (Figure 30B). Finally, we were 
able to determine the successful expression of PA-X from the measuring the absolute copy 
number. This was estimated by comparing its ct value to a standard curve calibrator, made 
with same plasmid (Figure 30C). 
Because PA-X was not involved in inducing the cleavage of the HDAC4 polypeptide, we 
decided to investigate if PA-X was antagonising HDAC4 at the mRNA level instead. For 
this, A549 cells were infected for 24 hours with PR8 at an MOI of 0.5 or 5.0, after which 
the cells were processed to isolate the total RNA content. The quality and quantity of the 
isolated RNA was analysed by measuring the 260/280 and 260/230 ratios using a 
Nanodrop reader spectrophotometer (ThermoScientific). Next, cDNA was synthesised 
and used as a template to measure the level of HDAC4 and viperin mRNA by qPCR using 
SYBR green chemistry. The ct values obtained were analysed using the relative quantitation 
method as described above, using the reference gene actin. The analysis revealed that IAV 
infection caused a significant 78.9% and 96.2% reduction in HDAC4 mRNA level at 0.5 
and 5.0 MOI, respectively (Figure 31A). Here, viperin, which was greatly increased in the 
infected samples, was used as an infection marker (Figure 31B).  
The above data indicated that IAV antagonises HDAC4 not only at the polypeptide level, 
but also at the mRNA. Next, we wanted to determine if PA-X was responsible for the 
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antagonism of the HDAC4 mRNA. In order to investigate this, A549 cells were transfected 
with CT siRNA or PA siRNA for 24 hours. Following this, the cells were infected for 24 
hours with PR8 at 1.0 MOI. The cells were then harvested for total RNA and processed 
to measure the levels of HDAC4 and actin mRNA and 18SRNA by qPCR. The level of 
HDAC4 mRNA in cells transfected with PA siRNA was significantly recovered as 
compared to cells transfected with CT siRNA. Specifically, when normalizing to the actin 
levels, the level of HDAC4 mRNA in the PA siRNA-treated cells recovered to a significant 
58.3% from its level at 8.7% in CT siRNA–treated cells. Similarly, when normalized to 
18SRNA, the levels recovered from 69.4% in PA siRNA-treated cells to 7.2% in CT 
siRNA-treated cells (Figure 32A). Finally, in order to confirm that PA-X was antagonising 
the HDAC4 mRNA, we expressed PA-X from a plasmid in A549 cells and subsequently 
analysed the level of HDAC4 mRNA by qPCR. Consistent with the above observations, 
PA-X expression alone was sufficient to reduce the level of HDAC4 mRNA in A549 cells. 
When normalized to actin mRNA and 18SRNA levels and compared to cells transfected 
with empty plasmid, there was a 43.8% and 57.6% decrease, respectively, in HDAC4 
mRNA level in the cells transfected with PA-X (Figure 32B).   
110 
Figure 29. Knockdown of viral PA gene expression recovers full length HDAC4 
polypeptide (A-C) A549 cells were transfected in duplicate with CT siRNA or siRNA targeting 
viral NP, NS, PA or PB1 for 24 hours. The cells were then infected with PR8 at an MOI of 1.0 for 
24 hours. (A) One set of the cells were harvested and HDAC4, PDI and viral NP were detected 
by WB. (B) The intensity of the HDAC4 and PDI bands was quantified using the Image Studio 
Lite software (LI-COR). The levels of HDAC4 was then normalized with the corresponding PDI 
levels. Finally, the normalized level of HDAC4 in CT siRNA-treated UNI cells was considered 
100% to compare its levels in CT siRNA-treated INF cells and the viral gene siRNA-treated INF 
cells. (C) To confirm the knockdown of the different IAV genes, the second set of cells total RNA 
was processed to measure the levels of viral NP, NS1, PA, PA-X, PB1 and cellular actin mRNA 
by qPCR. Then, the levels of the respective IAV gene mRNA in CT siRNA-treated cells and the 
analogous IAV gene siRNA-treated cells were normalized with corresponding actin mRNA levels. 
Finally, the normalized levels of the viral gene mRNA in CT siRNA-treated cells were considered 
100% to compare their levels in the respective IAV gene siRNA-treated cells. (D) The culture 
media from (A) was titrated by plaque assay to determine the effect of the different IAV gene 
siRNAs on the replication efficiency of the virus by measuring the titres of the released viral 
progeny. The HDAC4 blot is the upper and lower half of the same blot. Error bars represent 
means ± standard errors of the means of 3 independent experiments. P value calculated using 






      
Figure 30. IAV PA-X expression alone is sufficient to downregulate HDAC4. (A-C) A549 
cells were transfected in duplicates with either lipofectamine 2000 (LF), 1 µg of empty plasmid 
pcDNA3.1(-) (pc) or 1 µg of plasmid expressing PA-X (PX) for 48 hours. (A) The first set of cells 
were harvested and HDAC4 and PDI polypeptides were detected in total cell lysates by WB. (B) 
The intensity of the HDAC4 and PDI bands in panel (A) blot were quantified using the Image 
Studio Lite software (LI-COR). The levels of HDAC4 was then normalized with the corresponding 
PDI levels. Finally, the normalized level of HDAC4 in pc-transfected cells was considered 100% 
to compare its levels in PX-transfected cells. (C) To confirm the overexpression of PA-X, the 
second set of cells were processed to determine the PA-X mRNA by qPCR using the PA-X plasmid 
as a calibrator. For this, PA-X mRNA was detected in PX-transfected cells and serial 10-fold 
dilutions of PA-X plasmid. The PA-X mRNA in serial dilutions were calculated using the plasmid 
DNA concentration and the molecular weight. Then, ct value versus copy number standard curve 
was generated, which was then used as a reference to calculate the PA-X mRNA in PX-transfected 
cells. The HDAC4 blot is the upper and lower half of the same blot. Error bars represent means 
± standard errors of the means of 3 independent experiments. P value calculated using unpaired t 
test. MW, molecular weight.  











Figure 31. IAV reduces HDAC4 mRNA level. A549 cells were infected with PR8 at either 0.5 
MOI or 5.0 MOI. After 24 hours of infection the levels of HDAC4 (A), viperin (B) and actin 
mRNA levels were detected by qPCR. Then the levels of HDAC4/viperin were normalized with 
the corresponding actin mRNA levels. Finally, normalized levels of HDAC4 (A) or viperin (B) 
mRNA in the uninfected (UNI) samples was considered 100% (A) or 1-fold (B) to compare their 
levels in the infected cells. Error bars represent means ± standard errors of the means of 3 




Figure 32. IAV protein PA-X downregulates HDAC4 mRNA. (A) A549 cells were transfected 
with 10 nM of CT or PA siRNA for 24 hours. The cells were subsequently infected with PR8 at 
1.0 MOI for 24 hours. The levels of HDAC4, actin and 18S ribosomal (18SRNA) RNA were 
detected by qPCR. Then, the levels of HDAC4 mRNA in all samples were normalized with 
corresponding actin mRNA or 18S RNA levels. Finally, the normalized levels of HDAC4 mRNA 
in CT siRNA-treated UNI cells were considered 100% to compare its levels in CT siRNA-treated 
INF cells and PA siRNA-treated cells. (B) A549 cells were transfected with 1 µg of pc plasmid or 
1 µg of PX plasmid for 48 hours. The mRNA levels of HDAC4, actin and 18S RNA were detected 
by qPCR. Then, the levels of HDAC4 mRNA in all samples were normalized with the 
corresponding actin mRNA or 18S RNA levels. Finally, the normalized level of HDAC4 mRNA 
in pc-transfected cells was considered 100% to compare its levels in PX-transfected cells. Error 
bars represent means ± standard errors of the means of 3 independent experiments. P value 




While investigating the anti-IAV role of HDAC4 in chapters II and III, we noticed that 
HDAC4 expression was severely diminished in IAV-infected cells. Therefore, the aim of 
this chapter was to identify the mechanism(s) by which IAV dysregulates HDAC4. 
Here, we demonstrated that the IAV-induced antagonism of HDAC4 polypeptide occurs 
in both A549 and MDCK cells in a time-dependent and H1N1 strain-independent manner 
(Figure 22, 23, 24, 25). It is well understood that in order to replicate effectively within 
host cells, IAV manipulates the expression and activity of host factors involved in its 
replication. It is likely, given its anti-IAV role established above, that HDAC4 is targeted 
by IAV in order to circumvent its antiviral potential. In further support of this, the IAV-
induced dysregulation of other HDACs which are also antiviral, has been well documented 
[79, 224-226]. However, the mechanisms by which IAV dysregulates each of these HDACs 
is distinct. For example, HDAC1 and 2 are degraded via the proteasome pathway, HDAC6 
is degraded by caspases and HDAC11 mRNA is profoundly depleted in IAV-infected cells. 
This indicates that IAV antagonises the various HDACs based upon the characteristics of 
the genes themselves. 
Therefore, we explored the IAV-induced antagonism of HDAC4 further and found that 
the observed antagonism was a result of the proteolytic cleavage of the polypeptide into 
smaller fragments. At approximately 12 hours post-infection, two cleavage products appear 
which also coincides with the activation of caspase 3 and the cleavage of viral NP (Figure 
25). Viral NP is cleaved by caspases and is important for its function in the late stages of 
infection [510]. Additionally, the cleavage of HDAC4 by caspase 2 and caspase 3 has been 
previously reported, both of which produce fragments of a similar size to the fragments 
seen here [429, 483, 488, 489]. Incidentally, these studies report the cleavage of HDAC4 
can be achieved via non-viral induced apoptosis. Additionally, another Class II HDAC, 
HDAC6, has already been shown to be cleaved by caspase-3 during IAV infection [369], 
adding further support to the notion that caspases are responsible for the IAV-induced 
cleavage of HDAC4. Therefore, IAV, which is known to induce apoptosis in mammalian 
cells, is able to create an environment which is favourable for the degradation of the 
HDAC4 polypeptide in infected cells. Consequently, both HDAC4 degradation and 
proteolytic caspase-3 activation was significantly reversed in IAV-infected cells upon 
treatment with a caspase-3 inhibitor (Figure 26). Furthermore, depletion of the 
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executioner caspases revealed that only caspase 3, but not caspase-6 or caspase-7, was 
responsible for the cleavage of the HDAC4 polypeptide in IAV-infected cells (Figure 27). 
However, despite partially restoring the full-length HDAC4 polypeptide, some of the 
cleavage fragments remained, indicating that another mechanism(s) is involved in the IAV-
induced cleavage of HDAC4. Indeed, when cells were treated with NH4Cl, a potent 
lysosomal pathway inhibitor, the HDAC4 polypeptide was also partially recovered (Figure 
26). However, some cleavage fragments remained which were different to the fragments 
appearing in the caspase inhibitor treated cells. This indicated that HDAC4 is cleaved by 
the activity of at least two distinct pathways during IAV infection and perhaps by the 
activation of other proteases. Due to the partial recovery seen in lysosomal inhibitor-
treated cells, a likely family of host proteases involved in the IAV-induced cleavage of 
HDAC4 are the lysosomal-associated proteases; cathepsins. In fact, a recent study showed 
that HDAC4 is cleaved by cathepsin H in a heterologous system [496]. In addition to this, 
the nature of the HDAC4 degradation seen here is very similar to the lysosome-mediated 
degradation of host cortactin polypeptide in IAV-infected cells [497]. Thus, it is quite likely 
that lysosomes are closely connected with the apoptotic pathway in IAV-infected cells. 
Interestingly, lysosomes have been shown to be involved in the induction of both intrinsic 
and extrinsic apoptotic pathways in heterologous systems [498-501]. Another mechanism 
by which HDAC4 is regulated which was not explored here, is by the activity of protein 
kinase A (PKA). It has been shown that PKA is able to interact directly with HDAC4 but 
not with any of the other class IIa HDACs as they lack the appropriate binding site. Once 
PKA binds to HDAC4, an unknown protease is then able to cleave HDAC4 at amino acid 
201, which generates a small N terminal fragment of similar size to what is observed here 
[481]. These findings demonstrate the complex nature by which HDAC4 is regulated 
within cells, both under normal and abnormal conditions. It is also interesting to note that 
different viruses antagonise HDAC4 utilising different mechanisms. For example, similar 
to IAV, the HCV core protein degrades HDAC4 polypeptide via proteasome-independent 
pathway [426]. Contrastingly, a recent study showed that the vaccinia virus C6 protein 
utilises the proteasome pathway to degrade HDAC4 polypeptide [422]. Even so, it is 
apparent that capsase-3 is involved in the IAV-induced cleavage of HDAC4, however, a 
thorough investigation is needed to identify other proteases that might also play a role. 
The ability of IAV to antagonise plasmid-expressed HDAC4 in A549 cells but not 
HEK293 cells is an interesting observation (Figure 11). Examining the effect of 
endogenous HDAC4 in HEK293 cells might reveal that these cells are resistant to IAV-
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induced HDAC4 antagonism, possibly due to the lack of a component that is essential for 
the antagonism. Alternatively, HEK293 cells transfect highly efficiently (Figure 11D), 
therefore, the apparent lack of antagonism could be due to the overabundance of HDAC4 
to A549 cells which transfect much less efficiently (Figure 11B). Nevertheless, it would 
be interesting to determine the effect IAV infection has on endogenous HDAC4 in 
HEK293 cells.  
In addition, we also identified that HDAC4 mRNA is significantly downregulated in IAV-
infected cells (Figure 31). Using an RNA interference screen we found that IAV-infected 
cells transfected with the siRNA targeting PA exhibited a partial recovery in the full length 
HDAC4 polypeptide (Figure 29). An important limitation for this experiment was that 
no uninfected controls using these siRNAs were used. This could potentially mean that 
the effects seen on HDAC4 polypeptide expression could be a result of off-target effects 
from the siRNA. Additionally, one could make the argument that this partial recovery 
could be due to impact on viral replication as the PA gene segment encodes the PA gene 
which is a vital gene for viral replication. While it is true that these siRNAs impair IAV 
replication as others have reported [494] and as we observed here, it is important to note 
that none of the other siRNAs affected HDAC4 expression. This is especially relevant in 
regards to the siRNA targeting the structural gene NP, which had a similar effect on viral 
growth as the PA siRNA. Interestingly, the knockdown of both PA and PB1 resulted in 
significantly reduced NP cleavage (Figure 29A). As mentioned previously this cleavage is 
known to be carried out via the activity of host caspase 3 [79]. It is likely that deleterious 
effects of the siRNA on viral replication means that the apoptotic pathway is not as 
profoundly activated in these cells compared to NS siRNA, which is only partially effective. 
Even so, despite the reduced NP cleavage in the PB1 siRNA-treated cells, HDAC4 
antagonism remains strong, indicating that perhaps partial activation of caspase 3 is 
sufficient to reduce HDAC4 polypeptide expression. It would be interesting to determine 
the amount caspase activation in IAV-infected cells treated with the different IAV siRNAs 
in order to clarify this anomaly. Additionally, we overexpressed PA-X and found its 
expression alone was sufficient to downregulate HDAC4 mRNA (Figure 32). PA-X is a 
recently discovered protein and is highly conserved in the IAV genome including the 
strains PR8 and CA09 that were used here [511, 512]. Recently, it has been shown that 
IAV PA-X is able to selectively target host mRNA transcribed by the RNA Pol II complex 
for degradation by the activity of the host exonuclease XrnI [48]. Additionally, a recent 
study reported that IAV downregulates HDAC4 mRNA in primary bronchial epithelial 
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cells [427]. However, in this case IAV promotes the expression of miR-22 which targets 
HDAC4 mRNA to decrease its expression. In addition, 2 other studies showed that 
HDAC4 mRNA is also antagonised during HBV infection. HBV promotes the expression 
of 2 miRs, miR-548ah and miR-1, which target HDAC4 mRNA to inhibit deacetylation of 
the cccDNA which ultimately enhances viral replication [423, 425]. Potentially, the 
combined HDAC4 characteristics: its antiviral activity and the relatively short half-life of 
its mRNA, make it an ideal candidate for viruses to target.  
It is interesting to note that the knockdown of PA-X did not completely recover the 
HDAC4 mRNA levels. Likewise, the overexpression of PA-X could not downregulate 
HDAC4 mRNA to similar levels seen in IAV-infected cells. A likely possibility is that IAV 
employs multiple mechanisms to dysregulate gene expression of the host cell. As 
mentioned previously, others found that IAV upregulates the expression of certain 
miRNAs such as miR-22 which is known to target HDAC4 [427]. It would be interesting 
to see if blocking this miRNA (and others known to target HDAC4) using an antisense 
miRNA would be sufficient to partially restore the HDAC4 mRNA expression in IAV-
infected cells. Additionally, we did completely investigate the role of NS1 (one of the most 
characterised IAV virulence factors) in the role of HDAC4 antagonism. The siRNA we 
used only partially inhibited NS1 expression. Remaining NS1 could have been sufficient 
to downregulate HDA4 mRNA, especially in the context of the short halflife of HDAC4 
mRNA which is less than 4 hours [429]. Furthermore, we did not examine the effect of 


















Like all viruses, IAV must utilise much of the host cell machinery in order to complete its 
replication cycle. Understanding how this interaction between host and virus is an 
important step to aid in the development of effective antiviral therapies. This is of 
particular importance in regards to IAV due to the lack of a universal vaccine and the rise 
in drug resistant strains [152]. The research presented here is the first evidence 
demonstrating the antiviral role of host HDAC4 in IAV infection. Thus, HDAC4 joins the 
list of other HDACs that are important in promoting an effective antiviral response to 
IAV. In addition, HDAC4 itself is severely antagonised during IAV infection, likely as 
means for the virus to inhibit its antiviral activity.  
 
5.1.1 The antiviral role of HDAC4 
Depletion of HDAC4 via RNAi resulted in enhanced IAV growth kinetics (section 2.2.2), 
while overexpression of HDAC4 inhibited IAV replication (section 2.2.3). The effect of 
HDAC4 depletion on IAV replication was observed using two different H1N1 strains – 
the lab adapted PR8 strain (Figure 7) and the clinically relevant strain CA09 (Figure 9). 
Furthermore, the effect on viral replication was observed at multiple levels including 
intracellular and extracellular NP polypeptide expression, infectious virus release via plaque 
assay and intracellular viral gene mRNA expression.  
Mechanistically, HDAC4 was found to play a role in regulating the innate immune 
response during IAV infection. The mRNA expression of IFNα (Figure 13) and the two 
ISGs; ISG15 and viperin (Figure 15) were decreased in HDAC4-depleted cells. 
Conversely, the opposite was observed during HDAC4 overexpression, where the mRNA 
levels of IFNα (Figure 17), ISG15 and viperin (Figure 18) were all increased as compared 
to cells expressing normal levels HDAC4. Furthermore, the kinetics of STAT1 
phosphorylation was delayed in HDAC4-depleted cells (Figure 14) which translated 
negative effect on the polypeptide expression of certain ISGs, namely IFITM3, viperin and 
ISG15 (Figure 16). Again, the opposite effect was observed in cells overexpressing 
HDAC4, whereby STAT1 phosphorylation was increased, as was the polypeptide 
expression of viperin and ISG15 (Figure 19). STAT1 is a transcription factor involved in 
promoting the expression of ISGs during infection with an invading pathogen. Upon 
cytokine stimulation, JAK activates STAT1 by phosphorylating it at serine and tyrosine 
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residues. Upon being phosphorylated, STAT1 can then translocate to the nucleus where it 
can induce the expression of many ISGs important in enhancing the immune response and 
inhibiting viral replication [435]. Interestingly, STAT1 acetylation of the lysine residues 
K410 and K413 within DNA binding domain inhibit DNA binding and facilitates the 
dephosphorylation of STAT1 [513]. The acetylation of these lysine residues induces a 
structural change in phosphorylated STAT1, ultimately exposing the phosphorylated 
tyrosine residue Y701 to the phosphatase TCP45 [514]. Others have also reported that 
STAT1 is regulated by a phosphorylation-acetylation switch, whereby STAT1 acetylation 
acts a memory mark indicating previously activated STAT1 [445]. Upon being acetylated, 
phosphorylated STAT1 is then able to become dephosphorylated via the activity of TCP45 
and is transported to the cytoplasm where it remains in an inactive and latent state. Only 
by the activity of HDACs can STAT1 be deacetylated, allowing it to become activated once 
again to stimulate expression of immune genes. In the context of IAV infection, HDAC4 
might be able to indirectly activate STAT1 by inducing its deacetylation. This would allow 
STAT1 to become phosphorylated once again, thus reactivating it where it can translocate 
back to the nucleus to promote the expression of innate immune genes (Figure 33). 
However, another study has reported that STAT1 is not under the control of a 
phosphorylation-acetylation switch [515]. However, the conditions used in those studies 
varied from the ones used here, and under certain circumstances the acetylation-
phosphorylation switch of STAT1 might not present at all. The conflicting information on 
the link between acetylation and phosphorylation of STAT1 leads to some uncertainty 
behind the exact mechanism of how the expression of HDAC4 can affect the 
phosphorylation of STAT1 during IAV infection. It is of interest to note that the 
phosphorylation of neither STAT2 nor STAT3 are reported to be affected by acetylation 
in the same way that STAT1 is [513]. Therefore, if phosphorylation of these STATs is 
affected by HDAC4 expression in a similar fashion to STAT1, it would suggest a different 
mechanism is in play. HDAC4 might directly activate the innate immune response. 
HDAC4 can localise within the nucleus or the cytoplasm, meaning that HDAC4 can 
coprecipitate with STAT1 and act directly on different ISG promoters. During HSV-1 
infection, HDAC4 is needed for the recruitment of STAT2 to various ISG promoters and 
likely plays a similar role during IAV infection [422].  
The effect on STAT1 phosphorylation by HDAC4 was also observed when using IFNα 
treatment as an innate immune stimulator (Figure 20). Although others have already 
identified the antiviral role of HDAC4 in other virus infections, this result solidifies the 
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role of HDAC4 as general antiviral host factor. Therefore, HDAC4 appears to be an 
important activator of the innate immune response through its deacetylase activity and 















Figure 33. Proposed model of how HDAC4 promotes STAT1 phosphorylation to mediate 
the antiviral response. Phosphorylated STAT1 is acetylated in the nucleus by different HAT 
enzymes. Acetylation induces conformational changes in STAT1, exposing phosphorylated 
tyrosine residue Y701 to the phosphatase TCP45. TCP45 dephosphorylates STAT1, resulting in 
its inactivation and translocation into the cytoplasm. HDAC4 is able to deacetylate STAT1, 
allowing it to become phosphorylated, where it localises to the nucleus where it can begin activation 




5.1.2 The IAV-induced antagonism of HDAC4 
While HDAC4 was found to play a role in activating the innate response during IAV 
infection, the results here also demonstrate that IAV negatively targets HDAC4. This is 
likely as a means to inhibit its role in innate immune activation. Upon IAV infection with 
different H1N1 strains and using 2 different cell lines, we observed the HDAC4 
polypeptide was significantly diminished (Figures 22-24).  The HDAC4 polypeptide was 
found to be cleaved by caspase 3 at approximately 12 hours post-infection where several 
cleavage fragments appeared (Figures 25-26). The depletion of caspase 3 was sufficient 
to partially recover the full length HDAC4 polypeptide during IAV infection whereas 
caspase 6 and 7 knockdown had no effect on IAV-induced HDAC4 cleavage (Figures 27-
28). However, despite the recovery of the HDAC4 full-length polypeptide in caspase 3 
depleted cells, some of the cleavage fragments still appeared during IAV infection. Thus, 
other proteases must also be involved in the IAV-induced cleavage of HDAC4, although 
these are yet to be identified. The significance of the cleavage of HDAC4 during IAV 
infection remains to be determined, however, based upon what is already known about 
HDAC4 regulation, some hypotheses can be postulated. Others have previously reported 
on the cleavage of HDAC4 via caspases and other proteases in various systems, however 
none of these been reported during IAV infection [486-489]. A commonly reported 
HDAC4 cleavage site recognised by caspase 3 is at Asp 289 [489]. Cleavage at this site 
results in two fragments, an N terminal segment of about 34 kDa and C terminal fragment 
of approximately 97 kDa. The larger C terminal fragment is retained in the cytoplasm, 
however the N terminal fragment contains a NLS, which allows it to localize to the nucleus. 
This N terminal fragment has two commonly reported functions, the first is that it 
represses MEF2 gene transcription and the second is that has a strong proapoptotic effect 
[488]. In the context of IAV infection, the proapoptotic effect of the N terminal fragment 
is of obvious significance. While the traditional view of apoptosis is that is an important 
antiviral response by an infected cell to prevent further spread of a virus, more recent views 
have shown that some IAV genes promote apoptosis at the late stages of infection, likely 
as means to avoid host immune inflammatory responses due to uncontrolled cell death 
[523]. Furthermore, a study revealed that activation of caspase 3 and apoptosis is actually 
beneficial for IAV replication and promotes viral propagation [505]. Thus, the cleavage of 
HDAC4 could be a mechanism by which IAV is able to subvert the antiviral properties of 
HDAC4 and at the same time benefit from the proapoptotic effects of the N terminal 
fragment (Figure 34). Indeed, the repression of MEF2 by the cleaved N-terminal fragment 
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may also be important in the context of IAV infection as the MEF2 transcription factors 
are known to regulate several cellular processes including differentiation, proliferation, 
morphogenesis, apoptosis [506], as well as immune and metabolic activities [507]. Thus, 
the repression of MEF2 transcription factors nuclear localized HDAC4 may also create a 
more favourable environment for IAV replication, however, not much is known about the 
role MEF2 transcription factors during IAV infection. In addition to the IAV-induced 
proteolytic cleavage of the HDAC4 polypeptide, the HDAC4 mRNA is also targeted by 
IAV (Figure 31). It is likely the viral endonuclease PA-X was targets the HDAC4 mRNA 
for degradation as expression of PA-X alone was found to be sufficient to reduce HDAC4 
mRNA levels while RNAi of PA during IAV infection recovered HDAC4 mRNA (Figure 
32). The targeting of the HDAC4 mRNA by IAV has at least 2 benefits for viral replication. 
Firstly, it reduces the overall HDAC4 polypeptide level within the cell which is important 
for inhibiting STAT1 activation as alluded to earlier. Secondly, it reduces ribosomal load, 
thus allowing for enhanced translation of viral proteins and host proteins important in viral 
replication. The severity with which HDAC4 is targeted by IAV, both at the polypeptide 
level and the mRNA level, further emphasise its importance as an antiviral host factor. 
In summary, this project follows in the wake of previous work done on the role of HDACs 
in IAV infection and was successful in determining that HDAC4 plays an antiviral role 
during IAV infection. Ever emerging drug-resistant strains of IAV and the lack of a 
universal vaccine emphasise the need to develop novel anti-IAV strategies. To aid in this 
endeavour, a deeper understanding of the molecular interplay between IAV and HDACs 
could aid in the development of such strategies. The findings presented here contribute to 















Figure 34. Proposed model of IAV antagonism of HDAC4. The HDAC4 polypeptide is 
cleaved by caspase 3 at the Asp 289 residue. The N terminal fragment then localises to the nucleus 
via its NLS where it promotes apoptosis. Meanwhile, the C terminal fragment is retained in the 
cytoplasm and is further degraded by caspases or some other proteases. At the same time, the IAV 
PA-X protein induces the degradation of the HDAC4 mRNA 
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5.2 Future directions 
An important next step in this research is to further understand the nature between STAT1 
phosphorylation and acetylation. Because of the conflicting body of knowledge in the 
literature surrounding the STAT1 phosphorylation-acetylation switch [445, 515], further 
work needs to be done to understand this phenomenon. Specifically, in the context of 
HDAC4 and IAV infection, mass spectrometry can be performed to determine how the 
levels of STAT1 acetylation change in response to HDAC4 depletion or overexpression 
and during IAV infection. 
One of the most exciting areas for future research is to elucidate the nature of the IAV-
induced cleavage of HDAC4. Using a site-directed mutagenesis approach would reveal 
exactly where the polypeptide is being cleaved by caspase 3. The most obvious site to 
mutate first would the 289 aspartic acid residue as this has been previously reported to be 
cleaved by caspase 3 in response to various stimuli [429, 483, 488, 489]. Upon obtaining 
an HDAC4 mutant that is resistant to IAV-induced cleavage, many more experiments 
could be performed to determine the significance HDAC4 cleavage. Firstly, the mutant 
would be useful in understanding how the cleavage of HDAC4 effects its antiviral 
capabilities. For example, determining if the innate immune signalling pathway is enhanced 
in cells expressing a cleavage-resistant HDAC4 mutant as compared to cells expressing 
wild type HDAC4 would be an obvious experiment to perform. This could be 
complemented by determining the effect on IAV replication in the presence cleavage 
resistant HDAC4. In addition, overexpressing specific HDAC4 fragments might also 
reveal a potential role that these fragments play during IAV infection, providing further 
insight into the importance of the HDAC4 proteolytic cleavage. Perhaps it is more 
important to understand whether the IAV-induced cleavage of HDAC4 polypeptide 
occurs just as means to antagonise its antiviral function, or also plays a significant role in 
IAV replication. The N-terminal HDAC4 fragment derived as a result of caspase cleavage 
is quite stable and translocates to the nucleus where it binds to MEF2 transcription factor 
and represses its activity [481]. In addition, this N terminal fragment also induces the 
intrinsic apoptotic pathway in mammalian cells under various conditions [488, 489]. 
Evidentially, both repressed host transcription and apoptosis are favourable conditions for 
IAV to proliferate [505]. It could be interesting to determine the effect that transfection of 
a plasmid containing only this N terminal fragment of HDAC4 might have in the context 
of IAV infection.Thus, further investigations into the significance of the HDAC4 cleavage 
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will reveal if IAV manipulates HDAC4 to antagonise its antiviral function, but also to 
promote its own replication. 
It is well understood that the subcellular distribution of HDAC4 plays a major a factor in 
how HDAC4 functions [488, 489]. Using confocal microscopy to determine where 
HDAC4 localises during IAV infection might reveal how and where HDAC4 exerts its 
antiviral function. Furthermore, manipulating its distribution by mutagenesis of the NLS 
or NES would create distinct pools of HDAC4 that accumulate in the nucleus or 
cytoplasm. Determining the effect on IAV replication in cells expressing these distinct 
pools of HDAC4 might highlight the importance of HDAC4 shuttling in its role as 
antiviral host factor.  
Given the traditional role assigned to HDAC4 as a deacetylase, it is important to determine 
what role this deacetylase activity has in promoting innate immune signalling. HDAC4 is 
known deacetylate the lysine residues at position 9, 14, 18 and 23 of histone 3 and 5, 8 12 
and 16 of histone 4. The reversible acetylation of these residues mediates decondensation 
of the nucleosome structure, altering histone and DNA interactions, thus facilitating the 
binding of transcription factors [430]. Thus, using an HDAC4-specific inhibitor such as 
tasquinimod, and utilising RNA-seq might reveal how HDAC4 is able to regulate the cell 
transcriptome, both in infected cells and during infection with IAV. In addition, HDAC4 
is known to deacetylate non-histone proteins in the cytoplasm including HIF-1α and 
MEKK2, both of which are known to be involved in regulating the immune response 
within cells [221]. Therefore, inhibiting the deacetylase activity of HDAC4 might reveal a 
role for deacetylation of these proteins during IAV infection.  
It would be of particular interest to further elucidate the exact mechanisms by which 
HDAC4 promotes the innate immune response through STAT1. It is likely that HDAC4 
not only promotes the innate immune response through enhancing STAT1 
phosphorylation, but that it also binds to ISRE-containing promoters with STAT1 to 
enhance ISG expression. HDAC4 is known co-precipitate with STAT2 during HSV-1 and 
vaccinia virus infection to ISG promoters and is actually required for the binding of STAT2 
to these promoters [422]. Therefore, a chromatin immunoprecipitation assay would reveal 
if HDAC4 does bind directly to the promoters of ISGs known to be important in inhibiting 
IAV replication. Furthermore, it would be interesting to determine if HDAC4 also 
precipitates with STAT1 and localises to the nucleus together in a complex as it has been 
shown with STAT2. 
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The IFN-α treatment experiments indicated that the HDAC4 antiviral role against IAV 
likely extends to other viral infections too. Indeed, others have already reported on the 
antiviral role that HDAC4 plays against other viruses. However, it would be interesting to 
determine if the antiviral mechanism of HDAC4 remains consistent between viruses 
through activating the innate immune pathway. Furthermore, it would be interesting to 
determine if other viruses actively target HDAC4 in a similar fashion to IAV in order to 
inhibit its antiviral function. 
It could also be of potential interest to study the effects of the HATs in response to IAV 
infection. Given the findings that describe the anti-IAV role of HDACs presented here 
and in other studies, it is probable that HATs aid in IAV infection. Similar experiments to 
the ones presented here could be performed to determine if HATs promote IAV infection. 
Finally, it would be interesting to perform in vivo experiments in HDAC4 knockout mice 
to see if the effect on IAV growth is comparable to cell culture. However, HDAC4 
knockout mice exhibit a lethal phenotype and die within the first week of life due to 
abnormalities in skeletal physiology. Nevertheless, a conditional gen knockout method 
could be utilised here. Using a Cre-lox recombination system, the HDAC4 gene could be 
knocked out once skeletogenesis is complete and the lethal HDAC4 knockout phenotype 
can be mitigated.  










CHAPTER VI:  
 
MATERIALS AND METHODS 
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6.1 Cells and viruses 
Human alveolar epithelial cells, A549, MDCK (Madin Darby Canine Kidney) and HEK293 
(human embryonic kidney) cells were used. Influenza virus strains A/Puerto 
Rico/8/1934(H1N1) (PR8), A/California/07/2009(H1N1) (CA09) and 
A/Wisconsin/1934(H1N1) (WSN) were used.  
  
6.2 Cell culture  
For regular maintenance, cells were grown in complete minimum essential medium (MEM) 
supplemented with 10% foetal bovine serum (FBS), 1% penicillin-streptomycin and 1% 
L-glutamine (Life Technologies) at 37°C and under 5% CO2
 atmosphere. For sub-
culturing, the medium was removed, cells were washed twice with phosphate buffered 
saline (PBS) (Thermo Scientific) and were then incubated with trypsin-EDTA (Thermo 
Scientific) for 5-10 minutes at 37°C. Fresh medium was added and cells were split in a 1:3, 
1:5 or 1:10 ratio.  
 
6.3 Virus propagation  
Influenza viruses were propagated in 10-day old embryonated chicken eggs, and titrated 
on MDCK cell monolayers by plaque assay as follows. Fertilized chicken eggs were 
incubated at 35°C under humidity. The eggs were examined under light every second day 
to check the development and viability of the embryo. On the 10th day, eggs were examined 
a final time to determine the location of the air sac cavity which was indicated using a 
pencil drawn on the egg shell. The marked area was first sterilized with 70% ethanol and 
then a small hole was punctured on the egg shell using an 18-gauge needle. 100 µL of virus 
inoculum containing 1000 PFU was inoculated into the eggs. The punctured area was then 
sealed off with tape and the eggs were incubated at 35°C for 48 hours. The embryos were 
then killed by placing the eggs in a cold room for 48 hours. Then, the tape was removed 
and the egg shell peeled away using sterile forceps, after which the chlorio-allantoic 
membrane was carefully removed. The virus-containing allantoic fluid was then harvested 
using a pipette and stored in a sterile 15 mL falcon tube. Care was taken not to disrupt the 
yolk sac or blood vessels which might contaminate the allantoic fluid. Viral titre of the 
131 
harvested samples was determined by performing the microplaque assay on MDCK cells 
(as described below).  
6.4 Infection  
Cell monolayers were washed twice with serum-free (SF)-MEM. The volume of virus stock 
required for the appropriate MOI was calculated and diluted in the appropriate volume of 
SF-MEM to make the viral infection media. 500 µL of the viral infection media then added 
to the cell monolayers for infection and incubated at 35°C for 1 hour. After the initial 
incubation period, the infection inoculum was removed and 1 mL of SF-MEM was added. 
For MDCK cells, the SF-MEM was supplemented with TPCK-trypsin (1 µg/Ml) (Sigma-
Aldrich) in order to aid the virus to continue multiple infection cycles. The initial infection 
inoculum was supplemented with the desired concentration of drugs where appropriate. 
MG132 (Calbiochem) and NH4Cl (Sigma-Alrich) were used for inhibiting proteasomal and 
lysosomal pathways, respectively.  
 
6.5 UV irradiation of virus  
To make the virus replication-deficient, the virus inoculum was irradiated with 1-2 mJ of 
UV light for 30 minutes prior to infection. UV light treatment results in the inactivation of 
the genetic material of the virus while maintaining the antigenic potential of the virus. 
 
6.6 Plaque assay  
The culture medium from infected cells was harvested and cell debris was removed by low-
speed centrifugation. The media was divided into two separate constituents, the first was 
subjected to protein precipitation by trichloroacetic acid (TCA) (Calbiochem) while the 
second part was mixed with 0.3% BSA (Sigma-Aldrich) and titrated on MDCK cells. The 
microplaque assay was performed using confluent monolayers of MDCK cells which were 
infected with 10-fold serial dilutions of the culture medium. After 1 hour, the viral 
inoculum was removed and the cells were then overlaid with 2X SF-MEM containing 
1µg.mL TPCK-trypsin and 0.8% Avicel (RC-581; FMC Biopolymer). After 24 hours of 
incubation, the overlay was removed and the cells were fixed with 4% formalin for 30 
minutes. Subsequently, the cells were permeabilized with 0.5% TritonX-100 and 20 mM 
glycine. Cells were then stained with mouse anti-NP antibody (BEI resources, 1:1000) and 
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left overnight, followed by 3 washes with PBS (Thermo Scientific). Horseradish 
peroxidase-conjugated anti-mouse IgG antibody (Thermo Scientific, 1:1000) was then 
added to the cells and incubated for 1 hour at room temperature followed by 3 washes 
with PBS. Plaques were developed using 150 µL of KPL TrueBlue peroxidase substrate 
(Sera Care) for 20 minutes Plaques were counted by eye using a dilution that contained 
between 25-250 plaques.  
 
6.7 Trichloroacetic acid precipitation of viral proteins 
Ice-cold TCA was mixed with culture medium at a final concentration of 20% and 
incubated on ice for 30 minutes. The supernatant was removed carefully and the resulting 
pellet was washed with ice-cold acetone followed by centrifugation at 20,000xg and 4°C 
for 15 minutes. The supernatant was then discarded and the pellet left to air dry overnight. 
The pellet was then suspended in 50 µL of SDS-PAGE sample buffer per pellet. Proteins 
were resolved by SDS-PAGE and viral NP and HA was detected by WB. 
 
6.8 RNA interference 
Pre-designed siRNA oligonucleotides targeting human HDAC4 gene – 
CAGCCAAGCUUCUGCAGCA, caspase 3 gene CAGCUUUCAUGAUUAGCAA and 
the siRNAs targeting individual influenza gene segments mentioned elsewhere [494] and a 
non-targeting MISSION control (Sigma Aldrich) were used for knockdown experiments. 
The lyophilized siRNA obtained from the supplier was reconstituted to obtain a master 
stock of 50µM and was further diluted to obtain working stocks of 1 µM and 10 µM. 
Finally, 1 nM of HDAC4 siRNA and 10 nM of caspase 3 siRNA was used to knockdown 
the expression of the respective genes. To achieve the knockdown of the target gene, 
OptiMEM (Invitrogen) medium was used for preparing the transfection complex. Desired 
concentrations of siRNA were added to 100 µL of OptiMEM. Simultaneously, 2 µL of 
RNAiMAX lipofectamine (Invitrogen) was added to 100 µL of OptiMEM. These were 
incubated at room temperature for 5 minutes, after which, the lipofectamine complex was 
added to the siRNA mix. This lipofectamine-siRNA mix was incubated at room 
temperature for 30 minutes in order to form the transfection complex. Meanwhile, during 
the incubation period, A549 cells were split and cells were counted using a 
haemocytometer in order to obtain a cell density of 200,000/mL. The A549 cells were 
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added to 200 µL of the transfection complex with the final volume reaching 1 mL through 
the addition of complete MEM. The cells were then incubated at 37°C under 5% CO2 
atmosphere for 24-72 hours before infection or further processing. 
6.9 Plasmid propagation and extraction 
Human HDAC4 cloned in plasmid pcDNA3.1 (gifted by Eric Verdin, Addgene plasmid 
#13821), human HDAC4 cloned in plasmid peGFP (gifited by Eric Verdin, Addgene 
plasmid #45636), and influenza A virus PA-X (WSN) plasmid (gifted by Yoshiro 
Kawaoka, The University of Tokyo, Japan) were amplified in Escherichia coli DH5α strain. 
The bacterial swabs (obtained from Addgene) were spread onto LB agar (Calbiochem) 
containing 50 µg/mL ampicillin and the plates were incubated overnight at 37°C. 
Individual colonies were picked from the LB agar plate and inoculated into 25 mL LB 
broth containing 50 µg/mL ampicillin (Sigma-Aldrich). Incubation was performed 
overnight at 37°C with constant agitation (200 rpm). Plasmids were extracted using a 
Qiagen midiprep plasmid extraction kit as per the manufacturers protocol. The DNA was 
resuspended in 0.5 mL of sterile miliQ water and quantified using a Nanodrop 
spectrophotometer (Thermo Scientific) and stored at -80°C. 
 
6.10 Plasmid DNA transfection 
Cells were grown to 80-90% confluency in a cell culture plate, and transfected with the 
plasmids using Lipofectamine 2000 reagent (Invitrogen) following the manufactures 
instructions. Briefly, 1 µg of plasmid DNA and 3 µL of Lipofectamine 2000 were diluted 
separately in 100 µL of OptiMEM (Invitrogen), and incubated for 5 minutes at room 
temperature. Following this, the Lipofectamine 2000 mix and the DNA mix were 
combined and incubated together at room temperature for 30 minutes to allow the 
formation of the DNA-Lipofectamine complex. This was then added to the cells in a 12 
well plate and incubated at 37°C for 24-48 hours before infection or further processing.  
 
6.11 Quantitative real-time PCR 
Total RNA was isolated from the uninfected and infected cells using Nucleospin RNA 
isolation kit (Macherey-Nagel) by following the manufactures instructions. The RNA was 
then quantified using Nanodrop spectrophotometer (Thermo Scientific) and the purity of 
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the isolated RNA was analysed using the 260/280 ratio obtained (an absorbance in 1.8-2.0 
range was considered acceptable). Following the successful isolation of the RNA, cDNA 
was then synthesised from 500 ng of total RNA using PrimeScript RT reagent kit (Takara) 
by following the manufactures protocol.  
The quantitative real-time PCR was performed using SYBR select master mix (Invitrogen). 
Predesigned KiCqStart primers (Sigma Aldrich) for HDAC4, viperin, caspase 3, caspase 6, 
caspase 7 and interferon-stimulated genes were used to amplify the respective genes using 
quantitative real-time PCR (qPCR) (ViiA 6, Applied Biosystems). Custom-designed 
primers were also used to amplify 18S rRNA, Beta-actin, IAV NP gene, IAV NS gene, 
IAV PA gene, IAV PA-X gene and IAV PB1 gene (Table 1). All of these primers had 
been tested previously by our lab or others to confirm that each primer pair amplifies a 
single amplicon [224, 494]. Beta-actin and 18S rRNA were used as reference genes for 
normalising the expression of the genes of interest, whereas, viperin was used as an 
infection marker. The percentage or fold change in the mRNA levels of target genes was 
calculated using 2-ΔΔct method.  
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Table 4: List of primers 
Gene Forward Primer Reverse Primer 
HDAC4 5’-AAAAGAGACCAGATGAGGAG-3’ 5’-AGACAGACAGACAAGAGAAC-3’ 
Caspase 3 5’-AAAGCACTGGAATGACATC-3’ 5’-CGCATCAATTTCCACAATTTC-3’ 
Caspase 6 5’-TGAGAAACTTTCCTGTTCAC-3’ 5’-AAGGATATTATTCTCACCGGG-3’ 
Caspase 7 5’-CCTGAATGAAGAAGAGTTTGC-3’ 5’-AAGCCTATGGAGAAGAAAATG-3’ 
IFITM1 5’-CTACTCCGTGAAGTCTAGG-3’ 5’-ATGAGGATGCCCAGAAATC-3’ 
IFITM2 5’-ACCTGTATTCCACTTACTCC-3’ 5’-ATTGTAGAAAAGCGTGTGAG-3’ 
IFITM3 5’-TCGCCTACTCCGTGAAAGTCT-3’ GGGATGACGATGAGCAGAAT-3’ 
ISG15 5’-AGATCACCCAGAAGATCG-3’ 5’-TGTTATTCCTCACCAGGATG-3’ 
Viperin 5’-CTTTTGCTGGGAAGCTCTTG-3’ 5’-CAGCTGCTGCTTTCTCCTCT-3’ 
CH25H 5’-AGTCTAGCTCACCTCAATAG-3’ 5’-TAGAGTCAGAAGTCAACACC-3’ 
MAVS 5’-CAAGGCCCCTATTCTCAG-3’ 5’-TCTTCTTCCAAGAGCTGG-3’ 
TRM22 5’-ATGAAAAGGAGTGGAAAGCTG-3’ 5’-CTCTGATCCACAGAAATAGC-3’ 
MX1 5’-CAGGCTTTGTGAATTACAGC-3’ 5’-TCTTCAATTTTGGACTTGGC-3’ 
OAS3 5’-AGTGTACCAAGATCTCCAAG-3’ 5’-ATGGTCCAGTAGATACAGAG-3’ 
18SRNA 5’-ATCGGGGATTGCAATTATTC-3’ 5’-TCACTAAACCATCCAATCG-3’ 
Actin 5’-GACGACATGGAGAAAATCTG-3’ 5’-ATGATCTGGGTCATCTTCTC-3’ 
IAV NP 5’-AGAAATAAGGAGAGTTTGGCGCCTAGC-3’ 5’-CATTCCGGTGCGAACAAGCGC-3’ 
IAV NS 5’-CAGGACATACTGATGAGGATG-3’ 5’-GTTTCAGAGACTCGAACTGTG-3’ 
IAV PA 5’-GCTTCTTATCGTTCAGGCTCTTAGG-3’ 5’-CCGAGAAGCATTAAGCAAAACCCAG-3’ 
IAV PA-X 5’-GCGACAATGCTTCAATCCGA-3’ 5’-TTGACTCGCCTTGCTCATTG-3’ 
IAV PB1 5’-CGGATTGATGCACGGATTGATTTC-3’ 5’-GACGTCTGAGCTCTTCAATGGTGGAAC-3’ 
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6.12 Western blotting 
At the desired time points, cells were scraped from the wells and pipetted into a 1.5 mL 
tube and centrifuged at 14,000 RPM for 30 seconds to pellet the cells. The supernatant was 
either stored or discarded and 10 µL of PBS was added to the cell pellet. The pellet was 
then resuspended in the PBS by vigorous vortexing. The cells were lysed in lysis buffer (50 
mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium dodecyl sulfate (SDS), 0.5% sodium 
deoxycholate, 1% TritonX-100, and 1X protease-inhibitor cocktail (Roche). Protease-
inhibitor cocktail was added just before cell lysis. 20 µg of protein was resolved on 10% or 
15% Tris-glycine SDS-PAGE along with SeeBluePlus 2 pre-stained protein standards 
(Invitrogen) and transferred on to Protran Premium nitrocellulose membrane (GE 
Healthcare). Subsequently, membranes were probed with desired primary antibodies and 
relevant secondary antibodies at appropriate dilutions (Table 2). Proteins were then 
visualised by chemiluminescence and/or fluorescence. Images were acquired and protein 
bands were quantified on Odyssey Fc imaging system (Li-COR). Images were exported as 
TIFF files and compiled in Adobe Photoshop CC 2015 and Microsoft PowerPoint 2016. 
Raw signals for each band were calculated after background removal using the Li-COR 
software (Image studio 5.2). The signal from the protein of interest was normalised by 
dividing with PDI or Actin signal. Then, each sample was normalised with their 
corresponding control samples. The control sample was either kept as 1 for fold change 
or as 100% for percentage expression and the corresponding treated samples were 
calculated for fold change or percentage change, respectively. 
An important limitation with the western blotting data is that no experiments were 
performed to check for the linearity of signal response for any of the target proteins or 
loading controls. In order to minimise error in western blot quantitation, experiments 
should have been performed for each detected protein to determine the range of sample 
loading that will produce a linear relationship between the amount of protein on the 
membrane and the band intensity recorded by the detector.  
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Table 5: List of antibodies 
Antibody Dilution Manufacture Cat #/Clone 
HDAC4 1:1000 Cell Signalling D15C3 
Actin 1:10,000 Abcam ab8227 
IAV-NP 1:10,000 BEI NR-19868 
IAV HA 1:1000 Gift from St Jude  G-57 
PDI 1:10,000 Sigma P7496 
Caspase 3 1:1000 Cell Signalling 8G10 
Viperin 1:1000 Cell Signalling D52TX 
pSTAT1 1:1000 BD Biosciences pY701 
total STAT1 1:1000 BD Biosciences 610185 
IFITM3 1:1000 Abcam ab15592 
ISG15 1:1000 Cell Signalling F-9 
Donkey anti-
rabbit HRP 
1:5000/1:2000 Thermo Scientific  626520 
Goat anti- 
mouse HRP 
1:5000 Thermo Scientific A16023 
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6.13 Immunofluorescent microscopy 
Cells were grown in a 24-well plate. After various treatments, the cells were washed 
carefully with PBS and then fixed with 4% paraformaldehyde (Sigma-Aldrich) for 20 
minutes at room temperature. Next, the cells were washed with PBS 3 times and then 500 
µL of 0.2% Triton-X100 was added to permeabilize the cells for 10 minutes. This was then 
followed by 3 washes of PBS and then the cells were incubated with mouse-NP primary 
antibody (1:500) in 10% FBS for 1 hour at room temperature. Cells were then washed with 
PBS 3 times and then incubated with donkey anti-mouse Alexa flour 594 dye (1:500) for 1 
hour at room temperature. The cells were washed again with PBS 3 times and then stained 
with Hoechst dye (Invitrogen) to identify the nucleus (1:5000) for 20 minutes at room 
temperature. Finally, the cells were washed 3 more times with PBS and the cells were 
examined under the fluorescent microscope (Olympus) at 10X maginfication.  
 
6.14 Statistical analyses 
All statistical analyses were performed using Prism 7 (GraphPad). The p-values were 
















Table 6: Composition of cell lysis buffer 
Reagent Concentration 
Tris-HCL (pH 7.4) 50 mM 
NaCl 150 mM 
SDS 0.50% 
Sodium deoxycholate 0.50% 
Triton-X 1% 
Protease-inhibitor cocktail 1X 
 
Table 7: Composition of SDS-sample buffer 
Reagent Concentration 
Tris-HCL (pH 6.8) 50 mM 
SDS 2% 
Glycerol 30% 




Table 8: Composition of resolving and stacking gels 
Reagent 
Resolving Gels Stacking Gel 
10% 15% 6% 
MiliQ-water (mL) 3.9 2.9 2.9 
Lower Tris (pH 8.8) (mL) 2 4 - 
Upper Tris (pH 6.8) (mL) - - 1.75 
10% SDS (µL) 80 80 60 
40% Acrylamide (mL) 2 4 0.7 
10% APS (µL) 80 80 60 
TEMED (µL) 8 8 5 




Table 9: Composition of running buffer (1X) 
Reagent Concentration Amount Manufacturer 
Glycine 192 mM 14.4 Calbiochem 
Tris base 25 mM 3.02g Calbiochem 
SDS 0.1% 1g Calbiochem 
MiliQ-water Final volume up to 1L - 
 
Table 10: Composition of transfer buffer (1X) 
Reagent Concentration Amount Manufacturer 
Glycine 192 mM 14.4 Calbiochem 
Tris base 25 mM 3.02g Calbiochem 
Methanol 20% (vol/vol) 200 mL LabServ 
MiliQ-water Final volume up to 1L - 
 
Table 11: List of blocking buffers 
Blocking Reagent Buffer Detection 
5% non-fat milk PBS All proteins 
1% BSA TBS Phosphorylated proteins 
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°C Degree Celsius 
µg Micro gram 
µL Micro litre 
µM Micro molar 
A549 Human lung carcinoma cell 




Complementary deoxyribonucleic acid 
Caspase cleaved 
Caspase full-length 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dsRNA Double stranded RNA 
EDTA Ethylenedinitrilotetraacetic acid 
eIF Eukaryotic translation initiation factor 
FBS Fetal bovine serum 
HA Hemagglutinin 
HBV Hepatitis B virus 
HCV Hepatitis C virus 
HIV Human immunodeficiency virus 
HEK293T Human embryonic kidney cell 
HeLa Human cervical cancer cell 
HRP Horseradish peroxidase 




IFITM Interferon inducible transmembrane protein 
IFN Interferon 
IFNα Interferon alpha 
IFNβ Interferon beta 
IKK Inhibitor of nuclear factor kappa-B kinase 
IKKα Inhibitor of nuclear factor kappa-B kinase alpha 
IRES Internal ribosome entry site 
IRF3 Interferon regulatory factor 3 
ISG15 Interferon stimulated gene 15 
ISGs Interferon stimulated genes 
ISREs Interferon stimulated response elements 
JAK Janus-activated kinase 
M1 Matrix protein 1 
M2 Matrix protein 2 
MAVS Mitochondrial antiviral signalling 
MDCK Madin-Darby canine kidney 
MEM Minimal essential medium 
MHC Major histocompatibility complex 
MOI Multiplicity of infection 
mRNA Messenger ribonucleic acid 
Mx1 Myxovirus resistance 1 
Myd88 Myeloid differentiation primary response gene 88 
NA Neuraminidase  
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NEP Nuclear export protein 
ng Nano gram 
NF-ΚB Nuclear factor-kappa B 
NLS Nuclear localization signal 
NP Nucleoprotein 
NS Non-structural protein 
PA Polymerase acid 
PB1 Polymerase basic 1 
PB2 Polymerase basic 2 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
PFU Plaque forming unit 
PI3K Phosphatidylinositol 3-kinase 
Pol Polymerase 
PRR Pathogen recognition receptor 
qPCR Quantitative real-time PCR 
RNA Ribonucleic acid 
RNP Ribonucleic protein 
Rpm Revolutions per minute 
SA Sialic acid 
siRNA Small interfering RNA 
STAT Signal transducers and activators of transcription 
UV Ultraviolet 
vRNA Viral RNA 
WB Western blot 
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